var title_f39_13_40144="Elliot type forceps";
var content_f39_13_40144=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Elliott type forceps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Elliot type forceps have overlapping shanks with blades that are short and have a roundish cephalic curve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Aron Schuftan, MD. Copyright &copy; Aron Schuftan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_13_40144=[""].join("\n");
var outline_f39_13_40144=null;
var title_f39_13_40145="Gottrons sign in DM II";
var content_f39_13_40145=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F50909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F50909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Gottron's sign in dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 367px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Erythematous to violaceous patches with overlying scale are present on the extensor surfaces of both knees in this child with dermatomyositis.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; 2012 American College of Rheumatology. Used with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_13_40145=[""].join("\n");
var outline_f39_13_40145=null;
var title_f39_13_40146="Spine MRI findings in leptomeningeal metastases";
var content_f39_13_40146=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F58160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F58160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spine MRI findings in patients with leptomeningeal metastases",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 386px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Post-contrast MR imaging through the cervical (A, B) spine showing abnormal thick and nodular leptomeningeal enhancement (yellow arrows)&nbsp;coating the spinal cord, consistent with widespread leptomeningeal metastases. Images C and D demonstrate characteristic nodular enhancement within the cauda equina.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Images A and B courtesy of Joseph Farnam, MD; Images C and D courtesy of Alexis Demopoulos, MD, and Jerome Posner, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_13_40146=[""].join("\n");
var outline_f39_13_40146=null;
var title_f39_13_40147="Phenylephrine (ophthalmic): Pediatric drug information";
var content_f39_13_40147=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Phenylephrine (ophthalmic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?23/7/23668?source=see_link\">",
"    see \"Phenylephrine (ophthalmic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/50/37668?source=see_link\">",
"    see \"Phenylephrine (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9504770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AK-Dilate&trade;;",
"     </li>",
"     <li>",
"      Altafrin;",
"     </li>",
"     <li>",
"      Mydfrin&reg;;",
"     </li>",
"     <li>",
"      Neofrin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9504797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dionephrine&reg;;",
"     </li>",
"     <li>",
"      Mydfrin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10513264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenergic Agonist Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenergic Agonist Agent, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Alpha-Adrenergic Agonist",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Ophthalmic Agent, Mydriatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sympathomimetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12705160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic procedures: Use combination products containing 1% phenylephrine (see specific monographs for details). In neonates, 2.5% phenylephrine has been shown to cause significant increases in blood pressure compared to 1% preparations (Chew, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10513272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/7/23668?source=see_link\">",
"      see \"Phenylephrine (ophthalmic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ophthalmic procedures:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants &lt;1 year: Instill 1 drop of 2.5% 15-30 minutes before procedures",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children and Adults: Instill 1 drop of 2.5% or 10% solution, may repeat in 10-60 minutes as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ophthalmic irritation (OTC formulation for relief of eye redness): Adults: Instill 1-2 drops 0.12% solution into affected eye, up to 4 times/day; do not use for &gt;72 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9505019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as hydrochloride [drops]: 2.5% (2 mL, 3 mL, 5 mL, 15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AK-Dilate&trade;: 2.5% (2 mL, 15 mL); 10% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Altafrin: 2.5% (15 mL); 10% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mydfrin&reg;: 2.5% (3 mL, 5 mL) [contains benzalkonium chloride, sodium bisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neofrin: 2.5% (15 mL); 10% (5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9504799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10513273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Instill drops into conjunctival sac of affected eye(s); avoid contact of bottle tip with skin or eye; finger pressure should be applied to the lacrimal sac during and for 1-2 minutes after instillation to decrease risk of absorption and systemic reactions",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10513265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a mydriatic in ophthalmic procedures and treatment of wide-angle glaucoma; OTC use as symptomatic relief of eye irritation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9504769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Mydfrin&reg; may be confused with Midrin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9504838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Systemic effects are rare at normal dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia (rare), hypertension (rare), myocardial infarction (rare), subarachnoid hemorrhage (rare), syncope (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Burning, irritation, vision changes, rebound miosis, floaters (transient)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10513266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phenylephrine or any component;  severe hypertension, ventricular tachycardia; narrow-angle glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10513267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use if solution turns brown or contains a precipitate. May contain sulfites which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9504840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9504801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9504802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted; therefore, the manufacturer classifies phenylephrine ophthalmic as pregnancy category C. When administered intravenously, phenylephrine crosses the placenta (refer to the Phenylephrine (Systemic) monograph for details). The amount of phenylephrine available systemically following ophthalmic application is generally less in comparison to oral or I.V. doses.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10513271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potent, direct-acting alpha-adrenergic stimulator with weak beta-adrenergic activity; causes vasoconstriction of the arterioles of the conjunctiva; activates the dilator muscle of the pupil to cause contraction",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F13172760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Mydriasis: 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Mydriasis 2.5% solution: 1-3 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13172780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Minimal systemic absorption (Kumar, 1986)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: &le;20 minutes (Kumar, 1986)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chew C, Rahman RA, Shafie SM, et al, \"Comparison of Mydriatic Regimens Used in Screening for Retinopathy of Prematurity in Preterm Infants With Dark Irides,\"",
"      <i>",
"       J Pediatr Ophthalmol Strabismus",
"      </i>",
"      , 2005, 42(3):166-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/13/40147/abstract-text/15977870/pubmed\" id=\"15977870\" target=\"_blank\">",
"        15977870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kumar V, Schoenwald RD, Barcellos WA, et al, \"Aqueous Vs Viscous Phenylephrine. I. Systemic Absorption and Cardiovascular Effects,\"",
"      <i>",
"       Arch Ophthalmol",
"      </i>",
"      , 1986, 104(8):1189-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/13/40147/abstract-text/3741249/pubmed\" id=\"3741249\" target=\"_blank\">",
"        3741249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16039 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-555B9DE994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_13_40147=[""].join("\n");
var outline_f39_13_40147=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504770\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504797\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10513264\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12705160\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10513272\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505019\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504799\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10513273\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10513265\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504769\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504838\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10513266\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10513267\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299869\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504840\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504801\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504802\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10513271\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13172760\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13172780\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16039\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16039|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/7/19572?source=related_link\">",
"      Phenylephrine (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/52/21316?source=related_link\">",
"      Phenylephrine (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/10/17572?source=related_link\">",
"      Phenylephrine (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/7/23668?source=related_link\">",
"      Phenylephrine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/50/37668?source=related_link\">",
"      Phenylephrine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/47/6903?source=related_link\">",
"      Phenylephrine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/59/33717?source=related_link\">",
"      Phenylephrine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/23/13686?source=related_link\">",
"      Phenylephrine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/53/30547?source=related_link\">",
"      Phenylephrine (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/36/20036?source=related_link\">",
"      Phenylephrine (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/16/5379?source=related_link\">",
"      Phenylephrine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_13_40148="Vulvar debridement";
var content_f39_13_40148=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar debridement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 412px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Extent of surgical excision in a diabetic with necrotizing fasciitis of the left vulva. Photograph taken on approximately hospital day 28, when closure was performed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sweet RL, Gibbs RS. Atlas of Infectious Diseases of the Female Genital Tract. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright &copy;2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_13_40148=[""].join("\n");
var outline_f39_13_40148=null;
var title_f39_13_40149="Tapentadol: Patient drug information";
var content_f39_13_40149=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tapentadol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/20/27975?source=see_link\">",
"     see \"Tapentadol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7878273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nucynta&reg;;",
"     </li>",
"     <li>",
"      Nucynta&reg; ER",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12785498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nucynta&reg; IR;",
"     </li>",
"     <li>",
"      Nucynta&trade; CR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915067",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause trouble breathing. Call your doctor right away if you have slow breathing, shallow breathing, or trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3519322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nucynta&reg; ER is used to treat lasting, long-term pain. It is not for mild pain or pain that comes and goes. Swallow tablets whole. Do not chew, break, or crush. Very bad effects may happen if you take or inject broken, chewed, or crushed tablets. Keep away from children, can cause deadly overdose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700304",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take with beer, wine, mixed drinks, or products that have alcohol. Unsafe effects may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will be watched closely to make sure you do not misuse, abuse, or become addicted to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702986",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tapentadol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703707",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Very bad lung disease or a slow-moving GI (gastrointestinal) tract.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697135",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a history of a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697136",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a history of head injury, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Agitation, twitching, sweating, or muscle stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3927405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with other strong pain drugs or if you are using a pain patch without talking to your doctor first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695325",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting tablet: Swallow it whole. Do not chew, break, or crush it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a pain diary.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699657",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any unused drug by flushing down a toilet or sink.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12222 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-103.10.120.51-1F944A4537-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_13_40149=[""].join("\n");
var outline_f39_13_40149=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7878273\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12785498\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021548\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021550\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021549\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021554\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021555\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021557\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021552\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021553\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021558\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021559\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/20/27975?source=related_link\">",
"      Tapentadol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_13_40150="Pautrier microabscess";
var content_f39_13_40150=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F61650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F61650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mycosis fungoides",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 356px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin biopsy from a patient with mycosis fungoides, showing a large cluster of atypical lymphocytes in the epidermis (Pautrier microabscess, arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_13_40150=[""].join("\n");
var outline_f39_13_40150=null;
var title_f39_13_40151="NADPH oxidase system";
var content_f39_13_40151=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F72548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F72548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    NADPH oxidase activation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 533px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Glucose-6-phosphate dehydrogenase is required for the production of nicotinamide adenine dinucleotide phosphate (NADPH), an essential component of the NADPH oxidase system (1). The phagocyte NADPH oxidase system generates superoxide anion (O",
"    <sup>",
"     -",
"    </sup>",
"    <sub>",
"     2",
"    </sub>",
"    ) by transferring electrons from NADPH to molecular oxygen (O",
"    <sub>",
"     2",
"    </sub>",
"    ) (2). Superoxide is metabolized to hydrogen peroxide (H",
"    <sub>",
"     2",
"    </sub>",
"    O",
"    <sub>",
"     2",
"    </sub>",
"    ) by superoxide dismutase (3). Hydrogen peroxide can follow different metabolic pathways: myeloperoxidase can convert it into hypochlorus acid (HOCl) (4), which in combination with other reactive oxygen species is involved in the oxygen-dependent killing of microorganisms (5). Hydrogen peroxide can also be degraded to H",
"    <sub>",
"     2",
"    </sub>",
"    O and O",
"    <sub>",
"     2",
"    </sub>",
"    , thereby avoiding deleterious effect on the cell (6, 7, dashed lines).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_13_40151=[""].join("\n");
var outline_f39_13_40151=null;
var title_f39_13_40152="Calcitriol: Drug information";
var content_f39_13_40152=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Calcitriol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/11/10421?source=see_link\">",
"    see \"Calcitriol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/58/35751?source=see_link\">",
"    see \"Calcitriol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Calcijex&reg; [DSC];",
"     </li>",
"     <li>",
"      Rocaltrol&reg;;",
"     </li>",
"     <li>",
"      Vectical&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F144220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Calcijex&reg;;",
"     </li>",
"     <li>",
"      Rocaltrol&reg;;",
"     </li>",
"     <li>",
"      Silkis&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F144265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vitamin D Analog",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F144224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypocalcemia in patients on chronic renal dialysis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: Initial: 0.25 mcg daily; may increase dose by 0.25 mcg daily at 4- to 8-week intervals, up to 0.5-1 mcg daily; patients with normal or mildly decreased serum calcium levels may respond to 0.25 mcg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Initial: 1-2 mcg 3 times weekly approximately every other day. Adjust dose by 0.5-1 mcg at 2- to 4-week intervals; dosing range: 0.5-4 mcg 3 times weekly. Gradual dose reduction and discontinuation of therapy may be necessary as PTH levels decrease below target of (1.5-3 x ULN) in response to therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Initial: 0.5 mcg 3 times weekly, approximately every other day. Adjust dose by 0.25-0.5 mcg at 2- to 4-week intervals; dosing range: 0.5-3 mcg 3 times weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypocalcemia in hypoparathyroidism/pseudohypoparathyroidism:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Initial: 0.25 mcg daily(may adjust dose at 2- to 4-week intervals); range: 0.5-2 mcg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Initial: 0.25 mcg daily; may increase dose by 0.25 mcg daily at 2- to 4-week intervals. Discontinue use immediately for hypercalcemia; may resume therapy after calcium levels normalize.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Psoriasis:",
"     </b>",
"     Topical: Apply twice daily to affected areas (maximum: 200 g weekly); Canadian labeling recommends maximum of 30 g daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Secondary hyperparathyroidism associated with moderate-to-severe CKD in patients not on dialysis:",
"     </b>",
"     Oral: 0.25 mcg daily; may increase to 0.5 mcg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      KDOQI guidelines for vitamin D therapy in CKD (KDOQI, 2003):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CKD stage 3: Oral: 0.25 mcg daily. Treatment should only be started with serum 25(OH) D &gt;30 ng/mL, serum iPTH &gt;70 pg/mL, serum calcium &lt;9.5 mg/dL and serum phosphorus &lt;4.6 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CKD stage 4: Oral: 0.25 mcg daily. Treatment should only be started with serum 25(OH) D &gt;30 ng/mL, serum iPTH &gt;110 pg/mL, serum calcium &lt;9.5 mg/dL and serum phosphorus &lt;4.6 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CKD stage 5:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peritoneal dialysis: Oral: Initial: 0.5-1 mcg 2-3 times weekly or 0.25 mcg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hemodialysis:",
"     <b>",
"      Note:",
"     </b>",
"     The following initial doses are based on plasma PTH and serum calcium levels for patients with serum phosphorus &lt;5.5 mg/dL and Ca-P product &lt;55. Adjust dose based on serum phosphate, calcium, and PTH levels. Intermittent I.V. administration may be more effective than daily oral dosing. Administer per hemodialysis session.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Plasma PTH 300-600 pg/mL and serum Ca &lt;9.5 mg/dL: Oral, I.V.: 0.5-1.5 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Plasma PTH 600-1000 pg/mL and serum Ca &lt;9.5 mg/dL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Oral: 1-4 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     I.V.: 1-3 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Plasma PTH &gt;1000 pg/mL and serum Ca &lt;10 mg/dL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Oral: 3-7 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     I.V.: 3-5 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vitamin D-dependent rickets type 1/pseudovitamin D deficiency rickets (PDDR):",
"     </b>",
"     <i>",
"      U.S. unlabeled use:",
"     </i>",
"     Oral: Initial: 0.5 mcg twice daily; subsequent dosing adjusted to  maintain normal serum calcium and PTH levels; median dose after 2 years: 0.25 mcg daily (range: 0.1-0.5 mcg daily) (Edouard, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vitamin D-resistant rickets:",
"     </b>",
"     <i>",
"      Canadian labeling (not in U.S. labeling):",
"     </i>",
"     Oral: Initial: 0.25 mcg daily; may increase dose by 25 mcg daily at 2- to 4-week intervals if response is inadequate; discontinue use immediately for hypercalcemia and do not resume until calcium levels normalize.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F144244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/58/35751?source=see_link\">",
"      see \"Calcitriol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypocalcemia in hypoparathyroidism/pseudohypoparathyroidism:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 1-5 years: Usual dosage range: 0.25-0.75 mcg once daily (may adjust dose at 2- to 4-week intervals)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;6 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Oral: Children: Initial: 0.03-0.05 mcg/kg/day; evaluate response after 2 weeks and increase dose by 25% if response is inadequate. Dose may be increased or decreased by 25% every 2 weeks thereafter until therapeutic response is achieved.",
"     <b>",
"      Note:",
"     </b>",
"     May consider initial dose of 0.05 mcg/kg/day for severe hypocalcemia/ symptoms (hospitalization recommended with close monitoring and dose reduction as soon as clinically possible). Maintenance dose: 0.014-0.04 mcg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Secondary hyperparathyroidism associated with moderate-to-severe CKD in patients not on dialysis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;3 years: Initial dose: 0.01-0.015 mcg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;3 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      KDOQI guidelines for vitamin D therapy in CKD:",
"     </b>",
"     Children (KDOQI, 2005):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CKD stage 2, 3: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;10 kg: 0.05 mcg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10-20 kg: 0.1-0.15 mcg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;20 kg: 0.25 mcg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Treatment should only be started with serum 25(OH) D &gt;30 ng/mL, serum iPTH &gt;70 pg/mL, serum calcium &lt;10 mg/dL and serum phosphorus less than or equal to the age appropriate level.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CKD stage 4: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;10 kg: 0.05 mcg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10-20 kg: 0.1-0.15 mcg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;20 kg: 0.25 mcg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Treatment should only be started with serum 25(OH) D &gt;30 ng/mL, serum iPTH &gt;110 pg/mL, serum calcium &lt;10 mg/dL and serum phosphorus less than or equal to the age appropriate level.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CKD stage 5: Peritoneal dialysis or hemodialysis: Oral, I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     The following initial doses are based on plasma PTH and serum calcium levels for patients with serum phosphorus &lt;5.5 mg/dL in adolescents or &lt;6.5 in infants and children, and Ca-P product &lt;55 in adolescents or &lt;65 in infants and children &lt;12 years. Adjust dose based on serum phosphate, calcium and PTH levels. Administer dose with each dialysis session (3 times weekly). Intermittent I.V./oral administration is more effective than daily oral dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Plasma PTH 300-500 pg/mL and serum Ca &lt;10 mg/dL: 0.0075 mcg/kg (maximum: 0.25 mcg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Plasma PTH &gt;500-1000 pg/mL and serum Ca &lt;10 mg/dL: 0.015 mcg/kg (maximum: 0.5 mcg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Plasma PTH &gt;1000 pg/mL and serum Ca &lt;10.5 mg/dL: 0.025 mcg/kg (maximum: 1 mcg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vitamin D-dependent rickets type 1/pseudovitamin D deficiency rickets (PDDR):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      U.S. unlabeled use:",
"     </i>",
"     Children: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Children: Initial: 0.01-0.025 mcg/kg/day; evaluate response after two weeks and increase dose by 25% if response is inadequate. Dose may be increased or decreased by 25% every 2 weeks thereafter until therapeutic response is achieved.",
"     <b>",
"      Note:",
"     </b>",
"     May consider initial dose of 0.05 mcg/kg/day for severe hypocalcemia/ symptoms (hospitalization recommended with close monitoring and dose reduction as soon as clinically possible). Maintenance dose: 0.0046-0.015 mcg/kg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      X-linked hypophosphatemic rickets:",
"     </b>",
"     <i>",
"      Canadian labeling (not in U.S. labeling):",
"     </i>",
"     Children: Oral: Initial: 0.01-0.02 mcg/kg/day; evaluate response after 2 weeks and increase dose by 25% if response is inadequate. Dose may be increased or decreased by 25% every two weeks thereafter until therapeutic response is achieved.",
"     <b>",
"      Note:",
"     </b>",
"     May consider initial dose of 0.05 mcg/kg/day for severe hypocalcemia/ symptoms (hospitalization recommended with close monitoring and dose reduction as soon as clinically possible). Maintenance dose: 0.01-0.05 mcg/kg/day.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F144225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Start at the lower end of the dosage range.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15241758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F144266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      KDOQI guidelines:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Children (KDOQI, 2005): CKD stages 2-4:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Serum iPTH below target range: Hold calcitriol until levels rise above target range appropriate for CKD stage, than resume treatment at half the previous dose. If the lowest dose was being used, switch to alternate day therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Corrected total calcium &gt;10.2 mg/dL: Hold calcitriol until serum calcium returns to &lt;9.8 mg/dL then resume treatment at half the previous dose. If the lowest dose was being used, switch to alternate day therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Serum phosphorus greater than the age appropriate limits: Hold calcitriol and add/increase dose of phosphate binder until levels of phosphorous decrease to age appropriate levels, then resume at half the previous dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Adults (KDOQI, 2003): CKD stage 3 and 4:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     iPTH below target: Hold calcitriol until levels rise then resume treatment at half the previous dose. If the lowest dose was being used, switch to alternate day therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Corrected total calcium &gt;9.5 mg/dL: Hold calcitriol until serum calcium returns to &lt;9.5 mg/dL, then resume treatment at half the previous dose. If the lowest dose was being used, switch to alternate day therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Serum phosphorus &gt;4.6 mg/dL: Hold calcitriol (or add/increase dose of phosphate binder) until levels of phosphorous decrease, then resume at half the prior dose.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral: 0.25 mcg, 0.5 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rocaltrol&reg;: 0.25 mcg, 0.5 mcg [contains coconut oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 1 mcg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Calcijex&reg;: 1 mcg/mL (1 mL [DSC]) [contains aluminum]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vectical&reg;: 3 mcg/g (100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 1 mcg/mL (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rocaltrol&reg;: 1 mcg/mL (15 mL) [contains palm oil]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F15241805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Silkis&trade;: 3 mcg/g (5 g, 30 g, 100 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes ointment",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F144199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: May be administered as a bolus dose I.V. through the catheter at the end of hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: May be administered without regard to food. Administer with meals to reduce GI problems.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical: Apply externally; not for ophthalmic, oral, or intravaginal use. Do not apply to eyes, lips, or facial skins. Rub in gently so that no medication remains visible. Limit application to only the areas of skin affected by psoriasis.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F144272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, sterile water for injection.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F144198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Management of hypocalcemia in patients on chronic renal dialysis (oral, injection); management of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) (oral); management of hypocalcemia in patients with hypoparathyroidism and pseudohypoparathyroidism (oral); management of mild-to-moderate plaque psoriasis (topical)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Canadian labeling: Additional uses (not in U.S. labeling): Vitamin D-resistant rickets (oral)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F144262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vitamin D-dependent rickets type I/pseudovitamin D deficiency rickets (PDDR)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F144274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Calcitriol may be confused with alfacalcidol, Calciferol&trade;, calcitonin, calcium carbonate, captopril, colestipol, paricalcitol, ropinirole",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Dosage is expressed in mcg (micrograms),",
"       <b>",
"        not",
"       </b>",
"       mg (milligrams); rare cases of acute overdose have been reported",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F144263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oral, I.V.:",
"     </b>",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrhythmia, hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Apathy, headache, hyperthermia, psychosis, sensory disturbances, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Erythema multiforme, erythematous skin disorders, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration, growth suppression, hypercalcemia, hypercholesterolemia, libido decreased, polydipsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, metallic taste, nausea, pancreatitis, stomach ache, vomiting, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Nocturia, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site pain (mild)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone pain, myalgia, dystrophy, soft tissue calcification, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis, photophobia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Albuminuria, BUN increased, creatinine increased, hypercalciuria, nephrocalcinosis, polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, hypersensitivity reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Topical:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     &gt;10%: Endocrine: Hypercalcemia (24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Psoriasis (4%), skin discomfort (3%), pruritus (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: Urine abnormality (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Renal: Hypercalciuria (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Kidney stones",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F144202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     U.S. labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral, injection: Hypersensitivity to calcitriol or any component of the formulation; hypercalcemia, vitamin D toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Topical: There are no contraindications listed in the manufacturer's labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canadian labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral, injection: Hypersensitivity to calcitriol, vitamin D or its analogues or derivatives, or any component of the formulation or container; hypercalcemia, vitamin D toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Topical: Ophthalmic or internal use; hypercalcemia or a history of abnormal calcium metabolism; concurrent systemic treatment of calcium homeostasis; severe renal impairment or end-stage renal disease (ESRD)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F144182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Excessive vitamin D: Excessive vitamin D administration may lead to over suppression of PTH, progressive or acute hypercalcemia, hypercalciuria, hyperphosphatemia and adynamic bone disease. Withhold pharmacologic doses of vitamin D and its derivatives during therapy to avoid the potential for hypercalcemia to develop. In addition, several months may be required for ergocalciferol levels to return to baseline in patients switching from ergocalciferol therapy to calcitriol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercalcemia: Monitor calcium levels closely with initiation of therapy and with dose adjustments; discontinue use promptly in patients who develop hypercalcemia. Avoid abrupt dietary modifications (eg, increased intake of dairy products) which may lead to hypercalcemia; adjust calcium intake if indicated and maintain adequate hydration. Chronic hypercalcemia can result in generalized vascular and soft tissue calcification. Immobilized patients may be at a higher risk for hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Canadian labeling (topical formulation) does not recommend use in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malabsorption syndrome: Use oral calcitriol with caution in patients with malabsorption syndromes; efficacy may be limited and/or response may be unpredictable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use of calcitriol for the treatment of secondary hyperparathyroidism associated with CKD is not recommended in patients with rapidly worsening kidney function or in noncompliant patients. Increased serum phosphate levels in patients with renal failure may lead to ectopic calcification; the use of an aluminum-containing phosphate binder is recommended along with a low phosphate diet in these patients. Canadian labeling (topical formulation) does not recommend use in patients with mild-to-moderate renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium: Adequate dietary (supplemental) calcium is necessary for clinical response to vitamin D.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac glycosides: Use with caution in patients taking cardiac glycosides; digitalis toxicity is potentiated by hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Magnesium-containing products: Concomitant use with magnesium-containing products such as antacids may lead to hypermagnesemia in patients receiving chronic renal dialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coconut oil: Products may contain coconut oil (capsule).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Palm seed oil: Products may contain palm seed oil (oral solution).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tartrazine: Some products may contain tartrazine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical: May cause hypercalcemia; if alterations in calcium occur, discontinue treatment until levels return to normal. For external use only; not for ophthalmic, oral, or intravaginal use.  Do not apply to facial skin, eyes, or lips. Absorption may be increased with occlusive dressings. Avoid or limit excessive exposure to natural or artificial sunlight, or phototherapy. The safety and effectiveness has not been evaluated in patients with erythrodermic, exfoliative, or pustular psoriasis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium-phosphate product: Discontinue use immediately in patients with a calcium-phosphate product  (serum calcium times phosphorus) &gt;70 mg",
"     <sup>",
"      2",
"     </sup>",
"     /dL",
"     <sup>",
"      2",
"     </sup>",
"     ; may resume therapy at decreased doses when levels are appropriate.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F144260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F144187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the therapeutic effect of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcitriol may increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May decrease the serum concentration of Vitamin D Analogs. More specifically, orlistat may impair absorption of Vitamin D Analogs. Management: Monitor clinical response (including serum calcium) to oral vitamin D analogs closely if used with orlistat.  If this combination must be used, consider giving the vitamin D analog at least 2 hrs before or after orlistat.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sevelamer: May decrease the serum concentration of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F144190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5078799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in some animal reproduction studies. Mild hypercalcemia has been reported in a newborn following maternal use of calcitriol during pregnancy. Adverse effects on fetal development were not observed with use of calcitriol during pregnancy in women (N=9) with pseudovitamin D-dependent rickets. Doses were adjusted every 4 weeks to keep calcium concentrations within normal limits (Edouard, 2011). If calcitriol is used for the management of hypoparathyroidism in pregnancy, dose adjustments may be needed as pregnancy progresses and again following delivery. Vitamin D and calcium levels should be monitored closely and kept in the lower normal range.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F144230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5078801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Low levels are found in breast milk (~2 pg/mL)",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F144205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to food. Give with meals to reduce GI problems. Adequate calcium intake should be maintained during therapy; dietary phosphorous may need to be restricted.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F144204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Calcitriol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mcg (100): $120.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mcg (100): $193.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Rocaltrol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mcg (30): $51.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mcg (100): $268.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Calcitriol External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mcg/g (100 g): $640.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Vectical External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mcg/g (100 g): $713.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Calcitriol Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mcg/mL (1 mL): $6.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Calcitriol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mcg/mL (15 mL): $179.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Rocaltrol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mcg/mL (15 mL): $214.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F144192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Manufacturer&rsquo;s labeling:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dialysis patients: Serum calcium, phosphorus, magnesium, and alkaline phosphate monitored periodically",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hypoparathyroid patients: Serum calcium, phosphorus, 24 hour urinary calcium monitored periodically",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Predialysis patients: Serum calcium, phosphorus, alkaline phosphatase, creatinine, and intact PTH, initially; then serum calcium, phosphorus, alkaline phosphatase, and creatinine monthly x 6 months, then periodically. Intact PTH should be monitored every 3-4 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     During titration periods (all patients), monitor serum calcium levels at least twice weekly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. therapy:  Serum calcium and phosphorus twice weekly (following initiation and during dosage adjustments) and periodically during therapy; periodic magnesium, alkaline phosphatase, 24 hour urinary calcium and phosphorous",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      KDOQI Guidelines:",
"     </b>",
"     Oral and I.V. therapy:",
"     <b>",
"      Note:",
"     </b>",
"     More frequent monitoring may be necessary depending on the presence and magnitude of abnormalities, the rate of progression of CKD, and the use of treatments for CKD-mineral and bone disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Children (KDOQI, 2005):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Serum calcium and phosphorous: CKD stages 2-4: At least monthly for first 3 months following initiation of therapy and at least every 3 months thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     CKD stage 5: At least every 2 weeks for one month following initiation of therapy and dose increases and monthly thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Serum iPTH:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     CKD stages 2-4: At least every 3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     CKD stage 5: Monthly for at least 3 months following initiation of therapy or dose increases; once target levels are achieved monitor at least every 3 months thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Adults (KDOQI, 2003):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Serum calcium and phosphorous:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     CKD stages 3 and 4: At least monthly for first 3 months following initiation of therapy and every 3 months thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     CKD stage 5: At least every 2 weeks for one month following initiation of therapy or dose increases and monthly thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Serum iPTH:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     CKD stages 3 and 4: At least every 3 months for 6 months and every 3 months thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     CKD stage 5: Monthly for at least 3 months following initiation of therapy or dose increases and at least every 3 months once target levels are achieved",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F144195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corrected total serum calcium (KDOQI, 2003): CKD stages 3 and 4: 8.4-10.2 mg/dL (2.1-2.6 mmol/L); CKD stage 5: 8.4-9.5 mg/dL (2.1-2.37 mmol/L); KDIGO guidelines recommend maintaining normal ranges for all stages of CKD (3-5D) (KDIGO, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphorus (KDOQI, 2003):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CKD stages 3 and 4: 2.7-4.6 mg/dL (0.87-1.48 mmol/L) (adults); maintain within age-appropriate limits (children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CKD stage 5 (including those treated with dialysis): 3.5-5.5 mg/dL (1.13-1.78 mmol/L) (children &gt;12 years and adults); 4-6 mg/dL (1.29-1.94 mmol/L) (children 1-12 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     KDIGO guidelines recommend maintaining normal ranges for CKD stages 3-5 and lowering elevated phosphorus levels toward the normal range for CKD stage 5D (KDIGO, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum calcium-phosphorus product (KDOQI, 2003): CKD stage 3-5: &lt;55 mg",
"     <sup>",
"      2",
"     </sup>",
"     /dL",
"     <sup>",
"      2",
"     </sup>",
"     (children &gt;12 years and adults); &lt;65 mg",
"     <sup>",
"      2",
"     </sup>",
"     /dL",
"     <sup>",
"      2",
"     </sup>",
"     (children &le;12 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PTH: Whole molecule, immunochemiluminometric assay (ICMA): 1.0-5.2 pmol/L; whole molecule, radioimmunoassay (RIA): 10.0-65.0 pg/mL; whole molecule, immunoradiometric, double antibody (IRMA): 1.0-6.0 pmol/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Target ranges by stage of chronic kidney disease (KDIGO, 2009): CKD stage 3-5: Optimal iPTH is unknown; maintain normal range (assay-dependent); CKD stage 5D: Maintain iPTH within 2-9 times the upper limit of normal for the assay used",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F144206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Altrol (MX);",
"     </li>",
"     <li>",
"      Bocatriol (DE);",
"     </li>",
"     <li>",
"      Bonky (HK, KP);",
"     </li>",
"     <li>",
"      Cacare (TH);",
"     </li>",
"     <li>",
"      Calcijex (AU, CL, GB, HU, LU, MY, TW);",
"     </li>",
"     <li>",
"      Calcit (ID);",
"     </li>",
"     <li>",
"      Calcit SG (TH);",
"     </li>",
"     <li>",
"      Calcitriol (CO);",
"     </li>",
"     <li>",
"      Caleobrol (PY);",
"     </li>",
"     <li>",
"      Caraben (KP);",
"     </li>",
"     <li>",
"      Decostriol (DE, TH);",
"     </li>",
"     <li>",
"      Ecatrol (ID);",
"     </li>",
"     <li>",
"      Gyneamsa (MX);",
"     </li>",
"     <li>",
"      Hitrol (ID);",
"     </li>",
"     <li>",
"      Kolkatriol (ID);",
"     </li>",
"     <li>",
"      Kosteo (AU);",
"     </li>",
"     <li>",
"      Lemytriol (MX);",
"     </li>",
"     <li>",
"      Macolol (TW);",
"     </li>",
"     <li>",
"      Meditrol (TH);",
"     </li>",
"     <li>",
"      Nafartol (MX);",
"     </li>",
"     <li>",
"      Neobon (KP);",
"     </li>",
"     <li>",
"      Osteo-D (TW);",
"     </li>",
"     <li>",
"      Osteocap (MY);",
"     </li>",
"     <li>",
"      Osteotriol (DE);",
"     </li>",
"     <li>",
"      Poscal (KP);",
"     </li>",
"     <li>",
"      Raquitriol (AR);",
"     </li>",
"     <li>",
"      Renatriol (DE);",
"     </li>",
"     <li>",
"      Rocaltriol (DK);",
"     </li>",
"     <li>",
"      Rocaltrol (AE, AT, AU, BB, BE, BG, BH, BM, BR, BS, BZ, CH, CL, CN, CO, CY, CZ, DE, EC, EE, EG, ES, FI, FR, GB, GH, GY, HK, HN, HR, HU, IE, IL, IQ, IR, IT, JM, JO, JP, KE, KP, KW, LB, LU, LY, MT, MX, NL, NO, NZ, OM, PE, PH, PK, PL, PT, QA, RU, SA, SE, SG, SK, SR, SY, TH, TR, TT, TW, TZ, UG, UY, VE, YE, ZM);",
"     </li>",
"     <li>",
"      Roical (MY);",
"     </li>",
"     <li>",
"      Rolsical (IN);",
"     </li>",
"     <li>",
"      Sical (AU);",
"     </li>",
"     <li>",
"      Silkis (ES, FR, GB, GR, HK, IE, MX, NO, SG, TW);",
"     </li>",
"     <li>",
"      Tariol (KP);",
"     </li>",
"     <li>",
"      Tirocal (MX);",
"     </li>",
"     <li>",
"      Triocalcit (PE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F144181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcitriol is a potent active metabolite of vitamin D. Vitamin D promotes absorption of calcium in the intestines and retention at the kidneys thereby increasing calcium levels in the serum; decreases excessive serum phosphatase levels, parathyroid hormone levels, and decreases bone resorption; increases renal tubule phosphate resorption",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The mechanism by which calcitriol is beneficial in the treatment of psoriasis has not been established.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F144201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Oral, I.V.: 3-5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99.9%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily to calcitroic acid and a lactone metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Children ~27 hours; Healthy adults: 5-8 hours; Hemodialysis: 16-22 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: 3-6 hours; Hemodialysis: 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily feces; urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Callies F, Arlt W, Scholz HJ, et al, &ldquo;Management of Hypoparathyroidism During Pregnancy -- Report of Twelve Cases,&rdquo;",
"      <i>",
"       Eur J Endocrinol",
"      </i>",
"      , 1998, 139(3):284-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/13/40152/abstract-text/9758437/pubmed\" id=\"9758437\" target=\"_blank\">",
"        9758437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Edouard T, Alos N, Chabot G, et al, &ldquo;Short- and Long-Term Outcome of Patients with Pseudo-Vitamin D Deficiency Rickets Treated with Calcitriol,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2011, 96(1):82-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/13/40152/abstract-text/20926527/pubmed\" id=\"20926527\" target=\"_blank\">",
"        20926527",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Children With Chronic Kidney Disease.&rdquo; Available at  file://www.kidney.org/professionals/KDOQI/guidelines_pedbone/index.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Guideline 1. Evaluation of Calcium and Phosphorus Metabolism.&rdquo; Available at  file://www.kidney.org/professionals/KDOQI/guidelines_pedbone/guide1.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification, Part 4. Definition and Classification of Stages of Chronic Kidney Disease.&rdquo; Available at  file://www.kidney.org/professionals/KDOQI/guidelines_ckd/p4_class.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Guideline 3. Evaluation of Serum Phosphorus Levels.&rdquo; Available at  file://www.kidney.org/professionals/KDOQI/guidelines_bone/Guide3.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Guideline 6. Serum Calcium and Calcium-Phosphorus Product.&rdquo; Available at  file://www.kidney.org/professionals/KDOQI/guidelines_bone/Guide6.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Guideline 8A. Active Vitamin D Therapy in Patients With Stages 3 and 4 CKD.&rdquo; Available at  file://www.kidney.org/professionals/KDOQI/guidelines_bone/Guide8A.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Guideline 8B. Vitamin D Therapy in Patients on Dialysis (CKD Stage 5).&rdquo; Available at  file://www.kidney.org/professionals/KDOQI/guidelines_bone/Guide8B.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, \"KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD),\"",
"      <i>",
"       Kidney Int Suppl",
"      </i>",
"      , 2009, 76(S113):1-130.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/13/40152/abstract-text/19644521/pubmed\" id=\"19644521\" target=\"_blank\">",
"        19644521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Letsou AP and Price LS, &ldquo;Health Aging and Nutrition: An Overview,&rdquo;",
"      <i>",
"       Clin Geriatr Med",
"      </i>",
"      , 1987, 3(2):253-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/13/40152/abstract-text/3555761/pubmed\" id=\"3555761\" target=\"_blank\">",
"        3555761",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Myrianthopoulos M, &ldquo;Dietary Treatment of Hyperlipidemia in the Elderly,&rdquo;",
"      <i>",
"       Clin Geriatr Med",
"      </i>",
"      , 1987, 3(2):343-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/13/40152/abstract-text/3581018/pubmed\" id=\"3581018\" target=\"_blank\">",
"        3581018",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Uhlig K, Berns JS, Kestenbaum B, et al, &ldquo;KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD),",
"      <i>",
"       Am J of Kidney Disease",
"      </i>",
"      , 2010, 55 (5):773-99.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/13/40152/abstract-text/20363541/pubmed\" id=\"20363541\" target=\"_blank\">",
"        20363541",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9183 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-83.177.194.223-190351C039-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_13_40152=[""].join("\n");
var outline_f39_13_40152=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144219\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144220\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144265\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144224\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144244\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144225\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682398\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15241758\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144266\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144194\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15241805\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144178\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144199\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144272\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144198\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144262\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144274\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144263\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144202\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144182\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144260\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144187\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144190\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5078799\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144230\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5078801\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144205\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144204\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144192\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144195\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144206\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144181\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144201\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9183\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9183|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/11/10421?source=related_link\">",
"      Calcitriol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/58/35751?source=related_link\">",
"      Calcitriol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_13_40153="Mycoplasma genitalium infection in men and women";
var content_f39_13_40153=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mycoplasma genitalium infection in men and women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/13/40153/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/13/40153/contributors\">",
"     Victoria Mobley, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/13/40153/contributors\">",
"     Arlene C Se&ntilde;a, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/13/40153/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/13/40153/contributors\">",
"     Noreen A Hynes, MD, MPH, DTM&amp;H",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/13/40153/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/13/40153/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/13/40153/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11966203\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycoplasma genitalium is a bacterium that is a common cause of nongonococcal urethritis (NGU) in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/1-4\">",
"     1-4",
"    </a>",
"    ] and an emerging cause of cervicitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/5-9\">",
"     5-9",
"    </a>",
"    ] and pelvic inflammatory disease (PID) in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/10-15\">",
"     10-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    M. genitalium infection is discussed here. Other causes of urethritis, cervicitis, and pelvic inflammatory disease are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/43/19126?source=see_link\">",
"     \"Infectious causes of dysuria in adult men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/64?source=see_link\">",
"     \"Acute cervicitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/20/38217?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of Neisseria gonorrhoeae infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10729?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Chlamydia trachomatis infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infections caused by other Mycoplasma species are also discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/5/3162?source=see_link\">",
"     \"Mycoplasma pneumoniae infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/35/6713?source=see_link\">",
"     \"Mycoplasma pneumoniae infection in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/28/31177?source=see_link\">",
"     \"Mycoplasma hominis, Mycoplasma genitalium, and Ureaplasma urealyticum infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11966210\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. genitalium was first described in 1981 after being isolated from the urethral specimens of two men diagnosed with nongonococcal urethritis (NGU) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/16\">",
"     16",
"    </a>",
"    ]. It is a member of the Mycoplasmataceae family and Mollicutes class of bacteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/17\">",
"     17",
"    </a>",
"    ]. It lacks a cell wall and is thus not visible following Gram staining. With a genome of only 580 kilobases in size, M. genitalium is the smallest known free-living bacterium. Its genomic structure is similar to the larger and more well-known pathogen Mycoplasma pneumoniae, a cause of atypical bacterial pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/5/3162?source=see_link\">",
"     \"Mycoplasma pneumoniae infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Culture of M. genitalium is difficult, as the organism is fastidious and may require one to two months to grow. Growth is optimal at 37&deg; Celsius in an anaerobic atmosphere of nitrogen with 5 percent CO",
"    <sub>",
"     2",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/19\">",
"     19",
"    </a>",
"    ]. On culture, M. genitalium does not produce hemolysis, and its colonies look like a &ldquo;fried egg,&rdquo; having a dense center and paler outer zone. On electron microscopy, the organism has a flask or bottle-like shape.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11966217\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. genitalium has been isolated from multiple tissue sites, including the respiratory tract and synovial fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/20\">",
"     20",
"    </a>",
"    ], but its association with clinical disease appears to be limited to the urogenital tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Studies in both male and female nonhuman primates, in which genital infection developed following urogenital inoculation of M. genitalium, demonstrate its pathogenicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/23\">",
"     23",
"    </a>",
"    ]. A specialized terminal tip-like structure allows M. genitalium to attach and adhere to the surface of epithelial cells, but unlike most other mycoplasmas, it is also able to invade these cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/19\">",
"     19",
"    </a>",
"    ]. Upon entry into the epithelial cell, M. genitalium evades the host immune response through modulation of the immune system, including suppression and stimulation of lymphocytes and upregulation of cytokine expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/24\">",
"     24",
"    </a>",
"    ]. The tissue destruction caused by M. genitalium is partially due to the secretion of mycoplasmal toxins and harmful metabolites like",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    . However, the majority of clinical disease associated with M. genitalium infection is thought to be due to the host&rsquo;s immune response to cell invasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/22\">",
"     22",
"    </a>",
"    ]. M. genitalium can persist for months or years in infected individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11966231\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H860473\">",
"    <span class=\"h2\">",
"     Disease associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiological studies have linked M. genitalium infection with urethritis in men and, to a lesser extent, cervicitis and pelvic inflammatory disease (PID) in women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11966254\">",
"    <span class=\"h3\">",
"     Nongonococcal urethritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with M. genitalium has been strongly associated with acute nongonococcal urethritis (NGU). In a meta-analysis of 19 observational studies that evaluated M. genitalium infection using polymerase chain reaction (PCR) assays, 436 of 2069 patients with NGU (21.1 percent) had M. genitalium detected compared with 121 of 1810 controls (6.7 percent, pooled odds ratio [OR] 3.8, 95% CI 3.0-4.9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/22,25\">",
"     22,25",
"    </a>",
"    ]. Subsequent systematic reviews of additional observational studies have supported this association, which is particularly strong in cases of nonchlamydial NGU (NCNGU) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/19,26\">",
"     19,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    M. genitalium infection accounts for 15 to 25 percent of NGU cases reported per year among men in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/27\">",
"     27",
"    </a>",
"    ]. Among men with NCNGU, M. genitalium has been detected in 18 to 46 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/28\">",
"     28",
"    </a>",
"    ]. Similarly, M. genitalium detection is frequent in men with persistent or recurrent urethritis following empiric therapy, particularly when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    instead of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    was used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/19,26,29\">",
"     19,26,29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11966325\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    M. genitalium may also be associated with urethritis in women, although data are too limited to draw clear conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/19,26\">",
"     19,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11966261\">",
"    <span class=\"h3\">",
"     Cervicitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. genitalium is a newly recognized sexually transmitted infection (STI) in women, although its role in cervicitis is not fully established as epidemiological studies are conflicting. Several studies have reported associations between M. genitalium detection and clinical signs or symptoms of cervicitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/6-9,30\">",
"     6-9,30",
"    </a>",
"    ]. As an example, in a study of 719 women who had cervical specimens obtained at an STI clinic, women with M. genitalium detected by PCR were more likely to have mucopurulent cervicitis (defined by the presence of either visible purulent discharge or &ge;30 polymorphonuclear cells [PMNs] per high power field on Gram stain of cervical smear) compared with those without detectable M. genitalium (48 versus 28.6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/9\">",
"     9",
"    </a>",
"    ]. After controlling for infections with other STIs that cause cervicitis, the study observed a threefold increased risk of mucopurulent cervicitis in women infected with M. genitalium.",
"   </p>",
"   <p>",
"    In contrast, other studies of high-risk female populations have failed to demonstrate an association between M. genitalium detection and cervicitis, despite high M. genitalium detection rates. In one prospective study of 170 women who presented to an STI clinic in France with abnormal vaginal discharge, the prevalence of M. genitalium was 38 percent, but its detection was not associated with signs (erythematous cervix, mucopurulent discharge, or &ge;10 PMNs per high power field in the cervical smear) or symptoms of cervicitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/31\">",
"     31",
"    </a>",
"    ]. Similarly, in a study of 331 adolescent women presenting with genitourinary symptoms or STI risk factors to an urban health center in the United States, M. genitalium was detected in 22.4 percent but was not associated with vaginal symptoms or signs (purulent cervical discharge or cervical friability) of cervicitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inconsistent associations between M. genitalium and cervicitis are likely due to the lack of a standard definition of cervicitis. Most, but not all studies that defined cervicitis as &ge;30 PMNs per high power field in the cervical smear observed higher rates of M. genitalium among women with than without cervicitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/26\">",
"     26",
"    </a>",
"    ]. Nevertheless, further study is warranted to clarify its association with cervicitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11966268\">",
"    <span class=\"h3\">",
"     Pelvic inflammatory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. genitalium can ascend from the lower to upper genital tract after sexual transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/24\">",
"     24",
"    </a>",
"    ], and several studies have observed associations between detection of the organism and clinical signs or symptoms of PID [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/12,13,33-35\">",
"     12,13,33-35",
"    </a>",
"    ]. The following studies illustrate the range of findings:",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 50 women with nongonococcal, nonchlamydial PID, M. genitalium was present in 14 percent of endometrial biopsies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of women presenting to a Kenyan STI clinic with pelvic pain, M. genitalium was detected from cervical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      endometrial samples more frequently in the 58 women with histologically diagnosed endometritis than in the 57 without (16 versus 2 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study of 2246 sexually active female college students, the baseline prevalence of M. genitalium in self-collected vaginal specimens was low (3.3 percent), and there was a nonsignificant increase in incidence of PID over a 12-month period among women with detectable M. genitalium compared with those in whom it was not detected (risk ratio 2.35, 95% CI 0.74-7.46) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a smaller prospective study of women undergoing termination of pregnancy in Sweden, the incidence of postprocedure PID was higher among the 49 women who tested positive for M. genitalium at baseline than among the 168 STI-negative controls matched for age and procedure (12.2 versus 2.4 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these findings suggest a possible association and causative role between M. genitalium and PID.",
"   </p>",
"   <p>",
"    Although PID in general is associated with infertility, it is unclear whether M. genitalium leads to tubal factor infertility, with different studies showing conflicting results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23915319\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In studies from the United States, the prevalence of M. genitalium is approximately 1 percent among young adults in the general population, placing it between that of Neisseria gonorrhoeae (0.4 percent) and Chlamydia trachomatis (2.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/36\">",
"     36",
"    </a>",
"    ]. Globally, the prevalence estimates of M. genitalium range between 1 to 4 percent among men and 1 to 6.4 percent among women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/37\">",
"     37",
"    </a>",
"    ]. Much higher M. genitalium rates have been reported among STI clinic attendees, ranging from 4 to 38 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. As an example, one study found a prevalence of M. genitalium of 7.7 percent in women attending a Seattle STI clinic, compared with a prevalence of 5.8 percent for C. trachomatis and 2.4 percent for N. gonorrhoeae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23914721\">",
"    <span class=\"h2\">",
"     Risk factors for infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors associated with M. genitalium infection appear to be similar to those associated with C. trachomatis infection. In studies from the United States and Europe, these include young age (eg, &lt;20 to 22 years old), smoking, nonwhite race, recent sexual intercourse, and an increasing number of sexual partners [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/9,30,32,39-42\">",
"     9,30,32,39-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, having had &ge;2 sexual partners over the previous year and bacterial vaginosis were independently associated with M. genitalium colonization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/33\">",
"     33",
"    </a>",
"    ]. In a study of female sex workers in Uganda, the prevalence of M. genitalium was higher in HIV-positive women than in HIV-negative women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23915541\">",
"     'Co-infection with other sexually transmitted infections'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23915130\">",
"    <span class=\"h3\">",
"     Evidence of sexual transmissibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sexual transmissibility of M. genitalium is demonstrated by both clinical and molecular epidemiologic evidence. As above, M. genitalium is detected more frequently among sexually-experienced than sexually-naive adolescents, and infection is associated with an increasing number of sexual partners [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/9,33,36,40,41\">",
"     9,33,36,40,41",
"    </a>",
"    ]. Additionally, the organism is more likely to be detected from the sexual partners of M. genitalium-positive compared with negative individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/1,8,40,44,45\">",
"     1,8,40,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, in DNA-typing studies, sexual partners who were concurrently infected with M. genitalium often harbor genomically-identical bacterial strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. In one study comparing the M. genitalium genotype profiles of 31 concurrently infected couples and 74 unrelated pairs of individuals, a concordance rate of 87.1 percent was observed for the couples compared with only 5.4 percent for the unrelated pairs of individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23915541\">",
"    <span class=\"h2\">",
"     Co-infection with other sexually transmitted infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Co-infections with M. genitalium and other STIs have frequently been reported among high-risk men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/31,32,40,43,49-51\">",
"     31,32,40,43,49-51",
"    </a>",
"    ]. As an example, in a study of men with urethritis, 35 percent of those with C. trachomatis, 14 percent of those with N. gonorrhoeae, and 19 percent with both infections were also infected with M. genitalium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/50\">",
"     50",
"    </a>",
"    ]. C. trachomatis is the most commonly reported co-infecting organism. The high frequency of STI co-infections in M. genitalium-positive individuals suggests the possibility of shared epidemiologic characteristics. It has also created challenges in discerning the independent role of this pathogen in the development of urogenital disease.",
"   </p>",
"   <p>",
"    Numerous observational studies have suggested an association between M. genitalium and HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/43,52-57\">",
"     43,52-57",
"    </a>",
"    ]. In a nested case-control analysis, M. genitalium was detected more frequently in the 183 women who subsequently became infected with HIV compared with the 337 matched controls (14.8 versus 6.5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11966282\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11966290\">",
"    <span class=\"h2\">",
"     Urethritis in men",
"    </span>",
"    &nbsp;&mdash;&nbsp;When present, the typical symptoms of urethritis caused by M. genitalium are similar to those reported in urethritis from other causes and include dysuria, urethral pruritus, and purulent or mucopurulent urethral discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/58\">",
"     58",
"    </a>",
"    ]. Although up to 42 percent of nongonococcal urethritis (NGU) cases are asymptomatic, NGU due to M. genitalium infection is more frequently associated with symptomatic urethritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/1,4,7,42\">",
"     1,4,7,42",
"    </a>",
"    ]. As an example, in one study of 30 men with M. genitalium infection, 70 percent reported symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On exam, urethral discharge is often present. However, the discharge may not be grossly evident, and urethral stripping, or milking, may be necessary for detection, in contrast with gonococcal urethritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/50\">",
"     50",
"    </a>",
"    ]. Gram stain of the discharge generally shows more than five polymorphonuclear leukocytes per high-powered field.",
"   </p>",
"   <p>",
"    M. genitalium infection may also be associated with balanitis (inflammation of the glans penis) and posthitis (inflammation of the foreskin) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11966297\">",
"    <span class=\"h2\">",
"     Cervicitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with cervicitis due to M. genitalium frequently have no symptoms at all, similar to those with cervicitis due to C. trachomatis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/7,8,32,40\">",
"     7,8,32,40",
"    </a>",
"    ]. When present, symptoms associated with M. genitalium infection are usually nonspecific, with the most commonly reported symptom being vaginal discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/40,60,61\">",
"     40,60,61",
"    </a>",
"    ]. Other symptoms include vaginal itching, dysuria, and pelvic discomfort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cervical inflammation is the most common manifestation of M. genitalium infection in women and is usually described as mucopurulent cervicitis (MPC). A multitude of examination and microscopic findings of cervical inflammation have been associated with M. genitalium infection, including the presence of purulent or mucopurulent cervical discharge, cervical friability, and elevated numbers of polymorphonuclear leukocytes cells on vaginal wet smear or cervical fluid Gram stain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/6-8,62,63\">",
"     6-8,62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of cervicitis in general are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/64?source=see_link&amp;anchor=H3#H3\">",
"     \"Acute cervicitis\", section on 'Clinical findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11966304\">",
"    <span class=\"h2\">",
"     Pelvic inflammatory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of M. genitalium-associated pelvic inflammatory disease (PID) include mild to severe pelvic pain, abdominal pain, abnormal vaginal discharge,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bleeding, similar to PID due to C. trachomatis. In a study of women with clinically suspected PID, women with M. genitalium-associated PID were less likely to have elevated systemic inflammatory markers or elevated leukocyte count and were less likely to present with mucopurulent cervicitis or report high pain scores when compared with women with N. gonorrhoeae infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/64\">",
"     64",
"    </a>",
"    ]. Women with PID due to M. genitalium and C. trachomatis reported similar symptoms.",
"   </p>",
"   <p>",
"    The clinical manifestations of PID in general are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99103250\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other sexually transmitted pathogens, such as C. trachomatis, N. gonorrhoeae, Trichomonas vaginalis, Ureaplasma urealyticum, and herpes simplex virus, can cause similar disease presentations. Additionally, nonsexually transmitted infections and noninfectious conditions can cause signs and symptoms comparable to those in M. genitalium infections.",
"   </p>",
"   <p>",
"    The differential diagnoses of the specific syndromes associated with M. genitalium infection are discussed in detail elsewhere:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/43/19126?source=see_link\">",
"       \"Infectious causes of dysuria in adult men\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/43/19126?source=see_link&amp;anchor=H10#H10\">",
"       \"Infectious causes of dysuria in adult men\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/64?source=see_link&amp;anchor=H2#H2\">",
"       \"Acute cervicitis\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11992?source=see_link&amp;anchor=H3#H3\">",
"       \"Pathogenesis of and risk factors for pelvic inflammatory disease\", section on 'Microbiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical features and diagnosis of pelvic inflammatory disease\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11966311\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the clinical setting, the microbiological diagnosis of M. genitalium is infrequently made because of the absence of useful, commercially-available diagnostic tests. However, if locally available, the diagnosis of M. genitalium infection can be made through detection of the organism using nucleic acid amplification tests (NAATs), such as polymerase chain reaction (PCR) and transcription-mediated amplification (TMA), on urogenital specimens. The preferred specimens are a first-void urine sample in men and a vaginal swab in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/30,31,65-69\">",
"     30,31,65-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnoses of the clinical syndromes associated with M. genitalium are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/43/19126?source=see_link&amp;anchor=H9#H9\">",
"     \"Infectious causes of dysuria in adult men\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/64?source=see_link&amp;anchor=H6#H6\">",
"     \"Acute cervicitis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical features and diagnosis of pelvic inflammatory disease\", section on 'Diagnostic considerations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99103136\">",
"    <span class=\"h2\">",
"     Diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;NAATs are the only clinically useful method of detecting M. genitalium but are not widely available. Although there is currently no commercially-available NAAT that is internationally validated and approved for this purpose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/27,70\">",
"     27,70",
"    </a>",
"    ], these tests can be used after validation by individual laboratories.",
"   </p>",
"   <p>",
"    The two most common DNA targets for NAATs are a 78 base pair (bp) region of the M. genitalium adhesion protein and a 517 bp region of the 16S rRNA gene. Assays amplifying these two genomic targets are able to detect as few as 25 copies of DNA per reaction in vitro and demonstrate comparable sensitivity for M. genitalium detection from vaginal specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Traditional microbiological methods of bacterial diagnosis are not clinically useful in the diagnosis of M. genitalium infections. The lack of a cell wall prevents M. genitalium identification by routine Gram staining, and its fastidious growth requirements make its cultivation for diagnosis prohibitive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/17,20,71\">",
"     17,20,71",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11966210\">",
"     'Microbiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are no standardized serological tests for M. genitalium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11966318\">",
"    <span class=\"h2\">",
"     Optimal urogenital specimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal genital specimens for M. genitalium detection with NAATs in men and women are unclear. However, several studies suggest that testing first-void urine specimens in men and vaginal swabs in women yield the most accurate diagnostic results. The first-void urine is the first 10 mL of the initial stream of urine collected without precleaning of the genital areas. Ideally, the patient should not have voided in the two hours prior to specimen collection.",
"   </p>",
"   <p>",
"    Among men, the diagnostic performance of first-void urine specimens in detecting M. genitalium is higher than that of urethral smear specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. In a study of 1852 men presenting to a sexually transmitted infection (STI) clinic, the relative diagnostic sensitivity of PCR performed on first-void urine specimens was 97.6 percent compared with 82.5 percent on urethral swab specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among women, the highest diagnostic performance for M. genitalium detection has most consistently been observed with vaginal specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/30,31,67-69\">",
"     30,31,67-69",
"    </a>",
"    ]. In one study of 400 women presenting to a STI clinic, the relative sensitivity of PCR for M. genitalium was 86 percent with vaginal swabs, 73 percent with endocervical material, and 61 percent with first-void urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/68\">",
"     68",
"    </a>",
"    ]. In contrast, one small study described a higher sensitivity of PCR on first-void urine compared with vaginal swabs, although its evaluation of only seven women with detectable M. genitalium limits the interpretation of the finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/66\">",
"     66",
"    </a>",
"    ]. Other studies have reported higher sensitivity using first-void urine specimens compared with cervical swabs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/65,73\">",
"     65,73",
"    </a>",
"    ]. Discrepancies in the results from these studies may be related to the varying specificities of the different PCR assays used and methods used to process the specimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111028269\">",
"    <span class=\"h2\">",
"     Whom to test",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a NAAT for M. genitalium is readily available, we favor testing patients presenting to STI clinics with evidence of urethritis, cervicitis, or pelvic inflammatory disease for M. genitalium, given the high prevalence of this infection observed among this population. Additionally, we suggest testing patients with persistent symptoms of these conditions despite completion of appropriate therapy, regardless of initial cause, as M. genitalium infection is frequent in such settings.",
"   </p>",
"   <p>",
"    However, the cost-effectiveness of this strategy from a public health perspective is unknown. Further studies on the utility of routine testing in such situations will be helpful in determining a testing approach once NAAT for M. genitalium becomes more widely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11966325\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11854426\">",
"    <span class=\"h2\">",
"     Antimicrobial susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lack of a cell wall renders M. genitalium resistant to antibiotics which target cell wall synthesis, such as penicillins and other beta-lactams. M. genitalium is generally susceptible in vitro to the macrolides (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    &gt;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ), fluoroquinolones, tetracyclines, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/19\">",
"     19",
"    </a>",
"    ]. Azithromycin has at least 100-fold more activity against this organism than the tetracyclines or most fluoroquinolones. However, strains of M. genitalium with resistance to azithromycin have been reported following azithromycin treatment failure in patients with nongonococcal urethritis (NGU) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/74\">",
"     74",
"    </a>",
"    ]. Resistance to azithromycin was mediated by mutations in the 23S rRNA gene that developed following antibiotic exposure, suggesting antibiotic-induced resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1297481\">",
"    <span class=\"h2\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical syndromes with which M. genitalium is associated should generally be treated empirically, prior to or without knowledge of the specific causative pathogen. Our approach to therapy of M. genitalium depends on the timing of presentation, the availability of M. genitalium testing, and the treatment history.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1297537\">",
"    <span class=\"h3\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric treatment for urethritis, cervicitis, and pelvic inflammatory disease includes therapy for C. trachomatis with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    . Both agents have activity against M. genitalium, although clinical evidence suggests that azithromycin is superior to doxycycline (see",
"    <a class=\"local\" href=\"#H111028205\">",
"     'Directed therapy'",
"    </a>",
"    below). However, there are insufficient clinical data to recommend tailoring empiric therapy for patients initially presenting with such syndromes based on the possibility of M. genitalium infection.",
"   </p>",
"   <p>",
"    Details on the empiric regimens for urethritis, cervicitis, and pelvic inflammatory disease are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/43/19126?source=see_link&amp;anchor=H11#H11\">",
"     \"Infectious causes of dysuria in adult men\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/64?source=see_link&amp;anchor=H2014238#H2014238\">",
"     \"Acute cervicitis\", section on 'Empiric therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35832?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of pelvic inflammatory disease\", section on 'Recommended regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111028205\">",
"    <span class=\"h3\">",
"     Directed therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men and women with documented M. genitalium infection who have not yet received empiric therapy, we suggest treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11854546\">",
"    <span class=\"h4\">",
"     Urethritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The superiority of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    in men with urethritis due to M. genitalium has been demonstrated in several studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/26,28,31,75\">",
"     26,28,31,75",
"    </a>",
"    ]. In a systematic review of observational studies and randomized trials of M. genitalium treatment, the pooled microbiologic cure rate was 371 of 466 (80 percent) in men treated with azithromycin compared with 88 of 212 (42 percent) in those treated with doxycycline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/26\">",
"     26",
"    </a>",
"    ]. In the two trials that were included, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of men with NGU, 31 percent of participants tested positive for M. genitalium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/76\">",
"       76",
"      </a>",
"      ]. Clearance of M. genitalium occurred more frequently among the 45 men randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      than the 39 who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (67 versus 31 percent).",
"     </li>",
"     <li>",
"      In a separate trial of men with NGU, 20 percent of participants tested positive for M. genitalium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/28\">",
"       28",
"      </a>",
"      ]. Within 21 days posttreatment, more of the 23 men randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      experienced bacteriologic cure than the 31 who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (87 versus 45 percent). Four patients in each treatment group continued to have symptoms, regardless of M. genitalium eradication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies all evaluated a single 1 gram dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    . A longer course (ie, 500 mg on day one, then 250 mg daily on days two through five) may result in higher cure rates. In an observational study of men with M. genitalium urethritis, 33 of 39 men (85 percent) treated with a single dose of azithromycin had a negative follow-up M. genitalium test compared with 45 of 47 men (96 percent) who received the five-day azithromycin course after having initially failed a course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/77\">",
"     77",
"    </a>",
"    ]. However, these two azithromycin regimens have not been compared directly, and the single-dose regimen has the advantage of allowing directly observed therapy at the point of care, which improves adherence. Thus, we favor using the single 1 gram dose of azithromycin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11854836\">",
"    <span class=\"h4\">",
"     Cervicitis and pelvic inflammatory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have evaluated the efficacy of antibiotic regimens against M. genitalium in women. As in men,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    has been associated with higher rates of microbiologic cure than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    in observational studies of M. genitalium urogenital disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. In a study of women with clinically suspected pelvic inflammatory disease (PID) treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    and doxycycline, M. genitalium infection was associated with a high treatment failure rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/35\">",
"     35",
"    </a>",
"    ]. Of 56 women with M. genitalium detected in the cervix or endometrium at baseline, 23 (41 percent) had persistent infection at 30 days. Thus, for women with documented M. genitalium regimen, we suggest treatment with a regimen that contains azithromycin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65928965\">",
"    <span class=\"h4\">",
"     Asymptomatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the limited availability of accurate diagnostic methods and the absence of screening guidelines for M. genitalium, it would be unlikely to encounter a patient with laboratory-confirmed M. genitalium infection who did not have signs, symptoms, or other suspicion for a urogenital tract infection. Nevertheless, in such settings, we favor directed therapy for M. genitalium given its associations with urogenital disease and HIV infection as well as the possibility of very subtle presentations of these syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11854719\">",
"    <span class=\"h3\">",
"     Persistent or recurrent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent or recurrent signs or symptoms of urethritis, cervicitis, or PID following empiric treatment may be associated with suboptimally treated M. genitalium infection.",
"   </p>",
"   <p>",
"    If the initial empiric regimen did not include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , we suggest treating for M. genitalium infection with azithromycin. Treatment for other possible co-infections that were not initially targeted (eg, Trichomonas vaginalis) may also be warranted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34505?source=see_link&amp;anchor=H342782#H342782\">",
"     \"Treatment of Chlamydia trachomatis infection\", section on 'Recurrence of symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, even",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    is not 100 percent effective against M. genitalium. Treatment failure with the use of azithromycin may be mediated by the selection of drug resistance mutations during therapy. (See",
"    <a class=\"local\" href=\"#H11854426\">",
"     'Antimicrobial susceptibility'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If the initial empiric regimen did include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , we favor testing for M. genitalium with nucleic acid amplification tests (NAATs) if available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with documented M. genitalium infection as determined by NAAT, either on initial presentation or at follow-up, who fail",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      therapy, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      In the absence of M. genitalium NAAT availability, empiric treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      is reasonable for patients with persistent symptoms who were unresponsive to previous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      treatment for nongonococcal urethritis or cervicitis and have no alternate identified etiological agent on repeat testing for other sexually transmitted infections (eg, N. gonorrhoeae, C. trachomatis, HSV, or, in women, T. vaginalis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limited evidence from observational studies suggests that the fluoroquinolone",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    may be useful for persistent M. genitalium infection despite",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/26,79\">",
"     26,79",
"    </a>",
"    ]. In a study of men and women with persistent M. genitalium after initial therapy with azithromycin, 32 patients were treated with moxifloxacin (400 mg orally for seven days) and all of the 23 patients who returned for follow-up had microbiologic cure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40153/abstract/79\">",
"     79",
"    </a>",
"    ]. In contrast, only 8 of 23 (34 percent) of those who failed an initial single-dose regimen of azithromycin were cured with a subsequent five-day course of azithromycin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8890831\">",
"    <span class=\"h1\">",
"     PARTNER MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no guidelines for partner referral and treatment, it is reasonable to screen all sexual partners of laboratory-confirmed cases of M. genitalium (see",
"    <a class=\"local\" href=\"#H99103136\">",
"     'Diagnostic tests'",
"    </a>",
"    above) and treat if positive. If screening of sexual partners of index patients with confirmed M. genitalium is not possible, we favor empirically treating for M. genitalium given the evidence of sexual transmission of this organism. Although the incubation period of this pathogen remains undefined, screening should target sexual partners in the past 60 days.",
"   </p>",
"   <p>",
"    Treatment for partners of patients with confirmed M. genitalium infection is the same as for patients. (See",
"    <a class=\"local\" href=\"#H111028205\">",
"     'Directed therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11966339\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mycoplasma genitalium is an important cause of nongonococcal urethritis (NGU) in men, and there is growing evidence to support an association with cervicitis and pelvic inflammatory disease (PID) in women. (See",
"      <a class=\"local\" href=\"#H11966203\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H860473\">",
"       'Disease associations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      M. genitalium is a member of the Mycoplasmataceae family of bacteria. It is not visible following Gram staining because of its lack of a cell wall, and culture of the organism is difficult. M. genitalium has been isolated from multiple tissue sites, including the respiratory tract and synovial fluid, but its association with clinical disease appears to be limited to the urogenital tract. (See",
"      <a class=\"local\" href=\"#H11966210\">",
"       'Microbiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11966217\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of M. genitalium is approximately 1 percent in the general population but is considerably higher among individuals at high risk for other sexually transmitted infections. The risk factors for M. genitalium infection are similar to those associated with Chlamydia trachomatis infection, and include young age, nonwhite race, and an increasing number of recent sexual partners. (See",
"      <a class=\"local\" href=\"#H11966231\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of M. genitalium urogenital infection are similar to those caused by C. trachomatis infection in both men and women. Urethritis caused by M. genitalium is typically symptomatic, whereas women with cervicitis associated with M. genitalium are more frequently asymptomatic. (See",
"      <a class=\"local\" href=\"#H11966282\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10729?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Chlamydia trachomatis infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There are currently no commercially available detection methods for M. genitalium. However, if locally available, the diagnosis of M. genitalium infection can be made through detection of the organism using nucleic acid amplification tests (NAATs), such as polymerase chain reaction (PCR) and transcription-mediated amplification (TMA), on urogenital specimens such as first-void urine in men and a vaginal or cervical swab in women. (See",
"      <a class=\"local\" href=\"#H11966311\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our approach to therapy of M. genitalium depends on the timing of presentation, the availability of M. genitalium testing, and the treatment history. (See",
"      <a class=\"local\" href=\"#H11966325\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients initially presenting with signs or symptoms of urethritis, cervicitis, or pelvic inflammatory disease should be treated empirically based on the recommendations for the presenting syndrome. We suggest not basing the choice of empiric regimen on the possibility of M. genitalium infection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/43/19126?source=see_link&amp;anchor=H11#H11\">",
"       \"Infectious causes of dysuria in adult men\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/64?source=see_link&amp;anchor=H2014238#H2014238\">",
"       \"Acute cervicitis\", section on 'Empiric therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35832?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment of pelvic inflammatory disease\", section on 'Recommended regimens'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For men with urethritis and documented M. genitalium infection who have not yet received empiric therapy, we suggest treatment with a regimen that contains",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For women with cervicitis or PID and documented M. genitalium infection who have not yet received empiric therapy, we suggest treatment with a regimen that contains",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with persistent signs or symptoms of urethritis, cervicitis, or PID whose initial regimen did not include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      , we suggest treating with azithromycin (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with persistent signs or symptoms of urethritis, cervicitis, or PID following",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      therapy who had documented M. genitalium infection at either the initial or follow-up presentation, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      rather than an additional or longer course of azithromycin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In the absence of M. genitalium NAAT availability, treatment with moxifloxacin is also reasonable for patients who have persistent symptoms despite azithromycin therapy and no alternate identified cause after repeat testing for other sexually transmitted infections.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/1\">",
"      Falk L, Fredlund H, Jensen JS. Symptomatic urethritis is more prevalent in men infected with Mycoplasma genitalium than with Chlamydia trachomatis. Sex Transm Infect 2004; 80:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/2\">",
"      Totten PA, Schwartz MA, Sj&ouml;str&ouml;m KE, et al. Association of Mycoplasma genitalium with nongonococcal urethritis in heterosexual men. J Infect Dis 2001; 183:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/3\">",
"      Taylor-Robinson D. The Harrison Lecture. The history and role of Mycoplasma genitalium in sexually transmitted diseases. Genitourin Med 1995; 71:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/4\">",
"      Jensen JS, Orsum R, Dohn B, et al. Mycoplasma genitalium: a cause of male urethritis? Genitourin Med 1993; 69:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/5\">",
"      Taylor-Robinson D. Mycoplasma genitalium -- an up-date. Int J STD AIDS 2002; 13:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/6\">",
"      Gaydos C, Maldeis NE, Hardick A, et al. Mycoplasma genitalium as a contributor to the multiple etiologies of cervicitis in women attending sexually transmitted disease clinics. Sex Transm Dis 2009; 36:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/7\">",
"      Anagrius C, Lor&eacute; B, Jensen JS. Mycoplasma genitalium: prevalence, clinical significance, and transmission. Sex Transm Infect 2005; 81:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/8\">",
"      Falk L, Fredlund H, Jensen JS. Signs and symptoms of urethritis and cervicitis among women with or without Mycoplasma genitalium or Chlamydia trachomatis infection. Sex Transm Infect 2005; 81:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/9\">",
"      Manhart LE, Critchlow CW, Holmes KK, et al. Mucopurulent cervicitis and Mycoplasma genitalium. J Infect Dis 2003; 187:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/10\">",
"      M&oslash;ller BR, Taylor-Robinson D, Furr PM. Serological evidence implicating Mycoplasma genitalium in pelvic inflammatory disease. Lancet 1984; 1:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/11\">",
"      Simms I, Eastick K, Mallinson H, et al. Associations between Mycoplasma genitalium, Chlamydia trachomatis, and pelvic inflammatory disease. Sex Transm Infect 2003; 79:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/12\">",
"      Haggerty CL, Totten PA, Astete SG, Ness RB. Mycoplasma genitalium among women with nongonococcal, nonchlamydial pelvic inflammatory disease. Infect Dis Obstet Gynecol 2006; 2006:30184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/13\">",
"      Cohen CR, Manhart LE, Bukusi EA, et al. Association between Mycoplasma genitalium and acute endometritis. Lancet 2002; 359:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/14\">",
"      Cohen CR, Mugo NR, Astete SG, et al. Detection of Mycoplasma genitalium in women with laparoscopically diagnosed acute salpingitis. Sex Transm Infect 2005; 81:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/15\">",
"      Clausen HF, Fedder J, Drasbek M, et al. Serological investigation of Mycoplasma genitalium in infertile women. Hum Reprod 2001; 16:1866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/16\">",
"      Tully JG, Taylor-Robinson D, Cole RM, Rose DL. A newly discovered mycoplasma in the human urogenital tract. Lancet 1981; 1:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/17\">",
"      Patel MA, Nyirjesy P. Role of Mycoplasma and ureaplasma species in female lower genital tract infections. Curr Infect Dis Rep 2010; 12:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/18\">",
"      Svenstrup HF, Jensen JS, Bj&ouml;rnelius E, et al. Development of a quantitative real-time PCR assay for detection of Mycoplasma genitalium. J Clin Microbiol 2005; 43:3121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/19\">",
"      Taylor-Robinson D, Jensen JS. Mycoplasma genitalium: from Chrysalis to multicolored butterfly. Clin Microbiol Rev 2011; 24:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/20\">",
"      Baseman JB, Cagle M, Korte JE, et al. Diagnostic assessment of Mycoplasma genitalium in culture-positive women. J Clin Microbiol 2004; 42:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/21\">",
"      Razin S, Yogev D, Naot Y. Molecular biology and pathogenicity of mycoplasmas. Microbiol Mol Biol Rev 1998; 62:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/22\">",
"      Jensen JS. Mycoplasma genitalium infections. Diagnosis, clinical aspects, and pathogenesis. Dan Med Bull 2006; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/23\">",
"      Taylor-Robinson D, Furr PM, Tully JG, et al. Animal models of Mycoplasma genitalium urogenital infection. Isr J Med Sci 1987; 23:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/24\">",
"      Ross JD, Jensen JS. Mycoplasma genitalium as a sexually transmitted infection: implications for screening, testing, and treatment. Sex Transm Infect 2006; 82:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/25\">",
"      Jensen JS. Mycoplasma genitalium: the aetiological agent of urethritis and other sexually transmitted diseases. J Eur Acad Dermatol Venereol 2004; 18:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/26\">",
"      Manhart LE, Broad JM, Golden MR. Mycoplasma genitalium: should we treat and how? Clin Infect Dis 2011; 53 Suppl 3:S129.",
"     </a>",
"    </li>",
"    <li>",
"     www.cdc.gov/std/treatment/2010/urethritis-and-cervicitis.htm (Accessed on December 22, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/28\">",
"      Mena LA, Mroczkowski TF, Nsuami M, Martin DH. A randomized comparison of azithromycin and doxycycline for the treatment of Mycoplasma genitalium-positive urethritis in men. Clin Infect Dis 2009; 48:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/29\">",
"      Wikstr&ouml;m A, Jensen JS. Mycoplasma genitalium: a common cause of persistent urethritis among men treated with doxycycline. Sex Transm Infect 2006; 82:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/30\">",
"      Mobley VL, Hobbs MM, Lau K, et al. Mycoplasma genitalium infection in women attending a sexually transmitted infection clinic: diagnostic specimen type, coinfections, and predictors. Sex Transm Dis 2012; 39:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/31\">",
"      Casin I, Vexiau-Robert D, De La Salmoni&egrave;re P, et al. High prevalence of Mycoplasma genitalium in the lower genitourinary tract of women attending a sexually transmitted disease clinic in Paris, France. Sex Transm Dis 2002; 29:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/32\">",
"      Huppert JS, Mortensen JE, Reed JL, et al. Mycoplasma genitalium detected by transcription-mediated amplification is associated with Chlamydia trachomatis in adolescent women. Sex Transm Dis 2008; 35:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/33\">",
"      Oakeshott P, Aghaizu A, Hay P, et al. Is Mycoplasma genitalium in women the \"New Chlamydia?\" A community-based prospective cohort study. Clin Infect Dis 2010; 51:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/34\">",
"      Bjartling C, Osser S, Persson K. The association between Mycoplasma genitalium and pelvic inflammatory disease after termination of pregnancy. BJOG 2010; 117:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/35\">",
"      Haggerty CL, Totten PA, Astete SG, et al. Failure of cefoxitin and doxycycline to eradicate endometrial Mycoplasma genitalium and the consequence for clinical cure of pelvic inflammatory disease. Sex Transm Infect 2008; 84:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/36\">",
"      Manhart LE, Holmes KK, Hughes JP, et al. Mycoplasma genitalium among young adults in the United States: an emerging sexually transmitted infection. Am J Public Health 2007; 97:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/37\">",
"      Cazanave C, Manhart LE, B&eacute;b&eacute;ar C. Mycoplasma genitalium, an emerging sexually transmitted pathogen. Med Mal Infect 2012; 42:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/38\">",
"      Manhart LE, Kay N. Mycoplasma genitalium: Is It a Sexually Transmitted Pathogen? Curr Infect Dis Rep 2010; 12:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/39\">",
"      Hancock EB, Manhart LE, Nelson SJ, et al. Comprehensive assessment of sociodemographic and behavioral risk factors for Mycoplasma genitalium infection in women. Sex Transm Dis 2010; 37:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/40\">",
"      Tosh AK, Van Der Pol B, Fortenberry JD, et al. Mycoplasma genitalium among adolescent women and their partners. J Adolesc Health 2007; 40:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/41\">",
"      Andersen B, Sokolowski I, &Oslash;stergaard L, et al. Mycoplasma genitalium: prevalence and behavioural risk factors in the general population. Sex Transm Infect 2007; 83:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/42\">",
"      Wetmore CM, Manhart LE, Lowens MS, et al. Demographic, behavioral, and clinical characteristics of men with nongonococcal urethritis differ by etiology: a case-comparison study. Sex Transm Dis 2011; 38:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/43\">",
"      Vandepitte J, Muller E, Bukenya J, et al. Prevalence and correlates of Mycoplasma genitalium infection among female sex workers in Kampala, Uganda. J Infect Dis 2012; 205:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/44\">",
"      Bradshaw CS, Chen MY, Fairley CK. Persistence of Mycoplasma genitalium following azithromycin therapy. PLoS One 2008; 3:e3618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/45\">",
"      Thurman AR, Musatovova O, Perdue S, et al. Mycoplasma genitalium symptoms, concordance and treatment in high-risk sexual dyads. Int J STD AIDS 2010; 21:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/46\">",
"      Musatovova O, Baseman JB. Analysis identifying common and distinct sequences among Texas clinical strains of Mycoplasma genitalium. J Clin Microbiol 2009; 47:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/47\">",
"      Hjorth SV, Bj&ouml;rnelius E, Lidbrink P, et al. Sequence-based typing of Mycoplasma genitalium reveals sexual transmission. J Clin Microbiol 2006; 44:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/48\">",
"      Ma L, Taylor S, Jensen JS, et al. Short tandem repeat sequences in the Mycoplasma genitalium genome and their use in a multilocus genotyping system. BMC Microbiol 2008; 8:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/49\">",
"      Gaydos C, Maldeis NE, Hardick A, et al. Mycoplasma genitalium compared to chlamydia, gonorrhoea and trichomonas as an aetiological agent of urethritis in men attending STD clinics. Sex Transm Infect 2009; 85:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/50\">",
"      Mena L, Wang X, Mroczkowski TF, Martin DH. Mycoplasma genitalium infections in asymptomatic men and men with urethritis attending a sexually transmitted diseases clinic in New Orleans. Clin Infect Dis 2002; 35:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/51\">",
"      Taylor-Robinson D, Renton A, Jensen JS, et al. Association of Mycoplasma genitalium with acute non-gonococcal urethritis in Russian men: a comparison with gonococcal and chlamydial urethritis. Int J STD AIDS 2009; 20:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/52\">",
"      Johnston LG, Paz-Bailey G, Morales-Miranda S, et al. High prevalence of Mycoplasma genitalium among female sex workers in Honduras: implications for the spread of HIV and other sexually transmitted infections. Int J STD AIDS 2012; 23:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/53\">",
"      M&aring;nsson F, Camara C, Biai A, et al. High prevalence of HIV-1, HIV-2 and other sexually transmitted infections among women attending two sexual health clinics in Bissau, Guinea-Bissau, West Africa. Int J STD AIDS 2010; 21:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/54\">",
"      Cohen CR, Nosek M, Meier A, et al. Mycoplasma genitalium infection and persistence in a cohort of female sex workers in Nairobi, Kenya. Sex Transm Dis 2007; 34:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/55\">",
"      Lusk MJ, Konecny P, Naing ZW, et al. Mycoplasma genitalium is associated with cervicitis and HIV infection in an urban Australian STI clinic population. Sex Transm Infect 2011; 87:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/56\">",
"      Soni S, Alexander S, Verlander N, et al. The prevalence of urethral and rectal Mycoplasma genitalium and its associations in men who have sex with men attending a genitourinary medicine clinic. Sex Transm Infect 2010; 86:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/57\">",
"      Mavedzenge SN, Van Der Pol B, Weiss HA, et al. The association between Mycoplasma genitalium and HIV-1 acquisition in African women. AIDS 2012; 26:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/58\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/59\">",
"      Horner PJ, Taylor-Robinson D. Association of Mycoplasma genitalium with balanoposthitis in men with non-gonococcal urethritis. Sex Transm Infect 2011; 87:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/60\">",
"      Korte JE, Baseman JB, Cagle MP, et al. Cervicitis and genitourinary symptoms in women culture positive for Mycoplasma genitalium. Am J Reprod Immunol 2006; 55:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/61\">",
"      P&eacute;pin J, Labb&eacute; AC, Khonde N, et al. Mycoplasma genitalium: an organism commonly associated with cervicitis among west African sex workers. Sex Transm Infect 2005; 81:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/62\">",
"      H&ouml;gdahl M, Kihlstr&ouml;m E. Leucocyte esterase testing of first-voided urine and urethral and cervical smears to identify Mycoplasma genitalium-infected men and women. Int J STD AIDS 2007; 18:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/63\">",
"      Moi H, Reinton N, Moghaddam A. Mycoplasma genitalium in women with lower genital tract inflammation. Sex Transm Infect 2009; 85:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/64\">",
"      Short VL, Totten PA, Ness RB, et al. Clinical presentation of Mycoplasma genitalium Infection versus Neisseria gonorrhoeae infection among women with pelvic inflammatory disease. Clin Infect Dis 2009; 48:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/65\">",
"      Jensen JS, Bj&ouml;rnelius E, Dohn B, Lidbrink P. Comparison of first void urine and urogenital swab specimens for detection of Mycoplasma genitalium and Chlamydia trachomatis by polymerase chain reaction in patients attending a sexually transmitted disease clinic. Sex Transm Dis 2004; 31:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/66\">",
"      Shipitsyna E, Zolotoverkhaya E, Dohn B, et al. First evaluation of polymerase chain reaction assays used for diagnosis of Mycoplasma genitalium in Russia. J Eur Acad Dermatol Venereol 2009; 23:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/67\">",
"      Wroblewski JK, Manhart LE, Dickey KA, et al. Comparison of transcription-mediated amplification and PCR assay results for various genital specimen types for detection of Mycoplasma genitalium. J Clin Microbiol 2006; 44:3306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/68\">",
"      Lillis RA, Nsuami MJ, Myers L, Martin DH. Utility of urine, vaginal, cervical, and rectal specimens for detection of Mycoplasma genitalium in women. J Clin Microbiol 2011; 49:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/69\">",
"      Ross JD, Brown L, Saunders P, Alexander S. Mycoplasma genitalium in asymptomatic patients: implications for screening. Sex Transm Infect 2009; 85:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/70\">",
"      Twin J, Taylor N, Garland SM, et al. Comparison of two Mycoplasma genitalium real-time PCR detection methodologies. J Clin Microbiol 2011; 49:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/71\">",
"      Shipitsyna E, Savicheva A, Solokovskiy E, et al. Guidelines for the laboratory diagnosis of mycoplasma genitalium infections in East European countries. Acta Derm Venereol 2010; 90:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/72\">",
"      Waites KB, Xiao L, Paralanov V, et al. Molecular methods for the detection of Mycoplasma and ureaplasma infections in humans: a paper from the 2011 William Beaumont Hospital Symposium on molecular pathology. J Mol Diagn 2012; 14:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/73\">",
"      Edberg A, Aronsson F, Johansson E, et al. Endocervical swabs transported in first void urine as combined specimens in the detection of Mycoplasma genitalium by real-time PCR. J Med Microbiol 2009; 58:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/74\">",
"      Jensen JS, Bradshaw CS, Tabrizi SN, et al. Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clin Infect Dis 2008; 47:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/75\">",
"      Se&ntilde;a AC, Lensing S, Rompalo A, et al. Chlamydia trachomatis, Mycoplasma genitalium, and Trichomonas vaginalis infections in men with nongonococcal urethritis: predictors and persistence after therapy. J Infect Dis 2012; 206:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/76\">",
"      Schwebke JR, Rompalo A, Taylor S, et al. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens--a randomized clinical trial. Clin Infect Dis 2011; 52:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/77\">",
"      Bj&ouml;rnelius E, Anagrius C, Bojs G, et al. Antibiotic treatment of symptomatic Mycoplasma genitalium infection in Scandinavia: a controlled clinical trial. Sex Transm Infect 2008; 84:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/78\">",
"      Falk L, Fredlund H, Jensen JS. Tetracycline treatment does not eradicate Mycoplasma genitalium. Sex Transm Infect 2003; 79:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40153/abstract/79\">",
"      Jernberg E, Moghaddam A, Moi H. Azithromycin and moxifloxacin for microbiological cure of Mycoplasma genitalium infection: an open study. Int J STD AIDS 2008; 19:676.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83202 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-CCFD8525CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_13_40153=[""].join("\n");
var outline_f39_13_40153=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11966339\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11966203\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11966210\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11966217\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11966231\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H860473\">",
"      Disease associations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11966254\">",
"      - Nongonococcal urethritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11966261\">",
"      - Cervicitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11966268\">",
"      - Pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23915319\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23914721\">",
"      Risk factors for infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23915130\">",
"      - Evidence of sexual transmissibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23915541\">",
"      Co-infection with other sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11966282\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11966290\">",
"      Urethritis in men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11966297\">",
"      Cervicitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11966304\">",
"      Pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H99103250\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11966311\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H99103136\">",
"      Diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11966318\">",
"      Optimal urogenital specimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H111028269\">",
"      Whom to test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11966325\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11854426\">",
"      Antimicrobial susceptibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1297481\">",
"      Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1297537\">",
"      - Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H111028205\">",
"      - Directed therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11854546\">",
"      Urethritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11854836\">",
"      Cervicitis and pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H65928965\">",
"      Asymptomatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11854719\">",
"      - Persistent or recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8890831\">",
"      PARTNER MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11966339\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/64?source=related_link\">",
"      Acute cervicitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10729?source=related_link\">",
"      Clinical manifestations and diagnosis of Chlamydia trachomatis infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/20/38217?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of Neisseria gonorrhoeae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/43/19126?source=related_link\">",
"      Infectious causes of dysuria in adult men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/28/31177?source=related_link\">",
"      Mycoplasma hominis, Mycoplasma genitalium, and Ureaplasma urealyticum infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/5/3162?source=related_link\">",
"      Mycoplasma pneumoniae infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/35/6713?source=related_link\">",
"      Mycoplasma pneumoniae infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11992?source=related_link\">",
"      Pathogenesis of and risk factors for pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34505?source=related_link\">",
"      Treatment of Chlamydia trachomatis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35832?source=related_link\">",
"      Treatment of pelvic inflammatory disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_13_40154="Complementary and alternative therapies for cancer";
var content_f39_13_40154=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complementary and alternative therapies for cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/13/40154/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/13/40154/contributors\">",
"     Edzard Ernst, MD, PhD, FMEdSci, FSB, FRCP, FRCP (Edin.)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/13/40154/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/13/40154/contributors\">",
"     Paul J Hesketh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/13/40154/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/13/40154/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/13/40154/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complementary and alternative medicine (CAM) is defined by the National Center for Complementary and Alternative Medicine as a group of diverse medical and health care systems, practices, and products that are not normally considered to be conventional medicine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/1\">",
"     1",
"    </a>",
"    ]. Included in this type of therapy are herbs, acupuncture, chiropractic, and massage, among others. Use of these therapies is common in the general population.",
"   </p>",
"   <p>",
"    The use of CAM is widespread and increasing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/2\">",
"     2",
"    </a>",
"    ]. Multiple studies have found that within one year, up to 90 percent of patients with cancer used a CAM approach for at least a part of their therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/3-11\">",
"     3-11",
"    </a>",
"    ]. However, patients may not reveal the use of CAM unless specifically asked. In one study, disclosure of the use of these therapies increased from 7 to 43 percent when directed questions were added to standard history taking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/12\">",
"     12",
"    </a>",
"    ]. Unfortunately, communication between oncologists and patients about CAM is poor, infrequent, and mostly initiated by patients or their kin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Users of CAM are generally",
"    <strong>",
"     not",
"    </strong>",
"    dissatisfied with conventional medicine but find alternatives to be more congruent with their own values, beliefs, and philosophical orientations toward health and life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/14\">",
"     14",
"    </a>",
"    ]. Factors reported to be associated with use of CAM therapies in cancer patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased psychosocial stress (eg, anxiety, depression) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Being given a less hopeful prognosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Having the feeling of \"nothing to lose\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Attending support groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Age (younger versus older) and gender (women more than men) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the current popularity of CAM, most mainstream oncologists have little understanding of these therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/19\">",
"     19",
"    </a>",
"    ]. However, patients with cancer report feeling that their doctors \"should be more interested in, more informed about, and more willing to discuss unconventional therapies\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/20\">",
"     20",
"    </a>",
"    ]. Although many patients assume that CAM is associated with beneficial effects, at least one Norwegian longitudinal study of 515 cancer patients suggests that CAM use may be associated with shorter survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of the available evidence regarding CAM in cancer therapy is presented here. The primary focus is on results from clinical trials; uncontrolled trials are considered in areas where controlled studies are not available. The use of complementary therapies for patients with cancer-related pain is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=see_link&amp;anchor=H44713488#H44713488\">",
"     \"Psychological, rehabilitative, and integrative therapies for cancer pain\", section on 'Integrative therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ALTERNATIVE CANCER TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the purpose of this discussion, alternative cancer treatments (ACTs) are defined as CAM therapies that are promoted for reducing tumor burden or prolonging the life of cancer patients. These are typically biologically active and promoted as replacements for, rather than adjuncts to, mainstream therapy. The use of ACTs dates back to the 1940s with the use of Koch antitoxins, and new therapies have been introduced each decade, including Hoxsey treatment in the 1950s, krebiozen in the 60s, laetrile in the 70s (which is again popular today [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/22\">",
"     22",
"    </a>",
"    ]), immunotherapy in the 80s, and Di Bella therapy in the 90s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All of these therapies have evolved through a strikingly similar life cycle; initially they were aggressively promoted by interested parties based on anecdotal evidence. Mainstream oncologists eventually succumbed to mounting pressure, conducting rigorous clinical trials. When these turned out to be negative, proponents claimed that the studies were flawed and that a conspiracy was underway to discredit a valuable therapy. In the end, each of these therapies submerged into a medical subculture, and cancer patients continued to be attracted to them despite negative scientific evidence.",
"   </p>",
"   <p>",
"    The following ACTs are currently popular and will be discussed in more detail [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dietary treatments",
"     </li>",
"     <li>",
"      Herbal medicinal products",
"     </li>",
"     <li>",
"      Non-herbal supplements",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Dietary treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diet can influence cancer outcomes. The influence of conventional dietary patterns on prognosis in cancer survivors is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43321?source=see_link&amp;anchor=H435221609#H435221609\">",
"     \"The roles of diet, physical activity, and body weight in cancer survivorship\", section on 'Diet'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Proponents of \"alternative\" diets claim that prolongation of life through adherence to a specific diet is an achievable goal for cancer patients. However, a systematic review of the evidence found that none of the many dietary regimens has been convincingly shown to cure cancer or significantly prolong the life of cancer patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Gerson regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;One retrospective comparative analysis reported a six-fold increase in five-year survival rates of melanoma patients treated with the Gerson diet (a low sodium, high potassium, lactovegetarian diet that emphasizes fresh vegetables, fruit juices, and vitamin supplements), but the flawed methodology limits the reliability of this study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/25\">",
"     25",
"    </a>",
"    ]. Therefore, no good evidence supports this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Macrobiotic diets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scientific evidence of benefit from a macrobiotic diet (a high-complex carbohydrate, low fat vegetarian diet) in cancer patients is limited to two methodologically flawed retrospective studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/26\">",
"     26",
"    </a>",
"    ]; no controlled trials are available. In addition, one-third of cancer patients on a macrobiotic diet experience problems due to weight loss, the restrictive and unpalatable nature of the regimen, time spent preparing the food, and the expense and inaccessibility of some ingredients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Kelley-Gonzalez regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Kelley-Gonzalez regimen refers to a program of dietary restriction, intake of digestive aids (eg, pepsin and pancreatic enzymes), and a \"detoxification\" regimen that includes frequent coffee enemas. In one study that included 36 patients with unresectable or incompletely resected pancreatic cancer, only 11 were considered assessable for outcome for various reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/28\">",
"     28",
"    </a>",
"    ]. The median survival of treated patients was 17 months, compared to a literature control of four to six months. A trial comparing this therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    for pancreatic cancer was underway at Columbia University, but accrual issues forced a redesign of the study, which now compares outcome in patients who elect to receive the Gonzalez regimen with an externally matched group who receive standard gemcitabine-based combination chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Selected vegetables and herb mix",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selected vegetables and herb mix (SV) is a blended, boiled, and freeze-dried product containing ingredients with purported immune-stimulatory and anticancer properties: soybeans, mushrooms, mung beans, red dates, scallion, garlic, lentils, leek, hawthorn fruit, onion, ginseng, angelica, dandelion, senegal root, licorice, ginger, olives, sesame seeds, and parsley. Two small studies have been conducted in patients with cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In a matched-control study involving patients with stage",
"    <span class=\"nowrap\">",
"     III/IV",
"    </span>",
"    non-small cell lung cancer (NSCLC), median survival duration among the 11 patients who ingested SV daily was three-fold longer than that of 13 patients who did not receive the supplement (15 versus 4 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/30\">",
"     30",
"    </a>",
"    ]. A similar suggestion of prolonged survival was noted in a second study of 18 patients with stage",
"    <span class=\"nowrap\">",
"     III/IV",
"    </span>",
"    NSCLC who had either rejected or failed to respond to conventional therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/31\">",
"     31",
"    </a>",
"    ]. The median survival was 33.5 months for the 12 patients who used SV for two months or longer, and at five years, 50 percent of the patients remained alive.",
"   </p>",
"   <p>",
"    When these data were presented to the Cancer Advisory Panel for Complementary and Alternative Medicine, SV was judged worthy of further definitive research. Further information can be found at the NCI website (",
"    <a class=\"external\" href=\"file://cancer.gov/cancerinfo/pdq/cam/vegetables-sun-soup\">",
"     cancer.gov/cancerinfo/pdq/cam/vegetables-sun-soup",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Herbal medicinal products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous herbal medicinal products (HMPs) are promoted as ACTs. The examples listed below represent only a brief selection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Traditional Chinese medicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chinese herbal medicines are widely used in many areas of Asia to reduce the toxicity associated with conventional anticancer therapy; however, the efficacy of herbal therapy to minimize chemotherapy-related toxicity is unclear:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      This approach was assessed in a double-blind, placebo-controlled trial, in which 120 patients receiving adjuvant chemotherapy for breast or colon cancer were evaluated by a qualified Chinese herbalist [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/32\">",
"       32",
"      </a>",
"      ]. Treatment was prescribed and the active herbs or a matched control were dispensed in a blinded fashion. There was no difference between the two groups in hematologic toxicity, which was the primary end point. Among 16 non-hematologic parameters assessed, the only statistically significant difference was a reduction in the severity of nausea with active treatment.",
"     </li>",
"     <li>",
"      A systematic review was conducted of four trials in which 270 patients with advanced or late stage gastric cancer were randomly assigned to the traditional Chinese medicinal herb Huachansu (wild toad extract) plus chemotherapy compared with the same chemotherapy alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/33\">",
"       33",
"      </a>",
"      ]. The authors concluded that there was relatively weak evidence that Huachansu improved leukopenia when used together with chemotherapy, but it did not improve any other side effect or the short-term efficacy of chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, several Cochrane and other reviews were unable to find convincing evidence from randomized trials supporting the benefit of Chinese herbal medicine as a treatment for esophageal or lung cancer; none of the trials that claimed to be randomized were actually randomized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. At least one rigorously performed randomized phase II trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    with or without Huachansu in patients with locally advanced or metastatic pancreatic cancer failed to demonstrate any benefit from combined therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Green tea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Green tea is derived from the plant Camellia sinensis, and contains a number of biologically active polyphenols [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/6\">",
"     6",
"    </a>",
"    ]. Herbal products are widely used as CAMs in cancer patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/6,38\">",
"     6,38",
"    </a>",
"    ]. Green tea is the most widely used herbal product, used by 24 to 30 percent of all cancer patients.",
"   </p>",
"   <p>",
"    The polyphenols in green tea have a variety of biologic activities that might influence tumor behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. There are only limited data on possible clinical efficacy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single case control study from China suggested that consumption of large amounts of green tea may have a protective effect against the development of prostate cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/42\">",
"       42",
"      </a>",
"      ]. However, other case-control and cohort studies have not found a link between green tea intake and prostate cancer risk among Japanese men or Japanese-Americans living in Hawaii [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A phase I study in lung cancer patients and a phase II study in prostate cancer patients showed no antitumor activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/45,46\">",
"       45,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Consumption of large amounts of green tea may correlate with improved survival in patients with ovarian cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Green tea can interact in a variety of ways with conventional cancer treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/6\">",
"     6",
"    </a>",
"    ]. The polyphenols in green tea inhibit multiple cytochrome p450 enzymes that are important in drug metabolism; as a result, green tea could increase the plasma concentrations of a variety of chemotherapeutic agents (eg, anthracyclines and taxanes), possibly increasing drug toxicity. On the other hand, some drug-metabolizing enzymes are induced, which might lead to resistance to other chemotherapeutic agents.",
"   </p>",
"   <p>",
"    In addition, preclinical studies suggest that the polyphenols contained in green tea may inhibit the induction of tumor cell death by the proteasome inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    , which is used to treat multiple myeloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/48\">",
"     48",
"    </a>",
"    ]. While it is not clear that patients receiving this drug should refrain from drinking any green tea, it might be prudent to avoid ingesting large quantities, until further information is available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37114?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of relapsed or refractory multiple myeloma\", section on 'Bortezomib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Essiac",
"    </span>",
"    &nbsp;&mdash;&nbsp;Essiac is an herbal mixture originally formulated by a Canadian Ojibwa healer that has become popular in North America. The formula consists of burdock root (Arctium lappa), turkey rhubarb (Rheum palmatum), sheep or sheepshead sorrel (Rumex acetosella), and the inner bark of slippery elm (Ulmus fulva). Later, watercress, blessed thistle, red clover, and kelp were added.",
"   </p>",
"   <p>",
"    In vitro studies of the individual components of this mixture have demonstrated some evidence of biological activity, including antioxidant, antiestrogenic, immunostimulant, and antitumor actions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/49\">",
"     49",
"    </a>",
"    ]. However, an attempted systematic review did not find a single published clinical trial testing this mixture in cancer patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/50\">",
"     50",
"    </a>",
"    ]. The author concluded that there is no definitive evidence of its utility but that Essiac is unlikely to cause serious adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Mistletoe",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mistletoe extracts (Iscador, Helixor) contain various lectins and viscotoxins (including viscum fraxini-2). Evidence from in vitro experiments and animal models suggests that these components have some anticancer activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although dozens of matched pair cohort studies have largely supported a benefit for mistletoe extract in patients treated for cancer, randomized trials with various mistletoe preparations have given conflicting results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. Three independent systematic reviews of the clinical evidence concluded that there are insufficient data to support any benefit for mistletoe extracts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/51,58,59\">",
"     51,58,59",
"    </a>",
"    ]. A more recent meta-analysis suggested a modest survival benefit for cancer patients who received the mistletoe preparation Iscador [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/60\">",
"     60",
"    </a>",
"    ]. However, benefit was observed only in nonrandomized studies (hazard ratio [HR] for death 0.33, 95% CI 0.17 to 0.65) and not in randomized trials (HR for death 1.24, 95% CI 0.79 to 1.92), and there was a high probability of publication bias skewing the results. Numerous adverse effects are on record; the most serious is anaphylactic shock [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the available evidence, it cannot be concluded that there is benefit from mistletoe extract.",
"   </p>",
"   <p>",
"    Whether mistletoe improves quality of life in patients with cancer is unclear. Meta-analyses of controlled trials have concluded that there were positive effects in favor of Iscador [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/62\">",
"     62",
"    </a>",
"    ] and several European mistletoe extracts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/63\">",
"     63",
"    </a>",
"    ], but in general, the methodologic quality of the included studies has been poor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     PC-SPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;PC-SPES is an herbal dietary supplement consisting of seven Chinese and one American herbal extract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/64\">",
"     64",
"    </a>",
"    ]. The name of the product emphasizes its intention: PC stands for 'prostate cancer' and spes is Latin for 'hope'. The eight herbs were selected for their immune stimulating, cytotoxic, and cytostatic properties.",
"   </p>",
"   <p>",
"    PC-SPES has potent estrogenic activity. In men with advanced prostate cancer, decreases in serum prostate specific antigen, improvement in bone scans, and objective shrinkage of soft tissue measurable disease have been reported with PC-SPES. However, adulteration and toxicity (an acquired bleeding diathesis) forced a recall of this compound by the United States Food and Drug Administration in February 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/65\">",
"     65",
"    </a>",
"    ]. As a result, it is no longer commercially available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Sho-saiko-to",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sho-saiko-to is a traditional Chinese herbal mixture that contains extracts of seven medicinal herbs. It is widely administered in Japan to patients with chronic hepatitis and cirrhosis. Sho-saiko-to inhibits stellate cell activation and reduces hepatic fibrosis in vitro and in vivo. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/59/13242?source=see_link\">",
"     \"Emerging therapies for hepatic fibrosis\"",
"    </a>",
"    .) It also inhibits chemical hepatocarcinogenesis in animals, acts as a biological response modifier, and suppresses the proliferation of hepatoma cells by inducing apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective study of 260 cirrhotic patients found that a daily oral dose of sho-saiko-to (7.5 g) in addition to conventional therapy reduced the cumulative incidence of hepatocellular carcinoma over five years of follow-up compared with controls (p = 0.071) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/67\">",
"     67",
"    </a>",
"    ]. The difference was significant in patients who were hepatitis B surface antigen (HBsAg) negative (p = 0.024). Survival was also improved with sho-saiko-to therapy (p = 0.053), and again, the difference was significant in those who were HBsAg negative. Based on these results, the use of sho-saiko-to seems promising, but more clinical trials are required to be sure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     St. John's wort",
"    </span>",
"    &nbsp;&mdash;&nbsp;St. John's wort has primarily been used to treat depression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27784?source=see_link\">",
"     \"Clinical use of St. John's wort\"",
"    </a>",
"    .) An extract of St. John's wort, hypericin, has been noted to have a cytotoxic effect on tumor cells after photoactivation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. In vitro studies and in vivo investigations in mice have demonstrated that intralesional hypericin has the potential for use in a number of tumors, including bladder, squamous cell, pancreatic, and prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/70-73\">",
"     70-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The only human study has involved intralesional injection of hypericin into basal cell and squamous cell carcinomas of the skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/74\">",
"     74",
"    </a>",
"    ]. Injection with the extract three to five times per week was followed by irradiation with visible light. The authors claim that hypericin displayed selective tumor targeting; penetration in the surrounding tissues did not induce necrosis or cell loss, and generation of a new epithelium at the surface of the malignancy was noticed. Clinical remissions were observed after six to eight weeks. These preliminary results require replication in a randomized trial.",
"   </p>",
"   <p>",
"    Concerns have been raised about potential interactions of St John's wort with other medications and treatments in patients with cancer (see",
"    <a class=\"local\" href=\"#H41\">",
"     'Interactions of CAM with conventional treatment'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Astragalus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Chinese herb astragalus membranaceous is postulated to boost host immune function. A meta-analysis of randomized 34 trials found that the addition of astragalus to chemotherapy was associated with a reduced risk of death, an improved response rate, and a better performance status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/75\">",
"     75",
"    </a>",
"    ]. However, significant methodologic limitations in these trials prevented definitive conclusions about the efficacy of this herb.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Nonherbal supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the nonherbal supplements that have been evaluated are melatonin, shark and bovine cartilage, hydrazine, and thymus extracts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Melatonin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melatonin, a normal secretion of the pineal gland, has captured public attention because of its effects on mood, sleep, and jet lag. It has also been suggested that melatonin stimulates the immune system and has antioxidant, anticancer, and antiaging properties. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13034?source=see_link\">",
"     \"Physiology and clinical use of melatonin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although melatonin has been evaluated in a number of settings in patients with cancer, it does not have an established role. Examples of these studies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several studies have tested the efficacy of melatonin supplementation for slowing tumor progression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/76\">",
"       76",
"      </a>",
"      ]. One randomized, controlled trial suggested that patients with unresectable brain metastases from solid tumors who were treated with melatonin (20 mg daily by mouth, at 8 PM) experienced a significantly longer survival compared with those receiving supportive care only [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/77\">",
"       77",
"      </a>",
"      ]. However, a second randomized trial in patients with brain metastases did not find any benefit from using melatonin in conjunction with radiation therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with metastatic solid tumors who were treated with melatonin experienced less weight loss that those treated with supportive care alone, despite similar caloric intake [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/79\">",
"       79",
"      </a>",
"      ]. The authors hypothesized that the improvement in neoplastic cachexia was related to the effect of melatonin on decreasing the blood concentration of tumor necrosis factor.",
"     </li>",
"     <li>",
"      Melatonin has been evaluated in combination with aloe vera, which may have immunomodulating properties. In one report, 50 patients with advanced solid malignancies for whom no effective standard anticancer therapy existed, were treated either with melatonin (920 mg per day) or with melatonin and aloe vera tincture (1 mL twice daily) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/80\">",
"       80",
"      </a>",
"      ]. No response was seen in the former group while two partial responses were observed in the group treated with aloe vera. This result awaits confirmation through a more rigorous trial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Shark and bovine cartilage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shark and bovine cartilage are claimed to have anti-angiogenesis effects that might contribute to an inhibition of malignant growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Shark cartilage, in particular, is marketed aggressively with claims that it can cure cancer; such claims are invariably based upon anecdotal evidence at best.",
"   </p>",
"   <p>",
"    Despite these claims, two randomized trials, one in patients with unresectable nonsmall cell lung cancer and the other in patients with advanced breast or colorectal cancer, have demonstrated no improvement in survival with regimens including a shark cartilage derivative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Hydrazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrazine is a chemical with a variety of actions. It is an inhibitor of the enzyme phosphoenolpyruvate carboxykinase, a key enzyme in mammalian gluconeogenesis, a metabolic pathway that is thought to play a role in cancer cachexia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17960?source=see_link\">",
"     \"Clinical features and pathogenesis of cancer cachexia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Four controlled trials have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/85-88\">",
"     85-88",
"    </a>",
"    ]. The first study, which randomly assigned 64 patients with lung cancer to receive chemotherapy with or without hydrazine (60 mg three times daily) failed to show a significant difference in survival between the two groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/85\">",
"     85",
"    </a>",
"    ]. Three subsequent trials, two in lung cancer, and one in colorectal cancer, also failed to demonstrate a positive impact of hydrazine on survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/86-88\">",
"     86-88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Coenzyme Q10",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coenzyme Q10 (also known as Vitamin Q10, ubiquinone, or ubidecarenone) has been widely promoted for patients undergoing treatment for cancer, based upon the suggestion that it might improve tolerance for chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/89\">",
"     89",
"    </a>",
"    ]. However, in a double-blind placebo-controlled trial in patients with newly diagnosed breast cancer, there was no benefit from the use of coenzyme Q in self-reported cancer treatment-related fatigue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Previous randomized clinical studies have not supported any benefit from this molecule in patients with heart failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39221?source=see_link&amp;anchor=H9#H9\">",
"     \"Unproven therapies for chronic systolic heart failure\", section on 'Coenzyme Q10'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies evaluated coenzyme Q10 for possible cardioprotective effects in association with anthracycline therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. Two of these suggested a possible cardioprotective effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/91,93\">",
"     91,93",
"    </a>",
"    ], but all had serious design flaws, and no definitive conclusions could be drawn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/89\">",
"     89",
"    </a>",
"    ]. Although there were no adverse effects with coenzyme Q10, the molecule has procoagulant activity and may interfere with warfarin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Thymus extracts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several in-vitro studies have demonstrated that thymus extracts restore lymphocyte function, improve immunological variables, activate natural killer cells, and increase cytotoxic activity as well as mitogen-induced interferon levels in human lymphocytes. In addition, animal experiments have suggested that thymus extracts inhibit tumor growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review located 26 randomized, controlled trials of thymus extracts for various human cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/96\">",
"     96",
"    </a>",
"    ]. There was no evidence that the addition of purified thymus extracts or synthetic thymic peptides to antineoplastic treatment significantly reduced the risk of death or tumor progression, or improved tumor response rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Shiitake mushroom extract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shiitake mushrooms are among the most consumed mushrooms in the world, and they have been used in traditional Asian medicine for over 2000 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/97\">",
"     97",
"    </a>",
"    ]. In vitro, several polysaccharide components exhibit antitumor activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/98\">",
"     98",
"    </a>",
"    ]. The antitumor efficacy of a shiitake mushroom extract was tested in an open-label study in which 62 men with advanced prostate cancer received oral extracts of shiitake mushroom daily for six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/99\">",
"     99",
"    </a>",
"    ]. The clinical endpoint was the tumor marker, serum prostate specific antigen (PSA). By six months, 23 patients had a rising PSA, while 38 remained stable. No patient had a conventional PSA response, defined as a reduction of &ge;50 percent of serum PSA over baseline. The authors concluded that shiitake mushroom extract alone was an ineffective treatment for men with clinical advanced prostate cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Lycopene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have suggested that the carotenoid lycopene, which is particularly rich in tomatoes, may have a role in preventing prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/100,101\">",
"     100,101",
"    </a>",
"    ], although this has not been established in controlled clinical trials. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/24/42378?source=see_link&amp;anchor=H9#H9\">",
"     \"Cancer prevention\", section on 'Fruits and vegetables'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A detailed review of the available evidence by the United States Food and Drug Administration found that there was no credible evidence to support a relationship between lycopene intake and a reduced risk of cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Vitamin C",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have examined the hypothesis that antioxidants such as vitamin C can prevent cancer by augmenting the body's ability to dispose of toxic free radicals, thereby retarding oxidative damage. Although there is little evidence to support an important role for vitamin C in cancer prevention, many patients who have cancer take supplemental vitamin C, often at high doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/103\">",
"     103",
"    </a>",
"    ]. High-dose intravenous vitamin C is widely used by practitioners of CAM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/104\">",
"     104",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36586?source=see_link&amp;anchor=H18#H18\">",
"     \"Vitamin supplementation in disease prevention\", section on 'Antioxidant vitamins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While high-dose vitamin C is relatively nontoxic because excess doses of this water-soluble vitamin are excreted in the urine, concerns have been raised as to a potentially detrimental impact of vitamin C intake on the antitumor efficacy of cytotoxic chemotherapeutic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/105\">",
"     105",
"    </a>",
"    ], including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/106\">",
"     106",
"    </a>",
"    ]. Patients taking bortezomib should refrain from taking supplemental doses of vitamin C.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1342206520\">",
"    <span class=\"h3\">",
"     Modified citrus pectin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modified citrus pectin (MCP) is a form of pectin (a carbohydrate that is found in most plants and is particularly plentiful in the peels of apples, citrus fruits, and plums) that has been broken down into small molecules to facilitate absorption in the digestive tract. MCP inhibits metastases in animal models of prostate cancer and melanoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/107-109\">",
"     107-109",
"    </a>",
"    ]. One small uncontrolled clinical study of MCP demonstrated a significant slowing of the prostate-specific antigen (PSA) doubling time in 7 of 10 men in men with metastatic treatment-refractory prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/110\">",
"     110",
"    </a>",
"    ]. However, no study has demonstrated a reduction in solid tumor growth or enhanced survival with MCP. Randomized trials of larger groups of patients using conventional endpoints and an untreated control group are needed before any firm conclusions as to the benefit of MCP can be reached.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     COMPLEMENTARY SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complementary therapies are adjuncts to mainstream care that may be used to manage cancer symptoms, adverse effects of therapy or improve quality of life or even quality of death. In contrast to alternative therapies, many complementary therapies have been shown to be of benefit in patients with cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Acupuncture and related therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acupuncture has been studied in patients with cancer to reduce chemotherapy and radiotherapy-induced nausea and vomiting, for pain control, to reduce vasomotor symptoms in women receiving antiestrogen treatment for breast cancer as well as in men treated with gonadotropin analogs for prostate cancer, to diminish cancer&ndash;related fatigue, and to improve and prevent xerostomia in patients who have received radiation for head and neck cancer. Unfortunately, interpretation of the results of randomized trials is hampered by a high risk of bias in most studies, and lack of standardization of treatment methods and comparison groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/111\">",
"     111",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=see_link&amp;anchor=H18#H18\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Alternative strategies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27098?source=see_link&amp;anchor=H9#H9\">",
"     \"Cancer-related fatigue: Treatment\", section on 'Acupuncture'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=see_link&amp;anchor=H44713530#H44713530\">",
"     \"Psychological, rehabilitative, and integrative therapies for cancer pain\", section on 'Acupuncture and acupoint stimulation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=see_link&amp;anchor=H3822414#H3822414\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Acupuncture'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Nausea and vomiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different techniques have been used to stimulate the pericardium 6 (P6 or neiguan) site, which is commonly thought to be useful in the management of chemotherapy-induced nausea and vomiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/112\">",
"     112",
"    </a>",
"    ], and possibly radiotherapy-induced nausea and vomiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/113\">",
"     113",
"    </a>",
"    ]. These include manual stimulation with the insertion of fine needles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/114\">",
"     114",
"    </a>",
"    ], electrostimulation through needles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/115\">",
"     115",
"    </a>",
"    ] or percutaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/116-118\">",
"     116-118",
"    </a>",
"    ], and noninvasive pressure on the skin over the P6 pressure point (ie, acupressure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/113,119,120\">",
"     113,119,120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential benefits and limitations of these approaches are illustrated by two of the larger randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial, 739 patients beginning chemotherapy with a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      -containing regimen were randomly assigned to acupressure bands, an acustimulation band, or a no-band control in addition to standard antiemetics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/119\">",
"       119",
"      </a>",
"      ]. Patients who used the acupressure bands had significantly less nausea on day one than did controls, but there were no differences in acute vomiting or in rates of delayed nausea or emesis among the groups. &nbsp;",
"     </li>",
"     <li>",
"      Low frequency noninvasive electroacupuncture at classic antiemetic acupuncture points was evaluated in a trial in which 104 women with breast cancer were randomly assigned to the active intervention, mock electrostimulation on the same schedule, or no intervention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/115\">",
"       115",
"      </a>",
"      ]. All patients received concurrent three drug antiemetic pharmacotherapy and highly emetogenic chemotherapy. The number of emesis episodes occurring during the five days was significantly lower for patients receiving electroacupuncture compared with those receiving the mock procedure or antiemetic pharmacotherapy alone (median number of episodes, 5, 10, and 15, respectively). The observed effect had a limited duration, and by day 9, there were no differences between the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A year 2013 systematic review of acupuncture in cancer care included 11 randomized trials in which nausea and vomiting were assessed; eight were considered to have a high risk of bias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/111\">",
"     111",
"    </a>",
"    ]. Only one trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/115\">",
"     115",
"    </a>",
"    ] had a low risk of bias and was positive for short term benefit of electroacupuncture after chemotherapy for breast cancer; two other trials (one addressing benefit after chemotherapy and the other after radiotherapy) had unclear risk of bias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/121,122\">",
"     121,122",
"    </a>",
"    ], and one was positive, the other negative. All other trials were considered uninterpretable because of high risk of bias. The authors concluded that based upon the single positive study with low risk of bias that acupuncture could be considered an appropriate adjunctive treatment for chemotherapy-induced nausea and vomiting but that additional studies are needed. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Pain control and xerostomia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some trials have suggested that acupuncture can be useful in ameliorating cancer pain, a systematic review concluded that the value of acupuncture has not been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/123\">",
"     123",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=see_link&amp;anchor=H44713530#H44713530\">",
"     \"Psychological, rehabilitative, and integrative therapies for cancer pain\", section on 'Acupuncture and acupoint stimulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, benefit for acupuncture has been suggested in patients being treated for head and neck cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At least three randomized trials suggest that acupuncture improves treatment-related xerostomia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/124-126\">",
"       124-126",
"      </a>",
"      ]. In a representative trial, 70 patients with pain and salivary dysfunction three or more months after neck dissection and irradiation for head and neck cancer were randomly assigned to four weekly acupuncture treatments or usual care (physical therapy, analgesia, antiinflammatory drugs); the use of sialagogues was not described [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/124\">",
"       124",
"      </a>",
"      ]. Acupuncture was associated with a significant reduction in pain and dysfunction as well as a greater improvement in patient-reported xerostomia as compared to usual care. The duration of benefit was not stated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=see_link&amp;anchor=H3822348#H3822348\">",
"       \"Management of late complications of head and neck cancer and its treatment\", section on 'Salivary gland damage and xerostomia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      More recently, two small randomized trials of patients undergoing treatment for nasopharyngeal cancer suggested that prophylactic use of acupuncture may prevent radiation-induced xerostomia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/127,128\">",
"       127,128",
"      </a>",
"      ]. In the larger of the two, 86 patients in the treatment arm received acupuncture three times weekly during radiotherapy, while those in the control group received standard care only without sham acupuncture. Xerostomia questionnaire scores for the acupuncture group were significantly lower than for controls starting week 3 and continuing through six months. Significant differences in salivary flow favoring the acupuncture arm were seen as early as three weeks into treatment and persisted at six months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While intriguing, interpretation of these data is limited by the lack of a sham acupuncture control group in any of the trials. At least in the setting of chronic pain, both acupuncture and sham acupuncture have been shown to have much greater efficacy than no treatment, suggesting a strong placebo effect. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/50/28457?source=see_link&amp;anchor=H24#H24\">",
"     \"Acupuncture\", section on 'Summary'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Independent confirmation of these data in appropriately controlled trials is needed before acupuncture can be considered a standard approach to treatment or prevention of xerostomia in patients undergoing treatment for head and neck cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Vasomotor symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acupuncture has been studied as a potential therapy for hot flashes, but its value is unproven. In a meta-analysis of five trials comparing acupuncture to sham acupuncture in menopausal women with vasomotor symptoms, reductions in severity and frequency of hot flashes were seen with both therapies, but there were no significant differences between the two groups. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In men receiving gonadotropin analogs for prostate cancer, a small pilot study suggested that acupuncture decreases hot flashes, but there are no data from a randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/129\">",
"     129",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=see_link&amp;anchor=H15#H15\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Vasomotor symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Hypnotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several (mostly small) randomized, controlled trials have demonstrated the usefulness of hypnotherapy in palliative cancer care, with efficacy in controlling pain and",
"    <span class=\"nowrap\">",
"     nausea/vomiting",
"    </span>",
"    in various settings. A systematic review of hypnosis may be particularly useful for reducing the anticipatory emesis associated with chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/130\">",
"     130",
"    </a>",
"    ]. In addition, hypnosis can be useful in children for preventing anxiety and pain due to procedures such as lumbar puncture or bone marrow aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/131\">",
"     131",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=see_link&amp;anchor=H44713439#H44713439\">",
"     \"Psychological, rehabilitative, and integrative therapies for cancer pain\", section on 'Hypnotic analgesia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of hypnotherapy has also been evaluated as an adjunct to radiation therapy in a randomized study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/132\">",
"     132",
"    </a>",
"    ]. In a study of 69 patients undergoing curative radiotherapy for a variety of cancers, benefit could not be documented with formal instruments assessing anxiety and quality of life, although patients reported an improved sense of both overall and mental wellbeing.",
"   </p>",
"   <p>",
"    It is unclear to what extent these effects are due to specific or nonspecific (placebo) effects. An older review that summarized published clinical trials of hypnotherapy concluded that there is encouraging, albeit not compelling, evidence to suggest that hypnotherapy is helpful for controlling anxiety and pain as well as nausea and vomiting in cancer patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/133\">",
"     133",
"    </a>",
"    ]. A later systematic review of randomized trials of self-care strategies for managing common chemotherapy-related adverse effects concluded that randomized trials of reasonable quality provided limited support for the benefit of hypnosis in reducing nausea and vomiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Behavioral intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral intervention encompasses a number of techniques, which have been applied separately and in combination. Evidence of benefit for these psychoeducational strategies is provided by the following examples:",
"   </p>",
"   <p>",
"    In a randomized trial with 115 patients, a structured multidisciplinary program including cognitive, emotional, physical, social, and spiritual interventions was useful in patients receiving radiation therapy for advanced cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/135\">",
"     135",
"    </a>",
"    ]. Those receiving the active intervention were able to maintain their quality of life during the four week treatment period, while the control group who did not receive this adjunctive treatment had a significant decrease in quality of life. Six months after the intervention, quality of life was similar in the two groups.",
"   </p>",
"   <p>",
"    In a randomized trial conducted in 229 women after completion of surgery, chemotherapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy for breast cancer, an eight-week program of mindfulness-based stress reduction significantly improved mood, breast and endocrine-related quality of life, and well-being [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/136\">",
"     136",
"    </a>",
"    ]. The beneficial effects on fatigue and depression seen at eight weeks were no longer apparent at 12 weeks.",
"   </p>",
"   <p>",
"    The systematic review discussed above concluded that there was limited evidence to support the benefit of psychoeducation to reduce chemotherapy-related fatigue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/134\">",
"     134",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27098?source=see_link&amp;anchor=H5#H5\">",
"     \"Cancer-related fatigue: Treatment\", section on 'Cognitive-behavioral and psychosocial interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The data on cognitive-behavioral therapy to reduce chronic cancer and cancer treatment-associated pain is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=see_link&amp;anchor=H44713411#H44713411\">",
"     \"Psychological, rehabilitative, and integrative therapies for cancer pain\", section on 'Cognitive-behavioral interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Relaxation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relaxation techniques such as imagery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/137-139\">",
"     137-139",
"    </a>",
"    ], breathing exercises [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/137\">",
"     137",
"    </a>",
"    ], manual massage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/140-143\">",
"     140-143",
"    </a>",
"    ], music therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/144\">",
"     144",
"    </a>",
"    ], art therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/145\">",
"     145",
"    </a>",
"    ], yoga [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/146,147\">",
"     146,147",
"    </a>",
"    ], medical Qigong [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/148\">",
"     148",
"    </a>",
"    ] and reflexology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/149,150\">",
"     149,150",
"    </a>",
"    ] have been used to reduce symptoms (such as nausea and vomiting, pain, fatigue) and improve mood, sleep, and quality of life in cancer patients. The systematic review discussed above concluded that there was limited evidence to support a benefit for relaxation and exercise to reduce nausea and vomiting, with some benefit for this practice seen in 10 of 13 published randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/134\">",
"     134",
"    </a>",
"    ]. The benefit of yoga for reducing fatigue and improving sleep quality has been demonstrated in a randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/147\">",
"     147",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27098?source=see_link&amp;anchor=H11096059#H11096059\">",
"     \"Cancer-related fatigue: Treatment\", section on 'Yoga'",
"    </a>",
"    .) The impact of relaxation therapy on mood and quality of life are less certain. In one randomized study, 96 women receiving chemotherapy for newly diagnosed breast cancer were assigned to receive either regular relaxation training and imagery or standard care only [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/138\">",
"     138",
"    </a>",
"    ]. The experimental group experienced better quality of life than the control group. However, another trial of relaxation therapy in women with early breast cancer and hot flashes found no benefits in terms of anxiety or quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/151\">",
"     151",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Manual massage therapy can convey intensive relaxation to both the body and the mind, but benefits are usually transient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/140-143\">",
"     140-143",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective series of 1290 cancer patients in whom pain, fatigue, anxiety, and nausea were assessed before and after massage therapy, moderate to severe symptoms decreased by approximately 50 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/140\">",
"       140",
"      </a>",
"      ]. Therapeutic benefits persisted for at least 48 hours in outpatients, although the total duration of benefit was not reported.",
"     </li>",
"     <li>",
"      Massage therapy was compared to simple touch in a randomized trial involving 298 persons with advanced cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/143\">",
"       143",
"      </a>",
"      ]. Massage was associated with significant immediately beneficial effects on pain and mood (just after the treatment session), but they were not sustained in the following weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Not all behavioral interventions have been shown to be effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/130,146,152\">",
"     130,146,152",
"    </a>",
"    ]. Although many studies are encouraging, we need to determine which approaches are best for what type of patient and to establish how these interventions compare to conventional methods used in palliative care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/153\">",
"     153",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relaxation and massage therapy for management of chronic cancer and cancer treatment-associated pain are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=see_link&amp;anchor=H44713425#H44713425\">",
"     \"Psychological, rehabilitative, and integrative therapies for cancer pain\", section on 'Relaxation therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=see_link&amp;anchor=H676926816#H676926816\">",
"     \"Psychological, rehabilitative, and integrative therapies for cancer pain\", section on 'Massage therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Aromatherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aromatherapy uses various aromatic oils, often in conjunction with massage, to treat symptoms of anxiety and depression. This approach has been widely used, and evidence from small trials suggests that it may have some benefit in relieving self-reported symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/154\">",
"     154",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aromatherapy massage was assessed in a multicenter trial in which 282 cancer patients were randomly assigned to aromatherapy weekly for four weeks or to a control arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/155\">",
"     155",
"    </a>",
"    ]. No benefits were present at 10 weeks after treatment, the primary endpoint of the trial. Although patients experienced improvement two weeks after treatment, these benefits were no longer present at six weeks after therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Therapeutic touch",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several clinical trials have tested the effectiveness of therapeutic touch (Reiki) to reduce anxiety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/156\">",
"     156",
"    </a>",
"    ], improve wellbeing or quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/157,158\">",
"     157,158",
"    </a>",
"    ], or reduce pain in cancer patients. Some of these studies have yielded positive results. Due to weaknesses in study design, however, it is unclear whether the observed effects were due to specific therapeutic or nonspecific (placebo) effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/159\">",
"     159",
"    </a>",
"    ]. The use of therapeutic touch as a treatment for cancer pain is addressed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=see_link&amp;anchor=H44713516#H44713516\">",
"     \"Psychological, rehabilitative, and integrative therapies for cancer pain\", section on 'Biofield therapies: Reiki and therapeutic touch'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Self-help and support groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a trend for increasing participation in support groups among cancer patients. Although patients attending these groups do so mainly for psychosocial support, the data are conflicting as to whether these interventions prolong survival. Some reports have suggested a survival benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/160-163\">",
"     160-163",
"    </a>",
"    ]. However, these benefits were not confirmed in larger randomized trials, and a meta-analysis showed no significant effect on survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/164-170\">",
"     164-170",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Ginseng and guarana for fatigue",
"    </span>",
"    &nbsp;&mdash;&nbsp;A beneficial effect of American ginseng (2000 mg daily) on cancer-related fatigue was suggested in a preliminary report of a double-blind, placebo controlled trial conducted by the North Central Cancer Treatment Group. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27098?source=see_link&amp;anchor=H24908748#H24908748\">",
"     \"Cancer-related fatigue: Treatment\", section on 'Ginseng and guarana'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guarana is a stimulant derived from an extract of seeds from a plant in the Amazon (Paullinia cupana). In a double-blind, placebo-controlled study of breast cancer patients receiving chemotherapy, oral guarana at a dose of 100 mg daily significantly improved fatigue scores (p&lt;0.01) at the end of 21 days of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/171\">",
"     171",
"    </a>",
"    ]. Further studies are needed to confirm these results and to evaluate their generalizability to chronic cancer-related fatigue and to other types of cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Fish oil for symptom control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fish oil, which contains alpha-3 omega fatty acids, has been studied as a pharmacologic treatment for cancer-related",
"    <span class=\"nowrap\">",
"     anorexia/cachexia.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5113?source=see_link&amp;anchor=H14#H14\">",
"     \"Pharmacologic management of cancer anorexia/cachexia\", section on 'Eicosapentaenoic acid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At least one trial has examined the benefit of fish oil for control of cancer-related symptoms in addition to anorexia. Sixty patients with a variety of cancers were randomly assigned to fish oil capsules or placebo in addition to their conventional treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/172\">",
"     172",
"    </a>",
"    ]. Among the 60 patients who both began and completed two weeks of their allotted therapy (27 dropped out during treatment because they could not tolerate the regimen), supplemental fish oil did not influence appetite, fatigue, nausea, weight loss, caloric intake, nutritional status or sense of wellbeing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SAFETY ISSUES WITH COMPLEMENTARY AND ALTERNATIVE TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While many forms of complementary and alternative medicine (CAM) for cancer are associated with minimal or no risk, this is not true for all such therapies. Potential toxicities include direct toxicity of CAM medications and procedures, indirect effects of CAM due to interactions with other medications, and also the risk to the patient who uses CAM to avoid or delay established, effective treatment in the management of malignant disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/173\">",
"     173",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20554?source=see_link\">",
"     \"Overview of herbal medicine and dietary supplements\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Direct toxicity of CAM medications and procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of herbal medications may produce serious side effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20554?source=see_link\">",
"     \"Overview of herbal medicine and dietary supplements\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25642?source=see_link\">",
"     \"Hepatotoxicity due to herbal medications and dietary supplements\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6933?source=see_link\">",
"     \"Nephropathy induced by aristolochic acid (AA) containing herbs\"",
"    </a>",
"    .) Quality control of these preparations can be a major concern. Pertinent issues include variability in biologic potency in different crops, the realistic possibility of fungal or bacterial contamination, the use of incorrect plant species, and consumer fraud [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/174\">",
"     174",
"    </a>",
"    ]. One of the most severe examples of the potential for harm with herbal preparations is the development of renal failure and urothelial cancer in individuals who thought they were using the herbal preparation Stephania tetrandra for weight loss but who actually received the Chinese herb Aristolochia fangchi because of a manufacturing error [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/175,176\">",
"     175,176",
"    </a>",
"    ]. Numerous examples of potential side effects associated with the more commonly used herbal and other types of CAM are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef81493 \" href=\"mobipreview.htm?21/7/21628\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/46,177-184\">",
"     46,177-184",
"    </a>",
"    ]. Adverse events due to herbal remedies should be reported to the United States Food and Drug Administration (800-FDA-1088).",
"   </p>",
"   <p>",
"    Reported adverse effects of acupuncture include transmission of an infectious agent through needle insertion, broken, forgotten, or misapplied needles, pneumothorax, transient hypotension, minor bleeding, contact dermatitis, and pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/185\">",
"     185",
"    </a>",
"    ]. Therapeutic deep massage can result in hematoma, particularly in anticoagulated or thrombocytopenic patients, and other serious complications have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/186-188\">",
"     186-188",
"    </a>",
"    ]. Finally, severe complications of enema therapy include infection with enteric pathogens, severe dehydration and electrolyte imbalance, and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/189-191\">",
"     189-191",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Interactions of CAM with conventional treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many botanical agents are pharmacologically active, raising concerns about potential interactions with conventional therapy, both cytotoxic agents, and other medical therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/192-195\">",
"     192-195",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many common chemotherapy agents are metabolized through the cytochrome p450 system and the specific isoenzymes responsible for their metabolism are listed in the individual drug monographs section on",
"    <span class=\"nowrap\">",
"     Metabolism/Transport",
"    </span>",
"    Effects. What follows are selected examples of potential interactions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      St John's wort induces CYP3A4 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/196\">",
"       196",
"      </a>",
"      ], which can lead to subtherapeutic levels of chemotherapeutic agents that are metabolized by CYP3A4 (eg, taxanes, irinotecan, imatinib) as well as other drugs such as oxycodone. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27784?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical use of St. John's wort\", section on 'Herb-drug interactions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Essiac consists of multiple biologically active ingredients, which may act synergistically with chemotherapeutic agents by its inhibition of CYP3A or through the cytotoxic or immunosuppressive activities of anthraquinones present in this mixture [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As noted previously, the polyphenols in green tea inhibit multiple cytochrome p450 enzymes, which are important in drug metabolism and induce other drug-metabolizing enzymes (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Herbal medicinal products'",
"      </a>",
"      above). Several components of green tea and green tea extract can antagonize the effectiveness of bortezomib [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Because it can inhibit the cytochrome p450 system, milk thistle has the potential to decrease the metabolism of some cytotoxic agents such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/197,198\">",
"       197,198",
"      </a>",
"      ] and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/199\">",
"       199",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Panax ginseng and ginkgo biloba increase the functional activity of several drug-metabolizing enzymes of the CYP family and should be avoided in patients receiving cytotoxic agents metabolized by CYP3A4 or CYP2C19 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/192\">",
"       192",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Others have shown that pretreatment of cancer cells with some botanical agents (eg, berberine, a constituent of huang lian) reduces the sensitivity of these cells to chemotherapy-induced apoptosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/200\">",
"       200",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      PC-SPES, which is no longer commercially available in the United States, has been associated with elevations in the prothrombin time, which may promote bleeding in patients with drug or disease-induced thrombocytopenia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38520?source=see_link\">",
"       \"Secondary endocrine therapies for castration resistant prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific herbal remedies to discourage or avoid during chemotherapy are shown in the attached table (",
"    <a class=\"graphic graphic_table graphicRef71346 \" href=\"mobipreview.htm?20/58/21422\">",
"     table 2",
"    </a>",
"    ). This list is not comprehensive. Additional specific interactions may be determined using the drug interactions program included in UpToDate. This program can be accessed from the UpToDate new search page or through the individual drug monographs section on Drug Interactions.",
"   </p>",
"   <p>",
"    An extensive, although not all-inclusive, listing of herbs and their actions that may interact with certain drugs is found in the following tables. As examples, herbs with laxative properties may interact with antidiarrheal drugs, while those having anticoagulant effects may interact with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergenic herbs (",
"      <a class=\"graphic graphic_table graphicRef61350 \" href=\"mobipreview.htm?24/30/25069\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Amine, alkaloid, and sympathomimetic herbs (",
"      <a class=\"graphic graphic_table graphicRef50983 graphicRef63729 \" href=\"mobipreview.htm?43/7/44157\">",
"       table 4A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Anticoagulant and coagulant herbs (",
"      <a class=\"graphic graphic_table graphicRef65055 \" href=\"mobipreview.htm?11/22/11629\">",
"       table 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cardioactive herbs (",
"      <a class=\"graphic graphic_table graphicRef62487 \" href=\"mobipreview.htm?37/41/38556\">",
"       table 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Diuretic herbs (",
"      <a class=\"graphic graphic_table graphicRef82127 \" href=\"mobipreview.htm?11/16/11532\">",
"       table 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Herbs affecting blood sugar (",
"      <a class=\"graphic graphic_table graphicRef59340 \" href=\"mobipreview.htm?39/49/40732\">",
"       table 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Herbs affecting lipids (",
"      <a class=\"graphic graphic_table graphicRef72116 \" href=\"mobipreview.htm?23/31/24059\">",
"       table 9",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hormonally active herbs (",
"      <a class=\"graphic graphic_table graphicRef61831 \" href=\"mobipreview.htm?43/33/44571\">",
"       table 10",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypertensive herbs (",
"      <a class=\"graphic graphic_table graphicRef68095 \" href=\"mobipreview.htm?35/47/36603\">",
"       table 11",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypotensive herbs (",
"      <a class=\"graphic graphic_table graphicRef69652 \" href=\"mobipreview.htm?9/15/9469\">",
"       table 12",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Immunostimulating herbs (",
"      <a class=\"graphic graphic_table graphicRef65357 \" href=\"mobipreview.htm?15/9/15515\">",
"       table 13",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Irritant herbs (",
"      <a class=\"graphic graphic_table graphicRef50833 \" href=\"mobipreview.htm?16/35/16957\">",
"       table 14",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Laxative herbs (",
"      <a class=\"graphic graphic_table graphicRef72359 \" href=\"mobipreview.htm?26/59/27579\">",
"       table 15",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sedative herbs (",
"      <a class=\"graphic graphic_table graphicRef60526 \" href=\"mobipreview.htm?15/25/15772\">",
"       table 16",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Delay or avoidance of conventional therapy of known benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not a direct \"toxic\" effect, the use of CAM may result in a significant delay in instituting conventional treatment that is of documented benefit for a specific condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/201-204\">",
"     201-204",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, it is often required or \"recommended\" that only natural substances be ingested for the duration of the CAM treatment, as non-natural products are alleged to negate the benefit of the therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/191\">",
"     191",
"    </a>",
"    ]. This strategy of care can lead to the rejection of effective medical therapies such as opioid analgesics, regardless of the severity of pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/173\">",
"     173",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The adverse impact of",
"    <span class=\"nowrap\">",
"     refusing/delaying",
"    </span>",
"    standard treatments in favor of alternative therapies was shown in a series 61 patients with breast cancer who were identified in a community surgical practice over a ten-year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/205\">",
"     205",
"    </a>",
"    ]. At a median follow-up of 54 months, among the 26 patients who omitted or delayed surgery, 96 percent experienced disease progression, and one-half died of their disease. Of the 35 patients who were nonadherent to adjuvant therapy recommendations, only 14 percent remained relapse-free, and 20 percent died of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/33/25105?source=see_link\">",
"       \"Patient information: Alternative medicine (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/57/19346?source=see_link\">",
"       \"Patient information: Nausea and vomiting with cancer treatment (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/51/21300?source=see_link\">",
"       \"Patient information: Complementary and alternative medicine treatments (CAM) for cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is",
"      <strong>",
"       no",
"      </strong>",
"      compelling evidence that any alternative therapy is effective in patients with cancer. Nevertheless, outlandish and irresponsible claims continue to be published in the medical literature: \"With classic homeopathy it is possible to treat people suffering from cancer. The patients can be helped palliatively as well as curatively&rdquo; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/206\">",
"       206",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/17/26903?source=see_link\">",
"       \"Homeopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thus, it is understandable that oncologists are concerned about the high level of acceptance of alternative therapies by cancer patients. On the other hand, outright rejection of these treatments might be counter-productive for the following reasons:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Every now and then impressive case reports emerge from credible sources. An open mind toward plausible CAM options might therefore be a good general policy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/207\">",
"       207",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Outright rejection alienates patients and negatively affects the therapeutic relationship.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proponents of these therapies argue that it would be inhumane not to provide such treatments if patients want them. Oncologists should certainly not hinder patients from seeking such help. On the other hand, one should still insist that the usefulness of these therapies be demonstrated beyond reasonable doubt. The use of ineffective supportive treatments is ethically problematic; for instance, it might lead to a situation where such therapies replace others with proven effectiveness. An important point is that claims of efficacy should be supported with acceptable evidence by those who make these claims, rather than rejected through research carried out by those who doubt them. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Alternative cancer treatments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the interest of our patients, we should discuss the (lack of) evidence for alternative therapies openly and objectively. This includes the fact that some treatments carry considerable risks and many are neither associated with prolongation of life nor an enhanced quality of life. Information must be reliable and from reputable sources [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/13/40154/abstract/208\">",
"       208",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The role of complementary therapies in palliative and supportive cancer is a different matter and seems more promising. Several of these therapies have at least some potential for improving quality of life. The common denominator in achieving this goal may turn out to be the promotion of relaxation. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Complementary supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The often emotional conflicts between opponents and proponents of CAM are, to a large degree, a regrettable artifact caused by the lack of reliable evidence in this area. If more convincing data existed, there would be far less room for disagreement. It follows that more research efforts (and research funds) should be directed towards creating reliable evidence.",
"      <br/>",
"      <br/>",
"      In the United States, the National Institutes of Health (NIH) Center for Complementary and Alternative Medicine and the National Cancer Institute are supporting well designed studies of alternative medicine. Information on CAM is available through the NCI website (",
"      <a class=\"external\" href=\"file://cancer.gov/cancerinfo/treatment/cam\">",
"       cancer.gov/cancerinfo/treatment/cam",
"      </a>",
"      ), and in registry of systematic reviews of CAM (not limited to cancer) produced by a CAM field group within the Cochrane Collaborative (",
"      <a class=\"external\" href=\"file://www.compmed.umm.edu/cochrane.asp\">",
"       file://www.compmed.umm.edu/cochrane.asp",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/1\">",
"      Engel LW, Straus SE. Development of therapeutics: opportunities within complementary and alternative medicine. Nat Rev Drug Discov 2002; 1:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/2\">",
"      Kessler RC, Davis RB, Foster DF, et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med 2001; 135:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/3\">",
"      Shen J, Andersen R, Albert PS, et al. Use of complementary/alternative therapies by women with advanced-stage breast cancer. BMC Complement Altern Med 2002; 2:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/4\">",
"      Richardson MA, Sanders T, Palmer JL, et al. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000; 18:2505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/5\">",
"      Navo MA, Phan J, Vaughan C, et al. An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. J Clin Oncol 2004; 22:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/6\">",
"      Dy GK, Bekele L, Hanson LJ, et al. Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. J Clin Oncol 2004; 22:4810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/7\">",
"      Lee AH, Ingraham SE, Kopp M, et al. The incidence of potential interactions between dietary supplements and prescription medications in cancer patients at a Veterans Administration Hospital. Am J Clin Oncol 2006; 29:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/8\">",
"      Swarup AB, Barrett W, Jazieh AR. The use of complementary and alternative medicine by cancer patients undergoing radiation therapy. Am J Clin Oncol 2006; 29:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/9\">",
"      Vapiwala N, Mick R, Hampshire MK, et al. Patient initiation of complementary and alternative medical therapies (CAM) following cancer diagnosis. Cancer J 2006; 12:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/10\">",
"      Gansler T, Kaw C, Crammer C, Smith T. A population-based study of prevalence of complementary methods use by cancer survivors: a report from the American Cancer Society's studies of cancer survivors. Cancer 2008; 113:1048.",
"     </a>",
"    </li>",
"    <li>",
"     Hunt KJ, Ernst E. Patients' use of CAM: results from the Health Survey for England 2005. Focus Alt Compl Ther 2010; 15:101.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/12\">",
"      Metz JM, Jones H, Devine P, et al. Cancer patients use unconventional medical therapies far more frequently than standard history and physical examination suggest. Cancer J 2001; 7:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/13\">",
"      Schofield PE, Juraskova I, Butow PN. How oncologists discuss complementary therapy use with their patients: an audio-tape audit. Support Care Cancer 2003; 11:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/14\">",
"      Astin JA. Why patients use alternative medicine: results of a national study. JAMA 1998; 279:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/15\">",
"      Burstein HJ, Gelber S, Guadagnoli E, Weeks JC. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 1999; 340:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/16\">",
"      Risberg T, Kaasa S, Wist E, Melsom H. Why are cancer patients using non-proven complementary therapies? A cross-sectional multicentre study in Norway. Eur J Cancer 1997; 33:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/17\">",
"      Danielson KJ, Stewart DE, Lippert GP. Unconventional cancer remedies. CMAJ 1988; 138:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/18\">",
"      Boon H, Stewart M, Kennard MA, et al. Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol 2000; 18:2515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/19\">",
"      Newell S, Sanson-Fisher RW. Australian oncologists' self-reported knowledge and attitudes about non-traditional therapies used by cancer patients. Med J Aust 2000; 172:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/20\">",
"      Gray RE, Greenberg M, Fitch M, et al. Perspectives of cancer survivors interested in unconventional therapies. J Psychosoc Oncology 1997; 15:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/21\">",
"      Risberg T, Vickers A, Bremnes RM, et al. Does use of alternative medicine predict survival from cancer? Eur J Cancer 2003; 39:372.",
"     </a>",
"    </li>",
"    <li>",
"     Lagnado L. Laetrile makes a comeback on the web: Long deemed illegal by the FDA, it's selling briskly again to desperate patients online. The Wall Street Journal, April 22, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/23\">",
"      Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 1998; 83:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/24\">",
"      Ernst E, Boddy K. CAM cancer diets. Focus Altern Complement Ther 2006; 11:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/25\">",
"      Hildenbrand GL, Hildenbrand LC, Bradford K, Cavin SW. Five-year survival rates of melanoma patients treated by diet therapy after the manner of Gerson: a retrospective review. Altern Ther Health Med 1995; 1:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/26\">",
"      Carter JP, Saxe GP, Newbold V, et al. Hypothesis: dietary management may improve survival from nutritionally linked cancers based on analysis of representative cases. J Am Coll Nutr 1993; 12:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/27\">",
"      Downer SM, Cody MM, McCluskey P, et al. Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ 1994; 309:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/28\">",
"      Gonzalez NJ, Isaacs LL. Evaluation of pancreatic proteolytic enzyme treatment of adenocarcinoma of the pancreas, with nutrition and detoxification support. Nutr Cancer 1999; 33:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/29\">",
"      Richardson MA, Straus SE. Complementary and alternative medicine: opportunities and challenges for cancer management and research. Semin Oncol 2002; 29:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/30\">",
"      Sun AS, Ostadal O, Ryznar V, et al. Phase I/II study of stage III and IV non-small cell lung cancer patients taking a specific dietary supplement. Nutr Cancer 1999; 34:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/31\">",
"      Sun AS, Yeh HC, Wang LH, et al. Pilot study of a specific dietary supplement in tumor-bearing mice and in stage IIIB and IV non-small cell lung cancer patients. Nutr Cancer 2001; 39:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/32\">",
"      Mok TS, Yeo W, Johnson PJ, et al. A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Ann Oncol 2007; 18:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/33\">",
"      Gan T, Wu Z, Tian L, Wang Y. Chinese herbal medicines for induction of remission in advanced or late gastric cancer. Cochrane Database Syst Rev 2010; :CD005096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/34\">",
"      Wei X, Chen Z, Yang X, Wu T. Chinese herbal medicines for esophageal cancer. Cochrane Database Syst Rev 2009; :CD004520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/35\">",
"      Rui D, Xiaoyan C, Taixiang W, Guanjian L. Elemene for the treatment of lung cancer. Cochrane Database Syst Rev 2007; :CD006054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/36\">",
"      Xu M, Deng PX, Qi C, et al. Adjuvant phytotherapy in the treatment of cervical cancer: a systematic review and meta-analysis. J Altern Complement Med 2009; 15:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/37\">",
"      Meng Z, Garrett CR, Shen Y, et al. Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas. Br J Cancer 2012; 107:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/38\">",
"      Bernstein BJ, Grasso T. Prevalence of complementary and alternative medicine use in cancer patients. Oncology (Williston Park) 2001; 15:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/39\">",
"      Hussain T, Gupta S, Adhami VM, Mukhtar H. Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. Int J Cancer 2005; 113:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/40\">",
"      Mei Y, Qian F, Wei D, Liu J. Reversal of cancer multidrug resistance by green tea polyphenols. J Pharm Pharmacol 2004; 56:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/41\">",
"      Adhami VM, Siddiqui IA, Ahmad N, et al. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 2004; 64:8715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/42\">",
"      Jian L, Xie LP, Lee AH, Binns CW. Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer 2004; 108:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/43\">",
"      Kikuchi N, Ohmori K, Shimazu T, et al. No association between green tea and prostate cancer risk in Japanese men: the Ohsaki Cohort Study. Br J Cancer 2006; 95:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/44\">",
"      Sonoda T, Nagata Y, Mori M, et al. A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. Cancer Sci 2004; 95:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/45\">",
"      Laurie SA, Miller VA, Grant SC, et al. Phase I study of green tea extract in patients with advanced lung cancer. Cancer Chemother Pharmacol 2005; 55:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/46\">",
"      Jatoi A, Ellison N, Burch PA, et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003; 97:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/47\">",
"      Zhang M, Lee AH, Binns CW, Xie X. Green tea consumption enhances survival of epithelial ovarian cancer. Int J Cancer 2004; 112:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/48\">",
"      Golden EB, Lam PY, Kardosh A, et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 2009; 113:5927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/49\">",
"      Tamayo C, Richardson MA, Diamond S, Skoda I. The chemistry and biological activity of herbs used in Flor-Essence herbal tonic and Essiac. Phytother Res 2000; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/50\">",
"      Kaegi E. Unconventional therapies for cancer: 1. Essiac. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ 1998; 158:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/51\">",
"      Kaegi E. Unconventional therapies for cancer: 3. Iscador. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ 1998; 158:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/52\">",
"      Pae HO, Seo WG, Oh GS, et al. Potentiation of tumor necrosis factor-alpha-induced apoptosis by mistletoe lectin. Immunopharmacol Immunotoxicol 2000; 22:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/53\">",
"      Schumacher U, Feldhaus S, Mengs U. Recombinant mistletoe lectin (rML) is successful in treating human ovarian cancer cells transplanted into severe combined immunodeficient (SCID) mice. Cancer Lett 2000; 150:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/54\">",
"      Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al. The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 2001; 37:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/55\">",
"      Semiglazov VF, Stepula VV, Dudov A, et al. Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res 2006; 26:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/56\">",
"      Lenartz D, Dott U, Menzel J, et al. Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 2000; 20:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/57\">",
"      Kleeberg UR, Suciu S, Br&ouml;cker EB, et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness &gt;3 mm) or regional lymph node metastasis. Eur J Cancer 2004; 40:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/58\">",
"      Ernst E, Schmidt K, Steuer-Vogt MK. Mistletoe for cancer? A systematic review of randomised clinical trials. Int J Cancer 2003; 107:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/59\">",
"      Kienle GS, Kiene H. Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res 2007; 12:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/60\">",
"      Ostermann T, Raak C, B&uuml;ssing A. Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review. BMC Cancer 2009; 9:451.",
"     </a>",
"    </li>",
"    <li>",
"     Stein GM, Berg PA. Adverse effects during therapy with mistletoe extracts. In: Mistletoe: The Genus Viscum, B&uuml;ssig A (Ed), Hardwood Academic Publishers, Amsterdam 2000. p.195.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/62\">",
"      B&uuml;ssing A, Raak C, Ostermann T. Quality of life and related dimensions in cancer patients treated with mistletoe extract (iscador): a meta-analysis. Evid Based Complement Alternat Med 2012; 2012:219402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/63\">",
"      Kienle GS, Kiene H. Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther 2010; 9:142.",
"     </a>",
"    </li>",
"    <li>",
"     Fan S, Wang X. Herbal composition for treating prostate cancer. PC-SPES. Pending United States patent number 08/697920.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/65\">",
"      Weinrobe MC, Montgomery B. Acquired bleeding diathesis in a patient taking PC-SPES. N Engl J Med 2001; 345:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/66\">",
"      Shimizu I. Sho-saiko-to: Japanese herbal medicine for protection against hepatic fibrosis and carcinoma. J Gastroenterol Hepatol 2000; 15 Suppl:D84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/67\">",
"      Oka H, Yamamoto S, Kuroki T, et al. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 1995; 76:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/68\">",
"      Delaey E, Vandenbogaerde A, Merlevede W, de Witte P. Photocytotoxicity of hypericin in normoxic and hypoxic conditions. J Photochem Photobiol B 2000; 56:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/69\">",
"      Chen B, de Witte PA. Photodynamic therapy efficacy and tissue distribution of hypericin in a mouse P388 lymphoma tumor model. Cancer Lett 2000; 150:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/70\">",
"      Kamuhabwa AR, Agostinis P, D'Hallewin MA, et al. Photodynamic activity of hypericin in human urinary bladder carcinoma cells. Anticancer Res 2000; 20:2579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/71\">",
"      Liu CD, Kwan D, Saxton RE, McFadden DW. Hypericin and photodynamic therapy decreases human pancreatic cancer in vitro and in vivo. J Surg Res 2000; 93:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/72\">",
"      Chung PS, Rhee CK, Kim KH, et al. Intratumoral hypericin and KTP laser therapy for transplanted squamous cell carcinoma. Laryngoscope 2000; 110:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/73\">",
"      Colasanti A, Kisslinger A, Liuzzi R, et al. Hypericin photosensitization of tumor and metastatic cell lines of human prostate. J Photochem Photobiol B 2000; 54:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/74\">",
"      Alecu M, Ursaciuc C, H&atilde;l&atilde;l&atilde;u F, et al. Photodynamic treatment of basal cell carcinoma and squamous cell carcinoma with hypericin. Anticancer Res 1998; 18:4651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/75\">",
"      McCulloch M, See C, Shu XJ, et al. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol 2006; 24:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/76\">",
"      Jacobson JS, Workman SB, Kronenberg F. Research on complementary/alternative medicine for patients with breast cancer: a review of the biomedical literature. J Clin Oncol 2000; 18:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/77\">",
"      Lissoni P, Barni S, Ardizzoia A, et al. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer 1994; 73:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/78\">",
"      Berk L, Berkey B, Rich T, et al. Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119). Int J Radiat Oncol Biol Phys 2007; 68:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/79\">",
"      Lissoni P, Paolorossi F, Tancini G, et al. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 1996; 32A:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/80\">",
"      Lissoni P, Giani L, Zerbini S, et al. Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. Nat Immun 1998; 16:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/81\">",
"      Sheu JR, Fu CC, Tsai ML, Chung WJ. Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities. Anticancer Res 1998; 18:4435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/82\">",
"      Liu N, Lapcevich RK, Underhill CB, et al. Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth. Cancer Res 2001; 61:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/83\">",
"      Lu C, Lee JJ, Komaki R, et al. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst 2010; 102:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/84\">",
"      Loprinzi CL, Levitt R, Barton DL, et al. Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial. Cancer 2005; 104:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/85\">",
"      Chlebowski RT, Bulcavage L, Grosvenor M, et al. Hydrazine sulfate influence on nutritional status and survival in non-small-cell lung cancer. J Clin Oncol 1990; 8:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/86\">",
"      Kosty MP, Fleishman SB, Herndon JE 2nd, et al. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1994; 12:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/87\">",
"      Loprinzi CL, Goldberg RM, Su JQ, et al. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 1994; 12:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/88\">",
"      Loprinzi CL, Kuross SA, O'Fallon JR, et al. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 1994; 12:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/89\">",
"      Roffe L, Schmidt K, Ernst E. Efficacy of coenzyme Q10 for improved tolerability of cancer treatments: a systematic review. J Clin Oncol 2004; 22:4418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/90\">",
"      Lesser GJ, Case D, Stark N, et al. A Randomized, Double-Blind, Placebo-Controlled Study of Oral Coenzyme Q(10) to Relieve Self-Reported Treatment-Related Fatigue in Newly Diagnosed Patients with Breast Cancer. J Support Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/91\">",
"      Takimoto M, Sakurai T, Kodama K, et al. [Protective effect of CoQ 10 administration on cardial toxicity in FAC therapy]. Gan To Kagaku Ryoho 1982; 9:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/92\">",
"      Lucarelli G, Angelucci C, Giardini G, et al. Ubidecarenone and toxic cardiopathy from antiblastic therapy with daunoblastine. Boll Chim Farm 1986; 125:S34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/93\">",
"      Okuma K, Furuta I, Ota K. [Protective effect of coenzyme Q10 in cardiotoxicity induced by adriamycin]. Gan To Kagaku Ryoho 1984; 11:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/94\">",
"      Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994; 344:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/95\">",
"      Ben-Efraim S, Keisari Y, Ophir R, et al. Immunopotentiating and immunotherapeutic effects of thymic hormones and factors with special emphasis on thymic humoral factor THF-gamma2. Crit Rev Immunol 1999; 19:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/96\">",
"      Wolf E, Milazzo S, Boehm K, et al. Thymic peptides for treatment of cancer patients. Cochrane Database Syst Rev 2011; :CD003993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/97\">",
"      Chang R. Functional properties of edible mushrooms. Nutr Rev 1996; 54:S91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/98\">",
"      Borchers AT, Stern JS, Hackman RM, et al. Mushrooms, tumors, and immunity. Proc Soc Exp Biol Med 1999; 221:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/99\">",
"      deVere White RW, Hackman RM, Soares SE, et al. Effects of a mushroom mycelium extract on the treatment of prostate cancer. Urology 2002; 60:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/100\">",
"      Giovannucci E. Tomato products, lycopene, and prostate cancer: a review of the epidemiological literature. J Nutr 2005; 135:2030S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/101\">",
"      Jatoi A, Burch P, Hillman D, et al. A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group. Urology 2007; 69:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/102\">",
"      Kavanaugh CJ, Trumbo PR, Ellwood KC. The U.S. Food and Drug Administration's evidence-based review for qualified health claims: tomatoes, lycopene, and cancer. J Natl Cancer Inst 2007; 99:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/103\">",
"      Greenlee H, Gammon MD, Abrahamson PE, et al. Prevalence and predictors of antioxidant supplement use during breast cancer treatment: the Long Island Breast Cancer Study Project. Cancer 2009; 115:3271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/104\">",
"      Padayatty SJ, Sun AY, Chen Q, et al. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One 2010; 5:e11414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/105\">",
"      Heaney ML, Gardner JR, Karasavvas N, et al. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 2008; 68:8031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/106\">",
"      Perrone G, Hideshima T, Ikeda H, et al. Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 2009; 23:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/107\">",
"      Nangia-Makker P, Hogan V, Honjo Y, et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 2002; 94:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/108\">",
"      Pienta KJ, Naik H, Akhtar A, et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst 1995; 87:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/109\">",
"      Platt D, Raz A. Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin. J Natl Cancer Inst 1992; 84:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/110\">",
"      Guess BW, Scholz MC, Strum SB, et al. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer Prostatic Dis 2003; 6:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/111\">",
"      Garcia MK, McQuade J, Haddad R, et al. Systematic review of acupuncture in cancer care: a synthesis of the evidence. J Clin Oncol 2013; 31:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/112\">",
"      Ezzo J, Vickers A, Richardson MA, et al. Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. J Clin Oncol 2005; 23:7188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/113\">",
"      Roscoe JA, Bushunow P, Jean-Pierre P, et al. Acupressure bands are effective in reducing radiation therapy-related nausea. J Pain Symptom Manage 2009; 38:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/114\">",
"      Streitberger K, Friedrich-Rust M, Bardenheuer H, et al. Effect of acupuncture compared with placebo-acupuncture at P6 as additional antiemetic prophylaxis in high-dose chemotherapy and autologous peripheral blood stem cell transplantation: a randomized controlled single-blind trial. Clin Cancer Res 2003; 9:2538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/115\">",
"      Shen J, Wenger N, Glaspy J, et al. Electroacupuncture for control of myeloablative chemotherapy-induced emesis: A randomized controlled trial. JAMA 2000; 284:2755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/116\">",
"      Roscoe JA, Morrow GR, Bushunow P, et al. Acustimulation wristbands for the relief of chemotherapy-induced nausea. Altern Ther Health Med 2002; 8:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/117\">",
"      Treish I, Shord S, Valgus J, et al. Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy. Support Care Cancer 2003; 11:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/118\">",
"      Pearl ML, Fischer M, McCauley DL, et al. Transcutaneous electrical nerve stimulation as an adjunct for controlling chemotherapy-induced nausea and vomiting in gynecologic oncology patients. Cancer Nurs 1999; 22:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/119\">",
"      Roscoe JA, Morrow GR, Hickok JT, et al. The efficacy of acupressure and acustimulation wrist bands for the relief of chemotherapy-induced nausea and vomiting. A University of Rochester Cancer Center Community Clinical Oncology Program multicenter study. J Pain Symptom Manage 2003; 26:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/120\">",
"      Lee EJ, Frazier SK. The efficacy of acupressure for symptom management: a systematic review. J Pain Symptom Manage 2011; 42:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/121\">",
"      Yang Y, Zhang Y, Jing NC, et al.. Electroacupuncture at Zusanli (ST 36) for treatment of nausea and vomiting caused by chemotherapy of the malignant tumor. A multicentral randomized controlled trial (in Chinese). Zhonghua Zhenjiu 2009; 29:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/122\">",
"      Enblom A, Johnsson A, Hammar M, et al. Acupuncture compared with placebo acupuncture in radiotherapy-induced nausea--a randomized controlled study. Ann Oncol 2012; 23:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/123\">",
"      Paley CA, Johnson MI, Tashani OA, Bagnall AM. Acupuncture for cancer pain in adults. Cochrane Database Syst Rev 2011; :CD007753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/124\">",
"      Pfister DG, Cassileth BR, Deng GE, et al. Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trial. J Clin Oncol 2010; 28:2565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/125\">",
"      Cho JH, Chung WK, Kang W, et al. Manual acupuncture improved quality of life in cancer patients with radiation-induced xerostomia. J Altern Complement Med 2008; 14:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/126\">",
"      Simcock R, Fallowfield L, Monson K, et al. ARIX: a randomised trial of acupuncture v oral care sessions in patients with chronic xerostomia following treatment of head and neck cancer. Ann Oncol 2013; 24:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/127\">",
"      Meng Z, Garcia MK, Hu C, et al. Randomized controlled trial of acupuncture for prevention of radiation-induced xerostomia among patients with nasopharyngeal carcinoma. Cancer 2012; 118:3337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/128\">",
"      Meng Z, Kay Garcia M, Hu C, et al. Sham-controlled, randomised, feasibility trial of acupuncture for prevention of radiation-induced xerostomia among patients with nasopharyngeal carcinoma. Eur J Cancer 2012; 48:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/129\">",
"      Hammar M, Frisk J, Grim&aring;s O, et al. Acupuncture treatment of vasomotor symptoms in men with prostatic carcinoma: a pilot study. J Urol 1999; 161:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/130\">",
"      Redd WH, Montgomery GH, DuHamel KN. Behavioral intervention for cancer treatment side effects. J Natl Cancer Inst 2001; 93:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/131\">",
"      Richardson J, Smith JE, McCall G, Pilkington K. Hypnosis for procedure-related pain and distress in pediatric cancer patients: a systematic review of effectiveness and methodology related to hypnosis interventions. J Pain Symptom Manage 2006; 31:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/132\">",
"      Stalpers LJ, da Costa HC, Merbis MA, et al. Hypnotherapy in radiotherapy patients: a randomized trial. Int J Radiat Oncol Biol Phys 2005; 61:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/133\">",
"      Genuis ML. The use of hypnosis in helping cancer patients control anxiety, pain, and emesis: a review of recent empirical studies. Am J Clin Hypn 1995; 37:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/134\">",
"      Lotfi-Jam K, Carey M, Jefford M, et al. Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. J Clin Oncol 2008; 26:5618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/135\">",
"      Rummans TA, Clark MM, Sloan JA, et al. Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: a randomized controlled trial. J Clin Oncol 2006; 24:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/136\">",
"      Hoffman CJ, Ersser SJ, Hopkinson JB, et al. Effectiveness of mindfulness-based stress reduction in mood, breast- and endocrine-related quality of life, and well-being in stage 0 to III breast cancer: a randomized, controlled trial. J Clin Oncol 2012; 30:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/137\">",
"      Sloman R, Brown P, Aldana E, Chee E. The use of relaxation for the promotion of comfort and pain relief in persons with advanced cancer. Contemp Nurse 1994; 3:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/138\">",
"      Walker LG, Walker MB, Ogston K, et al. Psychological, clinical and pathological effects of relaxation training and guided imagery during primary chemotherapy. Br J Cancer 1999; 80:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/139\">",
"      Syrjala KL, Cummings C, Donaldson GW. Hypnosis or cognitive behavioral training for the reduction of pain and nausea during cancer treatment: a controlled clinical trial. Pain 1992; 48:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/140\">",
"      Cassileth BR, Vickers AJ. Massage therapy for symptom control: outcome study at a major cancer center. J Pain Symptom Manage 2004; 28:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/141\">",
"      Sims S. Slow stroke back massage for cancer patients. Nurs Times 1986; 82:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/142\">",
"      Ahles TA, Tope DM, Pinkson B, et al. Massage therapy for patients undergoing autologous bone marrow transplantation. J Pain Symptom Manage 1999; 18:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/143\">",
"      Kutner JS, Smith MC, Corbin L, et al. Massage therapy versus simple touch to improve pain and mood in patients with advanced cancer: a randomized trial. Ann Intern Med 2008; 149:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/144\">",
"      Bradt J, Dileo C, Grocke D, Magill L. Music interventions for improving psychological and physical outcomes in cancer patients. Cochrane Database Syst Rev 2011; :CD006911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/145\">",
"      Nainis N, Paice JA, Ratner J, et al. Relieving symptoms in cancer: innovative use of art therapy. J Pain Symptom Manage 2006; 31:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/146\">",
"      Moadel AB, Shah C, Wylie-Rosett J, et al. Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: effects on quality of life. J Clin Oncol 2007; 25:4387.",
"     </a>",
"    </li>",
"    <li>",
"     Mustian KM, Palesh O, Sprod L, et al. Effect of YOCAS yoga on sleep, fatigue, and quality of life: a URCC CCOP randomized controlled clinical trial among 410 cancer survivors (abstract 9013). J Clin Oncol 2010; 28:639s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/148\">",
"      Oh B, Butow P, Mullan B, et al. Impact of medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial. Ann Oncol 2010; 21:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/149\">",
"      Sharp DM, Walker MB, Chaturvedi A, et al. A randomised, controlled trial of the psychological effects of reflexology in early breast cancer. Eur J Cancer 2010; 46:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/150\">",
"      Stephenson NL, Weinrich SP, Tavakoli AS. The effects of foot reflexology on anxiety and pain in patients with breast and lung cancer. Oncol Nurs Forum 2000; 27:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/151\">",
"      Fenlon DR, Corner JL, Haviland JS. A randomized controlled trial of relaxation training to reduce hot flashes in women with primary breast cancer. J Pain Symptom Manage 2008; 35:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/152\">",
"      Chan YM, Lee PW, Fong DY, et al. Effect of individual psychological intervention in Chinese women with gynecologic malignancy: a randomized controlled trial. J Clin Oncol 2005; 23:4913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/153\">",
"      Stanton AL. How and for whom? Asking questions about the utility of psychosocial interventions for individuals diagnosed with cancer. J Clin Oncol 2005; 23:4818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/154\">",
"      Fellowes D, Barnes K, Wilkinson S. Aromatherapy and massage for symptom relief in patients with cancer. Cochrane Database Syst Rev 2004; :CD002287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/155\">",
"      Wilkinson SM, Love SB, Westcombe AM, et al. Effectiveness of aromatherapy massage in the management of anxiety and depression in patients with cancer: a multicenter randomized controlled trial. J Clin Oncol 2007; 25:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/156\">",
"      Samarel N, Fawcett J, Davis MM, Ryan FM. Effects of dialogue and therapeutic touch on preoperative and postoperative experiences of breast cancer surgery: an exploratory study. Oncol Nurs Forum 1998; 25:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/157\">",
"      Tsang KL, Carlson LE, Olson K. Pilot crossover trial of Reiki versus rest for treating cancer-related fatigue. Integr Cancer Ther 2007; 6:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/158\">",
"      Catlin A, Taylor-Ford RL. Investigation of standard care versus sham Reiki placebo versus actual Reiki therapy to enhance comfort and well-being in a chemotherapy infusion center. Oncol Nurs Forum 2011; 38:E212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/159\">",
"      Agdal R, von B Hjelmborg J, Johannessen H. Energy healing for cancer: a critical review. Forsch Komplementmed 2011; 18:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/160\">",
"      Spiegel D, Bloom JR, Kraemer HC, Gottheil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 1989; 2:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/161\">",
"      Fawzy FI, Fawzy NW, Hyun CS, et al. Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry 1993; 50:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/162\">",
"      Kuchler T, Henne-Bruns D, Rappat S, et al. Impact of psychotherapeutic support on gastrointestinal cancer patients undergoing surgery: survival results of a trial. Hepatogastroenterology 1999; 46:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/163\">",
"      K&uuml;chler T, Bestmann B, Rappat S, et al. Impact of psychotherapeutic support for patients with gastrointestinal cancer undergoing surgery: 10-year survival results of a randomized trial. J Clin Oncol 2007; 25:2702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/164\">",
"      Cunningham AJ, Edmonds CV, Jenkins GP, et al. A randomized controlled trial of the effects of group psychological therapy on survival in women with metastatic breast cancer. Psychooncology 1998; 7:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/165\">",
"      Goodwin PJ, Leszcz M, Ennis M, et al. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med 2001; 345:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/166\">",
"      Edelman S, Lemon J, Bell DR, Kidman AD. Effects of group CBT on the survival time of patients with metastatic breast cancer. Psychooncology 1999; 8:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/167\">",
"      Kissane DW, Love A, Hatton A, et al. Effect of cognitive-existential group therapy on survival in early-stage breast cancer. J Clin Oncol 2004; 22:4255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/168\">",
"      Smedslund G, Ringdal GI. Meta-analysis of the effects of psychosocial interventions on survival time in cancer patients. J Psychosom Res 2004; 57:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/169\">",
"      Spiegel D, Butler LD, Giese-Davis J, et al. Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: a randomized prospective trial. Cancer 2007; 110:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/170\">",
"      Boesen EH, Boesen SH, Frederiksen K, et al. Survival after a psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study. J Clin Oncol 2007; 25:5698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/171\">",
"      de Oliveira Campos MP, Riechelmann R, Martins LC, et al. Guarana (Paullinia cupana) improves fatigue in breast cancer patients undergoing systemic chemotherapy. J Altern Complement Med 2011; 17:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/172\">",
"      Bruera E, Strasser F, Palmer JL, et al. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol 2003; 21:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/173\">",
"      Markman M. Safety issues in using complementary and alternative medicine. J Clin Oncol 2002; 20:39S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/174\">",
"      Murch SJ, KrishnaRaj S, Saxena PK. Phytopharmaceuticals: problems, limitations, and solutions. Scientific Rev Alternative Med 2000; 4:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/175\">",
"      Nortier JL, Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000; 342:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/176\">",
"      Lord GM, Cook T, Arlt VM, et al. Urothelial malignant disease and Chinese herbal nephropathy. Lancet 2001; 358:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/177\">",
"      Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med 2002; 136:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/178\">",
"      Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000; 343:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/179\">",
"      MacGregor FB, Abernethy VE, Dahabra S, et al. Hepatotoxicity of herbal remedies. BMJ 1989; 299:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/180\">",
"      Moertel CG, Fleming TR, Rubin J, et al. A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med 1982; 306:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/181\">",
"      Miller DR, Anderson GT, Stark JJ, et al. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 1998; 16:3649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/182\">",
"      Ashar B, Vargo E. Shark cartilage-induced hepatitis. Ann Intern Med 1996; 125:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/183\">",
"      Buckner JC, Malkin MG, Reed E, et al. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc 1999; 74:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/184\">",
"      Hainer MI, Tsai N, Komura ST, Chiu CL. Fatal hepatorenal failure associated with hydrazine sulfate. Ann Intern Med 2000; 133:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/185\">",
"      Kaptchuk TJ. Acupuncture: theory, efficacy, and practice. Ann Intern Med 2002; 136:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/186\">",
"      Trotter JF. Hepatic hematoma after deep tissue massage. N Engl J Med 1999; 341:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/187\">",
"      Mikhail A, Reidy JF, Taylor PR, Scoble JE. Renal artery embolization after back massage in a patient with aortic occlusion. Nephrol Dial Transplant 1997; 12:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/188\">",
"      Kerr HD. Ureteral stent displacement associated with deep massage. WMJ 1997; 96:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/189\">",
"      Markman M. Medical complications of \"alternative\" cancer therapy. N Engl J Med 1985; 312:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/190\">",
"      Green S. A critique of the rationale for cancer treatment with coffee enemas and diet. JAMA 1992; 268:3224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/191\">",
"      Questionable methods of cancer management: 'nutritional' therapies. CA Cancer J Clin 1993; 43:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/192\">",
"      Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004; 22:2489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/193\">",
"      Shi S, Klotz U. Drug interactions with herbal medicines. Clin Pharmacokinet 2012; 51:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/194\">",
"      Zeller T, Muenstedt K, Stoll C, et al. Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center. J Cancer Res Clin Oncol 2013; 139:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/195\">",
"      Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998; 158:2200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/196\">",
"      Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000; 7:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/197\">",
"      Zuber R, Modriansk&yacute; M, Dvor&aacute;k Z, et al. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother Res 2002; 16:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/198\">",
"      Werneke U, Earl J, Seydel C, et al. Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 2004; 90:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/199\">",
"      Kivist&ouml; KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995; 40:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/200\">",
"      Lin HL, Liu TY, Wu CW, Chi CW. Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to Paclitaxel. Br J Cancer 1999; 81:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/201\">",
"      Ernst E. Intangible risks of complementary and alternative medicine. J Clin Oncol 2001; 19:2365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/202\">",
"      Coppes MJ, Anderson RA, Egeler RM, Wolff JE. Alternative therapies for the treatment of childhood cancer. N Engl J Med 1998; 339:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/203\">",
"      Brienza RS, Stein MD, Fagan MJ. Delay in obtaining conventional healthcare by female internal medicine patients who use herbal therapies. J Womens Health Gend Based Med 2002; 11:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/204\">",
"      Davis GE, Bryson CL, Yueh B, et al. Treatment delay associated with alternative medicine use among veterans with head and neck cancer. Head Neck 2006; 28:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/205\">",
"      Han E, Johnson N, DelaMelena T, et al. Alternative therapy used as primary treatment for breast cancer negatively impacts outcomes. Ann Surg Oncol 2011; 18:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/206\">",
"      Friedrich U. Hom&ouml;opathische Krebsbehandlung. Erfahrungsheilk 2000; 4:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/207\">",
"      Ernst E. Unconventional cancer therapies : what We need is rigorous research, not closed minds. Chest 2000; 117:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/13/40154/abstract/208\">",
"      Boddy K, Ernst E. Review of reliable information sources related to integrative oncology. Hematol Oncol Clin North Am 2008; 22:619.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2831 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-190.102.30.19-F4418191A5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_13_40154=[""].join("\n");
var outline_f39_13_40154=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H44\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ALTERNATIVE CANCER TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Dietary treatments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Gerson regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Macrobiotic diets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Kelley-Gonzalez regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Selected vegetables and herb mix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Herbal medicinal products",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Traditional Chinese medicine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Green tea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Essiac",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Mistletoe",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - PC-SPES",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Sho-saiko-to",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - St. John's wort",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Astragalus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Nonherbal supplements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Melatonin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Shark and bovine cartilage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Hydrazine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Coenzyme Q10",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Thymus extracts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Shiitake mushroom extract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Lycopene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Vitamin C",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1342206520\">",
"      - Modified citrus pectin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      COMPLEMENTARY SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Acupuncture and related therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Pain control and xerostomia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Vasomotor symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Hypnotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Behavioral intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Relaxation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Aromatherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Therapeutic touch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Self-help and support groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Ginseng and guarana for fatigue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Fish oil for symptom control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SAFETY ISSUES WITH COMPLEMENTARY AND ALTERNATIVE TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Direct toxicity of CAM medications and procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Interactions of CAM with conventional treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Delay or avoidance of conventional therapy of known benefit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2831\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2831|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/7/21628\" title=\"table 1\">",
"      Toxicity complement altern meds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/58/21422\" title=\"table 2\">",
"      Herbal remedies avoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/30/25069\" title=\"table 3\">",
"      Allergenic herbal ingredients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/40/32396\" title=\"table 4A\">",
"      Amine alkaloid sympath herbs A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/61/40924\" title=\"table 4B\">",
"      Amine alkaloid sympath herbs B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/22/11629\" title=\"table 5\">",
"      Anticoagulant coagulant herbs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/41/38556\" title=\"table 6\">",
"      Cardioactive herbal ingredients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/16/11532\" title=\"table 7\">",
"      Diuretic herbal ingredients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/49/40732\" title=\"table 8\">",
"      Herbs affecting glucose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/31/24059\" title=\"table 9\">",
"      Herbs affecting lipids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/33/44571\" title=\"table 10\">",
"      Hormonally active herbs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/47/36603\" title=\"table 11\">",
"      Hypertensive herbal ingredients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/15/9469\" title=\"table 12\">",
"      Hypotensive herbal ingredients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/9/15515\" title=\"table 13\">",
"      Immunostimulating herbs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/35/16957\" title=\"table 14\">",
"      Irritant herbal ingredients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/59/27579\" title=\"table 15\">",
"      Laxative herbal ingredients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/25/15772\" title=\"table 16\">",
"      Sedative herbal ingredients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/50/28457?source=related_link\">",
"      Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/24/42378?source=related_link\">",
"      Cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27098?source=related_link\">",
"      Cancer-related fatigue: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17960?source=related_link\">",
"      Clinical features and pathogenesis of cancer cachexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27784?source=related_link\">",
"      Clinical use of St. John's wort",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/59/13242?source=related_link\">",
"      Emerging therapies for hepatic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25642?source=related_link\">",
"      Hepatotoxicity due to herbal medications and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/17/26903?source=related_link\">",
"      Homeopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=related_link\">",
"      Menopausal hot flashes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6933?source=related_link\">",
"      Nephropathy induced by aristolochic acid (AA) containing herbs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20554?source=related_link\">",
"      Overview of herbal medicine and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/33/25105?source=related_link\">",
"      Patient information: Alternative medicine (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/51/21300?source=related_link\">",
"      Patient information: Complementary and alternative medicine treatments (CAM) for cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/57/19346?source=related_link\">",
"      Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5113?source=related_link\">",
"      Pharmacologic management of cancer anorexia/cachexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13034?source=related_link\">",
"      Physiology and clinical use of melatonin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=related_link\">",
"      Psychological, rehabilitative, and integrative therapies for cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38520?source=related_link\">",
"      Secondary endocrine therapies for castration resistant prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43321?source=related_link\">",
"      The roles of diet, physical activity, and body weight in cancer survivorship",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37114?source=related_link\">",
"      Treatment of relapsed or refractory multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39221?source=related_link\">",
"      Unproven therapies for chronic systolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_13_40155="DSM IV criteria for dementia";
var content_f39_13_40155=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV criteria for dementia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       1. Memory impairment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       2. At least one of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Aphasia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Apraxia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Agnosia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Disturbance in executive functioning",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. The disturbance in 1 and 2 significantly interferes with work, social activities, or relationships",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Disturbance does not occur exclusively during delirium",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Additional criteria for dementia type:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Dementia of the Alzheimer type:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Gradual onset and continuing cognitive decline",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Not caused by identifiable medical, psychiatric, or neurologic condition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Vascular dementia:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Focal neurological signs or laboratory evidence of cerebrovascular condition",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Dementia due to other medical conditions:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Evidence from history, physical exam, or laboratory findings of a specific medical condition causing cognitive deficits (HIV disease, head trauma, Parkinson disease, Huntington's chorea, Pick's disease, Creutzfeld-Jacob)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American Psychiatric Association Diagnostic and Statistical Manual, 4th ed, APA Press, Washington DC, 1994.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_13_40155=[""].join("\n");
var outline_f39_13_40155=null;
var title_f39_13_40156="TNM staging ampullary CA";
var content_f39_13_40156=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging for ampullary carcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"3\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"3\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis",
"      </td>",
"      <td colspan=\"3\">",
"       Carcinoma in situ",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor limited to the ampulla of Vater or sphincter of Oddi",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor invades duodenal wall",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor invades pancreas",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor invades peripancreatic soft tissues or other adjacent organs or structures other than pancreas",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Regional lymph nodes (N)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"3\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"3\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td colspan=\"3\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage 0",
"      </td>",
"      <td>",
"       Tis",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IA",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IB",
"      </td>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIA",
"      </td>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Stage IIB",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage III",
"      </td>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IV",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_13_40156=[""].join("\n");
var outline_f39_13_40156=null;
var title_f39_13_40157="Calcium versus estrogen on bone";
var content_f39_13_40157=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F62388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F62388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Methods to slow bone loss in postmenopausal women",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 249px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effects of three interventions on distal forearm bone density in postmenopausal women with low baseline forearm bone density. Bone loss was significantly slowed or prevented with either exercise plus estrogen or exercise plus calcium supplementation. The former regimen was both more effective and associated with a higher incidence of side effects, such as breast tenderness and vaginal bleeding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Prince RL, Smith M, Dick IM, et al. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy.&nbsp;N Engl J Med 1991; 325:1189.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_13_40157=[""].join("\n");
var outline_f39_13_40157=null;
var title_f39_13_40158="Diag modalities chest pain";
var content_f39_13_40158=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 577px\">",
"   <div class=\"ttl\">",
"    Diagnostic modalities in chest pain syndromes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 557px; height: 325px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Use of serum markers, electrocardiogram (ECG), and acute rest MPI in the spectrum of chest pain.",
"    <div class=\"footnotes\">",
"     CK: Creatine kinase; cTnT: Cardiac troponin T; cTnI: Cardiac troponin I.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Duca MD, Giri S, Wu AH, et al. J Nucl Cardiol 1999; 6:570.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_13_40158=[""].join("\n");
var outline_f39_13_40158=null;
var title_f39_13_40159="Wisconsin card sort test";
var content_f39_13_40159=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F50407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F50407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Wisconsin card sort test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 237px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADtAg0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAriPif8AEPTPAGkxXF7HJdX1yStrZxEBpSMZJPZRkZPPXgGu3rwl4E8SftUyw3q+ZBoGnLNEjfdD7UIOPXM+c+oHpQAQal8bfEqC5srHSvD1q/MaXKjfj/aDb2B+qj6VN/wj/wAdI/n/AOEv8Py452eSo3e3/HuP517hRQB4h/Zvx0/6DXh//vhf/jdH9m/HT/oNeH/++F/+N17fRQB4h/Zvx0/6DXh//vhf/jdH9m/HT/oNeH/++F/+N17fRQB4h/Zvx0/6DXh//vhf/jdH9m/HT/oNeH/++F/+N17fRQB4h/Zvx0/6DXh//vhf/jdIdM+Ojjb/AG74fjzxu2L8vv8A6o17hRQB4f8A8I58df8Aoc/D/wD35X/5Go/sH46w/N/wlnh+47bPKUfj/wAe4/nXuFFAHgV34++JngPZdeOtBs9R0RWVZbyxYBkycZODgf8AAlAJ4yK9t0PVbPXNIs9T02US2l1GJYnHGQfX0PbHrTtc06HWNGvtOulDwXcDwOD0wykH+deT/sp3slz8M5bWZjmy1CWBVJ5VSqP+HLtQB7NXEfFD4iab4A0mK4vI3ur65JS1s4yA0pHUknooyMnnrwDXb14Q1uniX9qqeK+HmQaBpySwowBG7ajA49Q0+c+oHpQAsGpfG3xKgubKx0rw9avzGlyo34/2g29gfqo+lTf2B8dYvn/4S7w/NjnZ5Sjd7f8AHuP517hRQB4h/Zvx0/6DXh//AL4X/wCN0f2b8dP+g14f/wC+F/8Ajde30UAeIf2b8dP+g14f/wC+F/8AjdH9m/HT/oNeH/8Avhf/AI3Xt9FAHiH9m/HT/oNeH/8Avhf/AI3R/Zvx0/6DXh//AL4X/wCN17fRQB4h/Zvx0/6DXh//AL4X/wCN0h0346EY/tvw+ueM7F49/wDVV7hRQB4f/wAI58df+hz8P/8Aflf/AJGo/sL46wfP/wAJX4fuO2zylH/tuP517hRQB4HeeP8A4meAilz460Cz1HRQwWS8sSAyZOM8HA+jKATxkV7Zoeq2euaRZ6npsoltLqMSxOOMg+voe2PWjX9Mi1nQ7/TbhQ0N3A8DBumGUj+teVfsp3z3fwveCQkrZ38sKA9lKo/83NAHstVtSvbbTbC4vb6ZILS3jaWWRzgIoGSTVmvHv2qNSlsPhcYYWKi+vYrZyP7uGk/nGKAMYfE/xz44vJo/hp4eiTS43Kf2jf8ARvcZIUf7vzGrI0L46z/P/wAJXoFv22eUp/H/AI9z/OvWvCujW/h3w5p2k2capDaQLENoxkgfMx9ycnPqa16APD/7L+Okfyf294flxxv2KN3v/qR/Kl/s346f9Brw/wD98L/8br2+igDxD+zfjp/0GvD/AP3wv/xuj+zfjp/0GvD/AP3wv/xuvb6KAPEP7N+On/Qa8P8A/fC//G6P7N+On/Qa8P8A/fC//G69vooA8Q/s346f9Brw/wD98L/8bo/s346f9Brw/wD98L/8br2+igDw/wDsL46z/P8A8JX4ft+2zylP/tuf50f8I58df+hz8P8A/flf/kavcKKAPCpJfjnoqmd00TW0QZaJAoJHtjyyT9PwFdp8KPiRB46gvLe4s303XLBtl3ZSE5XkjcuQDjPBB5B4PYn0GvCrmMaJ+1dYi2ARdb0tmmC/xEI/X8YFoA91prMI1LMQFAySeMU6uD+OmpS6T8JvElzbsVkMAgBHUCR1jP6OaAOI1P4t+IvFGt3OlfCrQU1GO2bbLqVzxF9VyVAHBwWOSOgpw0b463Y3/wDCS6DZd/LMaH/2g3867X4IaNb6L8LvD8Vsiq1zapeSsBy7SgOST3OCB9AK7ygDw/8Asn46Q/J/wkPh+fH/AC08tRn/AMhD+VL/AGb8dP8AoNeH/wDvhf8A43Xt9FAHiH9m/HT/AKDXh/8A74X/AON0f2b8dP8AoNeH/wDvhf8A43Xt9FAHiH9m/HT/AKDXh/8A74X/AON0f2b8dP8AoNeH/wDvhf8A43Xt9FAHiH9m/HT/AKDXh/8A74X/AON0f2b8dP8AoNeH/wDvhf8A43Xt9FAHh/8AYvx0uD/yM/h+22/9MlO7/wAgN/Sj/hHPjr/0Ofh//vyv/wAjV7hRQB4a8Hx10weYLvQdY2Z/dgIu/wD8dj/mK6H4XfE+XxLq914d8TaYdG8T2qlntzkJKBjJUHkHnOCTkcgkZx6jXhfxejGj/G/4bazbqFnvZzYyFeCy70Tn14nIoGe6UUUUCCvD/Cn/ACdf4z/7BEf/AKDaV7hXh/hT/k6/xn/2CI//AEG0oA9wooooAKKKKACiiigAooooAKKKKACiiigArw/9lYgeHvE0Z4kXVn3Keo+Rev5GvcK8Q/Zk/wCZ2/7C7f1oGe314f4U/wCTr/Gf/YIj/wDQbSvcK8P8Kf8AJ1/jP/sER/8AoNpQI9wooooAKKKKACiiigAoqpb39rc3l3awTxvcWjKs8anmMsoZQfqCDVugAooooAKKKKACvEP2VP8AkWvEn/YXf/0BK9vrw/8AZiGyPxpEvEaas21R0HXp+AFAz3CvD/2uv+Sb6b/2Fov/AETNXuFeH/tdf8k303/sLRf+iZqBI9wooooAKKKKACiioLu4jtLWa4nO2KFDI5AzgAEk/lQBPRXn0XxX8NTwpLCmsyRuoZHTSrghgRkEHZyK1fDXjvRPEWrvpmnm+S9WA3Pl3NnLBmMMqkguozyyjiso1qcpcqkm/UfK+x1lFFFaiCiiigArw/x9hf2l/AbDhjZyDI7jE3H6mvcK8P8AiXmD9ob4ezryXieLB7DLjP8A49QB7hXmv7R//JGfEP8A27/+lEVelV5r+0f/AMkZ8Q/9u/8A6URUAdL8Mv8Akm3hP/sE2n/olK6Wua+GX/JNvCf/AGCbT/0SldLQAUUVxGu/FLwZotw9vda5BJcqcNFaq1wwPofLBwfY4oSbdkB29Fefab8X/BF7OsJ1pbWVjgC8gkgH/fTqF/Wu8t5o7mFJoJElidQyuhBDD1B7im007NAnclooopAFFQXd1b2VtJcXk8VvbxrueWVgioPUk9BXnl98aPBltKY7e9ur8qSGaztJJFH/AALAB/AmqjGUnaKuJtLVnpVFefaN8XfBupXCW51Q2Nw5wqX8L24P/AmG39a79WEihlIKkZBHOaTi4u0lZgnfVDq8P/aKGPFPw1ccMurcHuPnhPH5V7hXh/7SmYr/AMA3a8tDqy4B6HlDz/3zSGj3CiiigArw/wAKf8nX+M/+wRH/AOg2le4V4f4U/wCTr/Gf/YIj/wDQbSgD3CiiigAooooAKKKKACiiigAooooAKKKKACvEP2ZP+Z2/7C7f1r2+vEP2af3V749tW/1kWrHcR06uOPxU0DPb68P8Kf8AJ1/jP/sER/8AoNpXuFeH+FP+Tr/Gf/YIj/8AQbSgR7hRRRQAUUVnatrOl6NGsmsalZWEb52vdTrEG6dCxAPUUAaNQXlzDZWk91dOsdvCjSSO3AVVGST+FcpdfE/wRbZEnijSTg4/d3Ak/wDQc1578WfifoOueD7jRPDGpG7vdRdLeQxwyr5cBJMjFioH3VK4zn5qG7EVKkacXKT0Ryfws8ZXMHxQfV7+R0s/FM7RSxueImJJtvyHyf8AAq+oK+Mb21FxZPbofLO0bGXgoR90j0wcGvd/CXxm8M3Og2J8RamLDV1jCXcUkEgAkHDEMF24JGeDwDzWVKfMjycozH65GSn8Sf4Pb7tvuPV6K5C1+Jfgq5x5finSFzn/AFt0sf8A6ERXQ6Xqmn6tbmfSr61voAdpktpVkXOAeqkjuK1PZL1FFFABXiH7Mn/M7f8AYXb+te314h+zJ/zO3/YXb+tAz2+vD/2uv+Sb6b/2Fov/AETNXuFeH/tdf8k303/sLRf+iZqBI9wooooAKKKKACs3xP8A8i3q3/XpL/6Aa47x9q+vxeLtG0fQNSttOW6tLi4llltBcZMbRgADcuPvnvWXeWXjS9tZra58Y2ohlRkYRaOikgjB5Ln1rx8dn2AwFT2OIqWla9rN/kmawoTmrxRP8P8A/kQvDf8A2DLb/wBFLT9H/wCSz23/AGL9x/6UQVd0HTxpGh6dpqyGVbO2jtw5GC4RQufbpmsrV9E1aTxNb63oesw6dcxWb2TCWyFwGVnVyfvrg5Ra/MMkx+Hwua/Wa0rQvLWz63ttqejWg5U+VbnqtFeR6xc+OtN0i+vf+ErsJPs0DzbP7HA3bVJxnzf1r0jwveS6j4a0m9uSpnubSKaQqMDcyAnHtk1+r4DNMLmKlLCz5kt9GvzSPMnTlT+I1KKKK9AgK8P+Kn/Je/hx/wAC/wDQjXuFeH/FT/kvfw4/4F/6EaAPcK81/aP/AOSM+If+3f8A9KIq9KrzX9o//kjPiH/t3/8ASiKgDpfhl/yTbwn/ANgm0/8ARKV0tc18Mv8Akm3hP/sE2n/olKzfjNq82i/DPXLm1crcyRC2iYdQ0rCPI9wGJ/Cmk27IDx74n+P7rxhqFxpmkXElt4at3MTvC2GvmHDEsOkfYAdep7AcTBBFbxhII1jQdAgAFLbQpb28cMYwkahQPbGKkr9Oy3LaWBpKMV73V/10PnMRiJVpXewjqsiFXUMrcEMMgj3Fa3grxbqPgG8WawaS40Nn3Xem53ALn5pIhn5WHXHQ9/WsqitcbgKWNpuFRej6oijXnRleLPr7TL+21TTba+sZVmtLmNZYpF6MjDIP5U3V9RtdI0y61DUJRDaW0bSyyHoqgZJry/8AZv1F5fCepaVIxI0y+ZIQf4YnUSKPzZqT9pG/dPCul6VGSE1K+VZh2aONTIV/FlSvzL6vL2/1f7V7fO9j6P2i5Ofpa55J4v8AEuoePNR+26sZI9MVi1np2fkiXszj+Jz6npnArPAAAAGAOABRRX6fgsFSwdNU6S+fV+p85WrSrS5pDZY0lQpKiOrcFWAIP4V1Xw08c3PgfUreyvriSXwtO4R0kJP2BiQA6E9I89V6DqO+eXpk8STwvFINyOpDD2I5rHMcup46k4SWvR9mVh8RKjK62PssEEAg5B7ivEf2m/8AmSf+wuv9K7X4J6nLqvwx0OW5ffPFG1q5PUmJ2jBP4KDXFftN/wDMk/8AYXX+lfmDTTsz6Rant9FFFIArw/wp/wAnX+M/+wRH/wCg2le4V4f4U/5Ov8Z/9giP/wBBtKAPcKKKKACiiigAooooAKKKKACiiigAooooAK8Q/Zz/AORl+JP/AGFz/wChy17fXiH7Of8AyMvxJ/7C5/8AQ5aBnt9eH+FP+Tr/ABn/ANgiP/0G0r3CvD/Cn/J1/jP/ALBEf/oNpQI9wooooAKxPFfhvS/FWizaXrVstxaycjPDI2DhkPZhng1t0UAfJnjHwjf+AdRW31AefpMz7LTUlUAHk4SXjCvgdeh6jvWZX1vrdlZahpV3a6tDFNYSRkTRyjKlMc5r460Ih9MidA6xuWaNXJJRCx2jPfC4FctaCjqj47Psvp0LV6el3t+qL1MnljghaWaQRxqMlmOAKeCCSAQSOoB5FT6I1tD4x8M3OoQR3FomoxJJHKoZMSZQMQf7rMp9sVlFczseJg6Cr140pO12dH4E+GN/418u+1mKXTPDrYZVZdtzeD2yP3aH16kdODmvozRtKsdF02Cw0q1itLOBdscUY2gD/H36nvWhRXbGKirI/RcNhqeGh7OkrIKKKKo3CvD/ANm3MOrfEG0HKQ6scHufmkH/ALKK9wrxD9nP/kZfiT/2Fz/6HLQM9vrw/wDa6/5Jvpv/AGFov/RM1e4V4f8Atdf8k303/sLRf+iZqBI9wooooAKKKKAPKPiZqtnovxF8OXupyNDajT7uMyCNnAYvEQPlB9DVc/EbwsASdUIA5JNtL/8AEV6/Wb4n/wCRb1b/AK9Jf/QDXzWa8L4bNK/t6s5J2S0tbT1TOiniZU48qRzFjdQX9lb3dpIJLa4jWaJwCAyMAVOPoazde8U6J4fmii1nUrezklUsiykgsM9RxUXw/wD+RC8N/wDYMtv/AEUtP0f/AJLPbf8AYv3H/pRBX5tlWV08dmP1Obaj72q30uehUqOFPnRzPif4heE7rw1q1vb67ZyTS2cqIik5ZihAA49a9V8AusngXw46HcrabbEH1HlLzW9RX6rk2SUsojOFKTfM762/Q82rWdWzYUUUV7JiFeH/ABU/5L38OP8AgX/oRr3CvD/jBmD41/DKdOXedoiD0xvUZ+vzGgD3CvNf2j/+SM+If+3f/wBKIq9KrzX9o/8A5Iz4h/7d/wD0oioA6X4Zf8k28J/9gm0/9EpWH8d7GS9+FutGBS0tsI7sAekciu3/AI6rVufDL/km3hP/ALBNp/6JSugnhjuYJIZ0WSKRSjowyGBHI+lNNxaaBq58dI6yIrodysAwI6EdQaWtTxx4VuPAOtNZXCyNoU0h/s+8bJUA5IhduzLjj1HNZdfqeAxtPG0lUg/VdmfM16MqM3FhRRUmjaXqHijWF0XQF3XTY8+fBMdpGTgu5HfrgdSa1xWKp4Wm6tV2SJp05VZcsT2L9m21caHr2osMRXeobI/9oRxqpb/vrcPwp37SVm58O6JqaAlLLUAsvoqSIybj/wACKj8a9L8LaJaeG/D1ho+nKRbWcQjUnqx6lj7kkk+5p/iPR7TxDod7pGop5lpdxGKQDggHuD2IOCD6ivy/6zL6x9Z683N+Nz6T2a9n7Ppax8k0VP4g0bUfCGrnSNeVt2SLW8xtju0HQg9m9V65qCv0/CYuni6aq0ndfl6nzlWlKlLlkFNkdY42dztVQWJPYY5NOJABJOAOSTW38P8AwfcePtWRFRk8OW7g3l1yBPg/6mP1J7kcAe+M5ZhjqeCpOpN69F3ZVCjKtLlXzPb/AIF6fLp/wu0QXKlZrhHuyD6SyM6/+Ostcf8AtN/8yT/2F1/pXtkaLFGqRqFRRgKBgAV4l+1L+70bwrcr/rYtWTb6fdJ/9lFflrbk22fSrQ9wooopAFeH+FP+Tr/Gf/YIj/8AQbSvcK8P8Kf8nX+M/wDsER/+g2lAHuFFFFABRRRQAUhIAJJwB3NLXlfx/wDFTaJ4UGk2LldT1ndAjKeY4R/rX/I7R7tntSbUVdl0qcqs1Tgrt6I85uPipcL8XD4gWct4Yjc6b5S9Gt92DOPX5/m9doxX0vG6yxq8bBkYZDA5BFfEiwxrbiAIPKC7dvbGOle//s9eKzqegS+Hb+UvqGkALEznmW2PCEeu37p9Pl9a5MNifatxZ9Hn2Rf2dTp1aeqtaX+Lv8z1+iiiuw+ZCiiigArxD9nP/kZfiT/2Fz/6HLXt9eIfs5/8jL8Sf+wuf/Q5aBnt9eH+FP8Ak6/xn/2CI/8A0G0r3CvD/Cn/ACdf4z/7BEf/AKDaUCPcKKKKACiiigDj/i7qZ0f4aeIrtDtk+xvDGR2eT92v/jzivnTwX4Y1XxdcR6Z4fAis7YCK51J1JigAx8qj+OTH8OeO5FfSnj/wpB4z0WPSb64lisTcJLcLFw0iJk7M9sttOfQVsaPpdlo2nQWGlWsVrZwrtjijGAo/z361MoKTVzjxOCp4mcJVdVG+nd+Z5pf/AAO8OPosUGlzXdjqsSnGpb/MeVj1Mqk7WHsAMdsV4r4/8O674UtpoPEFr5aEZt9RtstBI4OVyeqNkDhvwr7EqC6toLy2kt7uGOeCVSskUihlcehB4IpSgpahiMDRrtSkrSWzW+hS8Maout+G9L1SP7l7ax3GPTcoOP1rUqhoumWejabBYaZCILOEERxAkhQSTgZ7c9O1X6s7AooooAK8Q/Zz/wCRl+JP/YXP/octe314h+zn/wAjL8Sf+wuf/Q5aBnt9eH/tdf8AJN9N/wCwtF/6Jmr3CvD/ANrr/km+m/8AYWi/9EzUCR7hRRRQAUUUUAFVNWtje6XeWisFaeF4gx5A3KRn9at0UAeUaP4S8d6VpFjp1vqfhl4LOBLeMvaTliqKFBJEgGcCtbwp4V8QWvjT+3fEN9pMwTT5LGOKxgkj+9Ij7jvZv7mK9BorzqGU4OhV9vSppT119dzR1ZyVm9Aooor0TMKKKKACvEPjR/yWL4Xf9fZ/9GR17fXiHxo/5LF8Lv8Ar7P/AKMjoGj2+vNf2j/+SM+If+3f/wBKIq9KrzX9o/8A5Iz4h/7d/wD0oioEdL8Mv+SbeE/+wTaf+iUrpa5r4Zf8k28J/wDYJtP/AESldLQBU1LT7PVLKWz1G2hurWUbXhmQOjD3Bry3VPgZoMsrSaLqOqaSCeIUcTRL9FkBI/PFeu0VpTqzpPmpyafloTKKkrSVzxyy+BWliXdqmvaveRj/AJZRmOBWHoxVcn8CK9N8O+H9J8N6etjoVhb2NsDnbEuCx9WPVj7nJrWop1a1Ss71ZOT83cIwjDSKsFFFFZFGdrmjadr2nSWOsWUF5aSfeimQMM+oz0PuORXmt98CvDzyFtN1LWtOQniGO4WSNR6ASKxH5163RWlOrUpO9OTT8nYmUVLSSueV6V8EPC9rMsupS6lrBBDCO8uAIsg9diBQfocivTbS2gs7aO3s4Y4LeJQsccahVUegA4AqeilOpOo+abbfmNRUVZBXiH7Vf/IteG/+wun/AKA9e314h+1X/wAi14b/AOwun/oD1BSPb6KKKBBXh/hT/k6/xn/2CI//AEG0r3CvD/Cn/J1/jP8A7BEf/oNpQB7hRRRQAUUUUARyyxwRPLK4SNFLMzHAUAck18feM/ETeMPF1/rZZjZk/Z7FGyNsCk4OOxY5b8a9l/aH8UNp/h+Lw9Yybb7V8rMVPMVsP9YfbdkKM9QW9K8ERQihFGFAAAHYVwY6rZci6n2fCOXe0qPGTWkdF69X8haueH9cuPCviOw1+0DsbVttxEvWWBseYvPfHI9CKp0deDXm05unJSR9zjcJDGUJUKm0l/wz+R9o2F5BqFjb3lnKsttcRrLFIvIdWAII/A1Zrwz9nPxRiG58I3snzWoNzYFiPmhJ+ZB6lWOfo3oK9zr34SU4qSPxnE4eeGqyo1FrF2CiiiqMQrxD9nP/AJGX4k/9hc/+hy17fXiH7Of/ACMvxJ/7C5/9DloGe314f4U/5Ov8Z/8AYIj/APQbSvcK8P8ACn/J1/jP/sER/wDoNpQI9wooooAKKKKACiiigAorNtNasbvWr/SYJ1e+sUjeeLugkBK/yrSoAKKKKACiiigArxD9nP8A5GX4k/8AYXP/AKHLXt9eIfs5/wDIy/En/sLn/wBDloGe314f+11/yTfTf+wtF/6Jmr3CvD/2uv8Akm+m/wDYWi/9EzUCR7hRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXiHxo/wCSxfC7/r7P/oyOvb68Q+NH/JYvhd/19n/0ZHQNHt9ea/tH/wDJGfEP/bv/AOlEVelV5r+0f/yRnxD/ANu//pRFQI6X4Zf8k28J/wDYJtP/AESldLXNfDL/AJJt4T/7BNp/6JSuloAKKKKACiiigAooooAKKKKACiiigArxD9qv/kWvDf8A2F0/9Aevb68Q/ar/AORa8N/9hdP/AEB6Bo9vooooEFeH6CPI/au8R7D/AK/SU35/3YOn/fIr3CvENJ/5Ov1r/sEL/wCgxUAe30UUUAFFFFAHnnjD4U6D4q12TV9RudUjvHRYyYLkKoVRwoBU4HU/Umsf/hQ/hj/n/wBe/wDAtf8A4ivW6Klwi9WjeGJrU1ywm0vJs8k/4UP4Y/5/9e/8C1/+Io/4UP4Y/wCf/Xv/AALX/wCIr1uil7OPYr67if8An5L73/meYaD8G9A0PXLLV7G/1n7ZZvviMlyrA5GCpGzkEZBHpXp9FFUklojCdSVR803d+YUUUUyQrxD9nP8A5GX4k/8AYXP/AKHLXt9eIfs5/wDIy/En/sLn/wBDloGe314f4U/5Ov8AGf8A2CI//QbSvcK8P8Kf8nX+M/8AsER/+g2lAj3CiiigAoorF8T+JdI8L2K3mvXgs7VnCCRkZhuPY7QcUAbVQXdzFZ2s1zcuEghQySO3RVAyT+Qrz2b40eCE/wBTqN1cHniGwnP6lAK4r4l/FXT/ABH4Tu9E0C11VLi/KQyTzWxiRISQZOSc5KgrjHek5JamNTEUqablJK3mcX4L8Xzaf8SI/F967x22s3Tx3oc8RwSsBET6BNqc+ma+sq+NLi2intJLd1/dMhQgdhivW/BHxksLDw1YWHia01Y6nax+TLNDamVJdh2hsg5JIAJ465rKnUve54+UZosQpqq7NO6v2fT5HuFFebQ/GjwO/wDrtTubcnHE1jOPzIQgV2HhnxLpPiiwa90G8F5ahinmKjKMjqPmAzWx7kZKWqZs0UUUFBXiH7Of/Iy/En/sLn/0OWvb68Q/Zz/5GX4k/wDYXP8A6HLQM9vrw/8Aa6/5Jvpv/YWi/wDRM1e4V4f+11/yTfTf+wtF/wCiZqBI9woorktY+InhHR9Sn0/VNesrW8gIEkUhOUOAeePQigCp8WdQ1Cw8P6eNJvpbGe61S1tGniVWZUkkCtgMCM4PpWF/YviL/oedb/7823/xuqHxC8deGvEdtoVhoWqxX93/AG1YybIVYgKJhklsYH4muzr4DjDNsXga1OOGqOKad9u53YWlGcXzIp/Ca+1K7s/EMGrajNqMljq0lrFPMqK3liKJgCFAHVm7V3teN+BPG/hvw1f+L7PXdYtbG5fW5ZljlJBKGGEZ6eqsPwrtNN+JXg7U7+3srDxBZT3dw4jiiRjl2J4A4619pgJyqYanObu3FN/ccc1aTSOwoorD8R+K9C8NCL+3tVtbEygmMTOAXAIyQO/UV1klzXZ5LbRNQngbbNFbyOjYBwwUkH9K8p8N/wDCZat4d0vUZPHN5G95aRXDIunWhCl0DYz5fTmt/X/il4JuNC1GGHxJYPLJbSKqhjliVOB0qt8P/wDkQvDf/YMtv/RS18fxfmOJwFGnLDT5W277dvM68LTjNvmQzwze+IrP4i2Gk6t4jn1WyubC4n2SWkMW10aMAgogPRzXqdeQajrWm6F8UtCu9ZvrextTpl2glncIu4yQ4GT34Ndj/wALL8E/9DTo/wD4FL/jXrcPYmrisupVqzvJ3u/mzKvFRqNI66vEPjR/yWL4Xf8AX2f/AEZHXtNtPFdW8VxbyLJDKodHQ5DKRkEHuMV4t8aP+SxfC7/r7P8A6Mjr2jJHt9ea/tH/APJGfEP/AG7/APpRFXpVea/tH/8AJGfEP/bv/wClEVAjpfhl/wAk28J/9gm0/wDRKV0tc18Mv+SbeE/+wTaf+iUro2YIpLEBQMkngAUAZPifxFpfhfSpNR1u6S2tUOAW5LseiqvVmPoK8Y1n43azdysPDei2tpbfwzamzO7j18tCNv4sa4fxj4lm8beJ59Wld202B2i02E5CpGDgyY/vPjOeoGBWbX1uVcPQrU1WxPXZeXmeXice4ScKfQ7m1+MPjSCQNPb6HeR9SnkyQtj2beQPxBr0rwB8VdI8VXS6ddwyaTrLDK2lwwKy+8bjhvpwfavnyoLu2S5jCsWV1YNHIhw8bg5DKexHqK7cZw1QlBvD+7L70Y0sxmn+81R9oUVwHwa8WzeK/CmdSYNq1hJ9luyON7AArIB2DKQfrmu7lkSGJ5JWCIgLMzHAAHU18PKLhJxkrNHsppq6MfxZ4m0rwppD6jrdyIIAdqKBl5G7Kij7zHHSvF9Z+NfiC9lP9gaRZafaZ+V9QLSzMPXYhAU+xJrh/FPiKfxp4km1u5ZjZqzR6dA2cRQ9A2OzPjJP4dBVKvrMq4ehVpqtib67Ly8zy8Tj3GXJT6dTtrX4u+NreQNKuiXkeSWRoJIiR6Bg5x6cg16Z4A+KuleKLpNOvYZNJ1phlbadgyTf9cpBw304PtXz7UF3brcRhSSjqwaORDhkcHIZT2IrsxvDVCcG8P7svW6f3mVHMJp/vNUfaFeIftV/8i14b/7C6f8AoD12Pwa8WzeLPCIfUdv9q2MhtLsgYDsACJAPRlIP1zXHftV/8i14b/7C6f8AoD18PKLhJxluj2otPVHt9FFFSAV4hpP/ACdfrX/YIX/0GKvb68Q0n/k6/Wv+wQv/AKDFQB7fRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXiH7Of8AyMvxJ/7C5/8AQ5a9vrxD9nP/AJGX4k/9hc/+hy0DPb68P8NfuP2r/Fe//lvpKbMf7tt/8Sa9wrxDSf8Ak6/Wv+wQv/oMVAj2+iiigAqrqen2mqWE1lqNvFc2k6lJIZFBVx6EVaooA+YfiJ4AvPAkjXlj5174XJ++ctLY5I+V/wC9Hzw3UdD2J5ZGV0V0YMhAIIOQR619hzCMwuJgpiIwwbGMd8+1fGOlGOW2luLeMQ29xNLNFEowI0ZyVUDsMY4rmrQS95HyOf4ClSSxENG3Zrv5lyorq5htYWlncIg457nsB6n2oS5ged4EljaZACyA5YCpba8TStb0PVJQPKsdQgmkyAf3e4K/6MT7VjFXaTPBwtBVK8KVTRSa/E7zwB8Kr7xJ5eo+LY5rDRzhotOyUmuB6y4+4v8As9T3x3+grGzt7CzhtLKCO3toVCRxRKFVB6ADoKsUV3KKirI/RcPh6eGh7OkrIKKKKZuFeIfs5/8AIy/En/sLn/0OWvb68Q/Zz/5GX4k/9hc/+hy0DPb68P8A2uv+Sb6b/wBhaL/0TNXuFeH/ALXX/JN9N/7C0X/omagSPcK8q8P/API5+Of+wmn/AKTRV6rXnV94B1c6/q2o6R4pbT49RmE8kH2COYKwjVOGY+ijtXi8QZdVzLBSw9FpSbW+2j+ZtQmqc+ZmpRXH+KNN8TeF00m8m8Vfb4J9TtbSSBtOij3LJIFb5gSRwe1dhX5Hm2TV8qnGFdpuSvpr+iPTpVVUV4hXMeNv+Pzwl/2H7T/2aq+hWnifxRf6/JY+IrXTbWw1F7KOF9ME5IWONt27zF/v4xjtWk3w/wDEV1qWkz6p4ttrm3sL6K98mPSREXKH7u7zTjIJGcHFfTZJwvjaWIo4yTjypqW+tt+xhWxEHFw6np1ea+NAD8VPDeQDjTL0jPY74a9KrifGng/Udc13TNV0jW4tLubKCW3IksvtAdZChP8AGuPuD1r9AzXDTxeDqUKfxSTSOGlJRmpMlorn9T8LeMbHTbu7/wCEzspPIheXZ/YoG7apOM+dx0q14TvptT8LaNf3RBuLqyhnkKjALNGCce2TX4/mmQYrKoRniGrSdlZ3/RHqU60ajtE0ZYIpsGWKNyOm9QcVjeLbO3/4RTWtltFv+wzY2oM58s4xxVbW7jXLrxhpmiaFeWVn9otJ7mSW5t2m+4yKAAGXH3/WrV14N8Z3ltLbXHijSI4ZUKO0WlMWAII4zNXdlfDeOxVOniqTXK3ffs7dvIipiIRbizsPAbB/A/h1kIZTp1uQRyD+6XmvLvjR/wAli+F3/X2f/Rkdet+GNLOh+G9J0nzvP+wWkVr5u3bv2IF3bcnGcZxk4ryT40f8li+F3/X2f/RkdfsR5aPb681/aP8A+SM+If8At3/9KIq9KrzX9o//AJIz4h/7d/8A0oioEdL8Mv8Akm3hP/sE2n/olKb8T7mWz+HPieeA4lTTp9pH8J8sjP4dad8Mv+SbeE/+wTaf+iUrX1zTo9X0TUNNnOIry3kt3PoHUqf50AfH1lGsVnAifdVAox6YAqaq9pFcWfm6ffoY76xkNtcIeoZTjPuCBnPerFfrOFqRq0Yzhs0j5erFxm09woooroIPSP2dZXj8ZeIoFP7qayt5mHqyu6g/ka9W+Ks0lv8ADTxRJCxVxps4BHBGYyMj35rgP2btIf7FrPiKVcR38i29qT/FFFkFh7F2Yf8AAa9Z8Q6ZHregalpc5xFe20lux9A6lc/rX5XmVSNXF1Jw2bZ9Lh4uNKKe9j5CtUEdtCijCqgUD2xipar2sVxaebYX6eXf2Tm1uEPZ0OCfcHGc9wasV+m4apGrSjOGzSPnakXGTi9woooJAGTwB1NbkHpf7Ocjx+LPE0CAmKW0tpmPYMrSKPxI/lV/9qv/AJFrw3/2F0/9AerX7OGkPHpGreIJkKjU51jt9w6wRAgMP95mf8hVX9qv/kWvDf8A2F0/9AevyrMKkauKqThs2z6bDxcacU97Ht9FFFcZqFeIaT/ydfrX/YIX/wBBir2+vENJ/wCTr9a/7BC/+gxUAe30UUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4h+zn/yMvxJ/7C5/9Dlr2+vEP2c/+Rl+JP8A2Fz/AOhy0DPb68Q0n/k6/Wv+wQv/AKDFXt9eIaT/AMnX61/2CF/9BioEe30UUUAFFFFAHJ/FbVDovw48RXqttdLN0jPo7jYp/wC+mFfO/wAPPBuqeMxDbaUxs9EtgIrjU2XIYjqkIP3m/wBroPrgV9MeLPDll4p0j+y9VMjWDypJLEjY80IwYKT1xkKePTrWpY2lvYWkNrZQRwW0KhI4o1CqijoAOwqZRUtzlxGEp4iUZVNVHp0v5nC3Pwk8IT+HYdJTSxB5OWjvYW23Suer+ZjLE++R7cCvE/iH8PfEHhawu/tCHV9GaNlF/bJ+8iHODLGOw/vLkeuK+rqKJRUtx4jCUsRb2i1Wz6r+vuOa+G+sf2/4C0HUy++S4s4zKf8ApoBh/wDx4NXS1WsbO2sLcW9lBFbwBmYRxKFUFiWYgD1JJ+pqzVHSFFFFABXiH7Of/Iy/En/sLn/0OWvb68Q/Zz/5GX4k/wDYXP8A6HLQM9vrxD9rkE/DfTiBnGrRH6fuZq9vrxn9q/8A5JhF/wBhGH/0F6BI9kVg6gqQVIyCOQRTqraZ/wAg20/65J/IVZoA88+NM0Vt4d0ee4lSKCLW7F5JJGCqiiYEkk9AKpf8Jn4X/wChk0X/AMD4v/iq9JurWC7iMV3BFPETnZIoYfkaqf2Bo/8A0CdP/wDAZP8ACvnM64dpZvOE5zceVW0sb0a7pJpI4n4L3Vve2/i64s54ri3k16VklicOjjyIOQRwRXpFVrOztrGMx2dvDbxk5KRIEBPHOB34qzXu4eiqFKNJO6ikvuVjGT5m2FFFFbCM3xP/AMi3q3/XpL/6Aa8s8C+ItFg8EeHoptY02OWPTrdWR7qMFSIlyCM8H2r2KRFljZJFDIwwVIyCKxv+EQ8Nf9C9o/8A4BRf/E14md5JDN6cITm48rvtc2o1nSbdjgdG1Kx1H4u6O2n3ttdhNKuwxglWQLmSHrg8dK9arL0/QNH0248/T9KsLScjb5kFukbY9MgDitSuzLMCsvwsMNF3Ub6+rb/UipPnlzBXiHxo/wCSxfC7/r7P/oyOvb68Q+NH/JYvhd/19n/0ZHXeSj2+vNf2jFZ/g34iCgkgQHA9BcRn+lelV598fv8AkkHiT/rin/o1KBGz8LnWT4aeFGQ5A0q1Un3ESg/yrqK5H4Rf8kv8Lf8AYOh/9BFddQB5R8W/hnJ4hujrnhxooddRAksMhxHeIOgY/wALjs34HjkeD6k82j3X2XX7O50q6HBjukKA+6v91h7g19n1FcQRXMTRXEUcsbdUkUMD+Br1cvzjEYFcsNY9n+nY5q+Ep1tXoz4ubVrAEAXcLljgLGwck+gAzmu38F/DXW/F08cmq21xo/h84LvMNlxcr/dROqKf7zdugNfSVppdhZyeZaWNrbuRgtHEqn8wKu104ziHE4mDpxSin23M6WAp03zPVlbTrK206xgs7GFILWBBHFGgwEUDAAFWaKK8E7Tyn4sfDJ/EV1/bnh14rfXVQLLHJxFeIOgY9mHZvwPHTwnVDc6Jcm28Q2N1pVyDjbdIQrH/AGXHysPcGvsymSxpKhSVFdT2YZB/CvVwGcYjArlg7x7P9OxzV8JTray3Piz+1rJnWOK4WaVyAqQ5kZj2AC5ya73wT8L9Z8Vzxz6/bXGj6CCC8UwKXN0M/d2/wKe5PPoOcj6Ps7Czss/Y7S3t89fKjCZ/IVarfGcQYnFQdNWin23+8zpYGnTfNuyCztoLO1htrSJIbeFBHHGgwqKBgADsOK8X/ar/AORa8N/9hdP/AEB69vrxD9qv/kWvDf8A2F0/9AevDO5Ht9FFFAgrxDSf+Tr9a/7BC/8AoMVe314hpP8AydfrX/YIX/0GKgD2+iiigAooooAKKKKACiiigAooooAKKKKACvEP2c/+Rl+JP/YXP/octe314h+zn/yMvxJ/7C5/9DloGe314hpP/J1+tf8AYIX/ANBir2+vENJ/5Ov1r/sEL/6DFQI9vooooAKKKKACiiigAooooAKKKKACiiigArxD9nP/AJGX4k/9hc/+hy17fXiH7Of/ACMvxJ/7C5/9DloGe314z+1f/wAkwi/7CMP/AKC9ezV4z+1f/wAkwi/7CMP/AKC9Akeu6Z/yDbT/AK5J/IVZqtpn/INtP+uSfyFWaACiiigAooooAKKKKACiiigAooooAK8P+MX7741fDKFPvpO0hz0xvQ/+ymvcK8P+MGYPjX8Mp05d52iIPTG9Rn6/MaAPcK8++P3/ACSDxJ/1xT/0aleg1598fv8AkkHiT/rin/o1KANP4Rf8kv8AC3/YOh/9BFddXI/CL/kl/hb/ALB0P/oIrrqACiiigAooooAKKKKACiiigAooooAK8P8A2pzv0PwvAnM0mrJtX1+Vh/UV7hXiH7UmYtJ8KXS8vDqybQeh+Unn/vmgEe30UUUAFeB/EG4XwP8AtAaB4ovT5ej6rbG0uZjwEYAryfQZjbnsD6V75WB4y8LaX4w0ObStbgMtvIQyspw8bDoynsR/9bpQBuRussavGwZGGQwOQRT68Htfh38TvCAFp4L8YWtzpK/LHBqC8xjsACrgD/dI+lWF0/46MATrGgKTzgovHt/q6APcKK8Q/s346f8AQa8P/wDfC/8Axuj+zfjp/wBBrw//AN8L/wDG6APb6K8Q/s346f8AQa8P/wDfC/8Axuj+zfjp/wBBrw//AN8L/wDG6APb6K8Q/s346f8AQa8P/wDfC/8Axuj+zfjp/wBBrw//AN8L/wDG6APb6K8Q/s346f8AQa8P/wDfC/8Axuj+zfjp/wBBrw//AN8L/wDG6APb6K8Q/s346f8AQa8P/wDfC/8Axuj+zfjp/wBBrw//AN8L/wDG6APWfFGu2XhrQb7V9TkCWtpEZGyQCx7KPcnAA9a8u/Zg0+5HhPVtev0KT61fvOuf4kHG7/voyVTtvhB4k8UX9vdfFDxU+pW8LBhYWeViY+5AUL6HauSO4r2yytYLK1htbSFILeFBHHGgwqKBwAOwoAnrwPx9cp4G/aC0LxLekx6Pq1r9kuJjwEYfKcnsB+6b6Z9K98rA8Z+FtL8YaHNpOtQebbuQyspw0bjOGQ9iMn8ODwaAN1WEihlIKkZBHOadXg1r8Pfif4RUWngvxda3OkqcRwX6cxr2ABVwAP8AZI+lWV0/46MATrGgKTzgovHt/q6APcKK8Q/s346f9Brw/wD98L/8bo/s346f9Brw/wD98L/8boA9vorxD+zfjp/0GvD/AP3wv/xuj+zfjp/0GvD/AP3wv/xugD2+ivEP7N+On/Qa8P8A/fC//G6P7N+On/Qa8P8A/fC//G6APb6K8Q/s346f9Brw/wD98L/8bo/s346f9Brw/wD98L/8boA9vorxD+zfjp/0GvD/AP3wv/xukOnfHTH/ACGvD4/4Av8A8boA9Z8Va7ZeGtAvtX1KQJbWsZc5OCx7KPcnAHvXmH7L+m3MfhDU9cvk2T6zfPOOMbkHAP8A30XqjbfCDxH4ov7e6+KXil9TggYOthZ5WIn3O1Qvodq5x3Fe22dtBZ2sNtaRJDbwoI440GFRQMAAdhxQBPXmf7Q+hTa98LdTS1QvcWbJeIi9SEPzf+Olq9MoIBGDQBxnwl8UW/i3wJpd/BIGnjiWC6TOTHMgAYH69R7EV2deKa78HNQ0zXJ9a+GOutoF1Od0lm+fs7HPTgHC/wCyVYemOlQJp3x1HynWdAOB98onzf8AkP8ApQB7lRXiH9m/HT/oNeH/APvhf/jdH9m/HT/oNeH/APvhf/jdAHt9FeIf2b8dP+g14f8A++F/+N0f2b8dP+g14f8A++F/+N0Ae30V4h/Zvx0/6DXh/wD74X/43R/Zvx0/6DXh/wD74X/43QB7fRXiH9m/HT/oNeH/APvhf/jdH9m/HT/oNeH/APvhf/jdAHt9FeIf2b8dP+g14f8A++F/+N0f2b8dP+g14f8A++F/+N0Ae314JqF3H44/aT0mLTGE+n+G4Ga5lXBUSgtkA/77IuPVW9KluPBfxf8AESG01/xhYWGnuNsgsVw7Dv8AdRSRjjG4V6P8OfAWkeAdIay0hHkllIa4upcGSZhnGTjgDJwBwPqSSAdfXL/E3RJPEfgDXdKtxuuLi1byl/vSL8yD81FdRRQB5T+zj4nh1v4eWmnM+3UdIzazwtwyqCdjY9McfVTXq1eReN/hCb7xDJ4k8E6vN4e19zulMeRFMxOSTjkE9+oPcZyayk0v46RYi/tzQZQM/vSic/8AkIfyoGe5UV4h/Zvx0/6DXh//AL4X/wCN0f2b8dP+g14f/wC+F/8AjdAj2+ivEP7N+On/AEGvD/8A3wv/AMbo/s346f8AQa8P/wDfC/8AxugD2+ivEP7N+On/AEGvD/8A3wv/AMbo/s346f8AQa8P/wDfC/8AxugD2+ivEP7N+On/AEGvD/8A3wv/AMbo/s346f8AQa8P/wDfC/8AxugD2+ivEP7N+On/AEGvD/8A3wv/AMbo/s346f8AQa8P/wDfC/8AxugD2+vBPjJdp4u+KngzwdpjCd7O6F3f7cERLlTgnsQiscf7S1Yl8M/GrVl+z3/izStPtm4d7VQJMeqlYwQf+BCu0+F/wy0vwGlxPFNJf6xdDFxfzjDsM52qMnaM8nkknqTgYAO/ooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Wisconsin Card Sorting Test assesses the ability to divide attention and to change sets.&nbsp;",
"    <br>",
"     The cards have different number, color, and type of shape on the face. A number of cards (in this example, four) are presented to the subject. The test administrator decides, but does not tell the subject, whether&nbsp;subsequent cards are to be matched based on number, color, or shape. The subject is asked to make&nbsp;a match and then is told whether the match was right or wrong. In subsequent attempts, the&nbsp;matching rule is learned.&nbsp;During the test, the rules are changed and the subject&nbsp;adapts.&nbsp;The time taken for the patient to learn the new rules are analysed to arrive at a test score.",
"     <br>",
"      Originally performed with a physical deck of cards, the test is now most commonly carried out and scored by computer.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_13_40159=[""].join("\n");
var outline_f39_13_40159=null;
